% Exported from Psilocybin Research Publication Tracker
% Tracker site: https://psilocybin-research.com
% Publication tracker: https://psilocybin-research.com/
\documentclass[11pt]{article}
\usepackage[T1]{fontenc}
\usepackage[utf8]{inputenc}
\usepackage{enumitem}
\usepackage[hidelinks]{hyperref}
\usepackage[margin=1in]{geometry}
\title{Psilocybin and Psilocin Research Export}
\author{Psilocybin Research Publication Tracker}
\date{2026-07-12}
\begin{document}
\maketitle
\noindent Exported from \href{https://psilocybin-research.com}{psilocybin-research.com}. Records: 984.

\begin{enumerate}[leftmargin=*]
\item Unknown authors (2026). \textit{Phase 1 trial suggests benefit of psilocybin in OCD treatment}. The Brown University Psychopharmacology Update. [published; Crossref]. \href{https://doi.org/10.1002/pu.31474}{doi:10.1002/pu.31474}.
\item Bruyère Health Research Institute. (2026). \textit{PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07063862}{source link}.
\item Ottawa Hospital Research Institute (2026). \textit{PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04754061}{source link}.
\item Thomas Christopher W., LaMalfa Kayleigh S., Whelan Tobias P., Blackmore Thomas, Golden Caroline T., Pizzagalli Diego A., Bergman Jack, Gilmour Gary, Kangas Brian D. (2026). \textit{Psychedelics produce enduring enhancement of reward responsiveness in male rats}. Neuropsychopharmacology. [published; Crossref]. \href{https://doi.org/10.1038/s41386-026-02475-2}{doi:10.1038/s41386-026-02475-2}.
\item University Health Network, Toronto (2026). \textit{Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06341426}{source link}.
\item Yale University (2026). \textit{Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06624137}{source link}.
\item Raul Edison Luna Lazo, Nicole Milagritos Cardoso Azorza, Jatziri Yanina Vilca Yanac, Ahmad Kassem El Zein, Omar Abraham Ramírez Paucar, Luana Mota Ferreira, Roberto Pontarolo (2026). \textit{Therapeutic potential of psilocybin in the pharmacological treatment of obsessive-compulsive disorder: a scoping review protocol.}. Open Science Framework. [published; OpenAlex]. \href{https://doi.org/10.17605/osf.io/guqxr}{doi:10.17605/osf.io/guqxr}.
\item Douglass HM, Spriggs MJ, Godfrey K, Danby JL, de Magalhaes FJC, Macdonald L, Alderton KL, Archer S, Ahmad K, Martell J, Frias JT, Sawicka G, Read T, Blemings A, Lafrance A, Nicholls D, Erritzoe D, Park RJ, Nutt DJ, Carhart-Harris RL. (2026). \textit{Psilocybin therapy for adult females with anorexia nervosa: pilot study.}. The British Journal of Psychiatry. [published; Europe PMC]. \href{https://doi.org/10.1192/bjp.2026.10687}{doi:10.1192/bjp.2026.10687}.
\item University of Wisconsin, Madison (2026). \textit{Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone Formulation}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04161066}{source link}.
\item NYU Langone Health (2026). \textit{Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06349083}{source link}.
\item University of Colorado, Denver (2026). \textit{A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older Adults}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07516405}{source link}.
\item Matthew A. Boehm, Oriana Mayorga (2026). \textit{Policy Considerations for Psychedelics in Research and Medicine - What’s Next on the Schedule?}. Journal of Science Policy \& Governance. [published; OpenAlex]. \href{https://doi.org/10.38126/jspg280103}{doi:10.38126/jspg280103}.
\item Koning E, Richard J, Keshen A. (2026). \textit{Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions.}. International Journal of Eating Disorders. [published; Europe PMC]. \href{https://doi.org/10.1002/eat.70164}{doi:10.1002/eat.70164}.
\item Smith SA, Mohammad H, Lee LHN, Dennett L, Smith S, Burback L, Winkler O, Greenshaw A, Jetly R, Kennedy SH, Bhat V, Swainson J, Vermetten E, Cao B, Li XM, Zhang Y. (2026). \textit{Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s00213-026-07110-y}{doi:10.1007/s00213-026-07110-y}.
\item Sunstone Medical (2026). \textit{A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06902974}{source link}.
\item Orsini DK, Wong S, Di Luch S, Chan B, Vasudeva S, Lovell GFM, Le GH, Jones BDM, Chisamore N, Mollica A, Johnson DE, Kaczmarek ES, Goel A, Burke MJ, Mansur R, McIntyre RS, Husain MI, Rosenblat JD. (2026). \textit{Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1001/jamapsychiatry.2026.0255}{doi:10.1001/jamapsychiatry.2026.0255}.
\item Plourde L, Chang SL, Nguyen O, Garel N, Farzin H, Stephan JF, Fallu JS, Dorval M, P3A Research Group (2026). \textit{Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders.}. Palliative medicine. [published; PubMed]. \href{https://doi.org/10.1177/02692163261446141}{doi:10.1177/02692163261446141}.
\item Hoyer D (2026). \textit{Psychedelics, entactogens and psychoplastogens for depression and related disorders.}. British journal of pharmacology. [published; PubMed]. \href{https://doi.org/10.1111/bph.70088}{doi:10.1111/bph.70088}.
\item Wittenkeller L, Gudelsky G, Winhusen TJ, Amato D (2026). \textit{Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology.}. British journal of pharmacology. [published; PubMed]. \href{https://doi.org/10.1111/bph.70181}{doi:10.1111/bph.70181}.
\item Sjöström D, Schau Rybäck O, Claesdotter Knutsson E, Kajonius P, Jensen Sondén O, Carlbring P, Björkstrand J, Movahed Rad P. (2026). \textit{Study Protocol for "Exploring the safety and therapeutic potential of psilocybin in the treatment of anorexia nervosa in adolescents and young adults".}. PLoS ONE. [published; Europe PMC]. \href{https://doi.org/10.1371/journal.pone.0352246}{doi:10.1371/journal.pone.0352246}.
\item Estela-Fernandez CA, Mohamed Yousif Elsheikh R, Beatrice DB, A Alhendal A, Irene Ewe C, Montesinos SY, Wensel J, Mishra AP, Yousif AA, Ali HT. (2026). \textit{Psychedelics in treatment-resistant depression: a comprehensive review of mechanisms, clinical evidence, and recommendations.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s40211-026-00584-4}{doi:10.1007/s40211-026-00584-4}.
\item Stefanie Enriquez Geppert, Lisa Bevers, Arvid Rosander, Peter Fodran, Vince Polito (2026). \textit{Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical Development}. University of Groningen research database (University of Groningen / Centre for Information Technology). [published; OpenAlex]. \href{https://research.rug.nl/en/publications/370a82bd-d8db-4a02-b644-bf0c9131680b}{source link}.
\item Johns Hopkins University (2026). \textit{5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05452772}{source link}.
\item Guidetti C, Fava M, Papakostas GI. (2026). \textit{Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventions.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1038/s41380-026-03722-0}{doi:10.1038/s41380-026-03722-0}.
\item Mauro Pettorruso, Giacomo d’Andrea, Antonio Inserra, Clara Cavallotto, Stefano Censi, Étienne Billard, Antonio Di Stefano, Luisa De Risio, Maria Giulia Tullo, Claudio D’Addario, Giorgio Di Lorenzo, Richard G. Wise, Stefano L. Sensi, Francesca Zoratto, Giovanni Martinotti (2026). \textit{Mechanistic insights toward dissociating therapeutic from psychedelic effects: bridging the gap between psychedelic research and mental health care}. Translational Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1038/s41398-026-04203-2}{doi:10.1038/s41398-026-04203-2}.
\item Júlio César Claudino dos Santos, Sofia Januário Bolan, Guilherme Lodetti da Silva, Germano Lapa Viana, Eduardo Pacheco Rico, Cinara Ludvig Gonçalves (2026). \textit{Psychedelics and autism spectrum disorder: Mechanistic insights, translational evidence and ethical challenges}. Journal of Psychiatric Research. [published; OpenAlex]. \href{https://doi.org/10.1016/j.jpsychires.2026.06.035}{doi:10.1016/j.jpsychires.2026.06.035}.
\item University Health Network, Toronto (2026). \textit{Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07048743}{source link}.
\item University of Virginia (2026). \textit{Psilocybin-Assisted Therapy for Prolonged Grief}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06724289}{source link}.
\item Roswell Park Cancer Institute (2026). \textit{Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring Opioids}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06827054}{source link}.
\item University Health Network, Toronto (2026). \textit{Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Phase II Open-Label Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06416085}{source link}.
\item Frick A, Blest-Hopley G, Grin M, Erritzoe D, Nutt D, Carhart-Harris R. (2026). \textit{Sex-Specific Effects of Psilocybin Versus Escitalopram on Anxiety and Anhedonia: A Bayesian Reanalysis of Antidepressant Treatment Outcomes}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-9880403/v1}{doi:10.21203/rs.3.rs-9880403/v1}.
\item Astrit Sabani, Adnan Khatak (2026). \textit{Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidence}. Annals of Medicine and Surgery. [published; OpenAlex]. \href{https://doi.org/10.1097/ms9.0000000000005244}{doi:10.1097/ms9.0000000000005244}.
\item Lawrence Leeman, Maya Armstrong, Dara Menashi, Hanifa Nayo-Washington, Elliot Marseille, Janus Herrera, Crystal Romero, Janet Page-Reeves (2026). \textit{Community engagement as a foundation for implementation research for group psilocybin assisted therapy in New Mexico}. Frontiers in Public Health. [published; OpenAlex]. \href{https://doi.org/10.3389/fpubh.2026.1845943}{doi:10.3389/fpubh.2026.1845943}.
\item Julia Osipowska, Marlena Kwolek, Alicja Judzińska, Bartosz Piech, Kamila Sobczyńska, Justyna Ignarska, Magda Terbosh, Sabina Kubicz `Mzabi, Emilia Trojanowska, Magdalena Dubaj (2026). \textit{THE PSYCHEDELIC AND KETAMINE RENAISSANCE IN THE FACE OF THE CRISIS IN MODERN PSYCHIATRY}. International Journal of Innovative Technologies in Social Science. [published; OpenAlex]. \href{https://doi.org/10.31435/ijitss.2(50).2026.5605}{doi:10.31435/ijitss.2(50).2026.5605}.
\item Brigham and Women's Hospital (2026). \textit{Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07296094}{source link}.
\item SAIMSARA (2026). \textit{Psilocybin and Mental Health Outcomes: Scoping Review with ☸SAIMSARA}. SAIMSARA Journal. [published; OpenAlex]. \href{https://doi.org/10.62487/saimsara7a54f680}{doi:10.62487/saimsara7a54f680}.
\item Angel Labra-Lorenzana, Dania Nimbe Lima Sanchez, Christian Alejandro Delaflor-Wagner, Diana Martínez-Hernández, Christian Ramos-Jiménez, Christian Gabriel Toledo-Lozano (2026). \textit{Efficacy of Psilocybin-Assisted Therapy in Major Depressive Disorder: A Systematic Review and Meta-Analysis}. Psychiatry International. [published; OpenAlex]. \href{https://doi.org/10.3390/psychiatryint7030137}{doi:10.3390/psychiatryint7030137}.
\item Lucas Cruz, Fernando R. Beserra, Julia M.K. Freind, Sandro E. Rodrigues, Daniel C. Mograbi (2026). \textit{Music Playlist Use in Clinical Trials of Psychedelic Assisted Psychotherapy: A Systematic Review}. Journal of Clinical Psychology. [published; OpenAlex]. \href{https://doi.org/10.1002/jclp.70167}{doi:10.1002/jclp.70167}.
\item Yale University (2026). \textit{Psilocybin as a Treatment for Chronic Pain in Smokers}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07118332}{source link}.
\item Johns Hopkins University (2026). \textit{PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin Pretreatment}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07610135}{source link}.
\item Robin Carhart-Harris, PhD, MA (2026). \textit{Multivariate Neural and Physiological Correlates of Psychedelic Sub-states: a Within-subjects, Healthy Volunteer Study With Experience-sampling}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05698511}{source link}.
\item Samaneh Ahmadian-Moghadam, Shiva Roshan-Milani, Ehsan Saboory (2026). \textit{Prenatal stress, excitatory-inhibitory imbalance, and ADHD risk: a hypothesis-driven perspective on psilocybin-induced neuroplasticity}. Translational Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1038/s41398-026-04151-x}{doi:10.1038/s41398-026-04151-x}.
\item Elise C. Tarbi, Ian Bhatia, Nabil Balach, Suzannah Buehler, Magdalena Demeo-Meres, Cailin Gramling, Tej Thambi, Julia Hart, Maija Reblin, Donna M. Rizzo, Robert Gramling, Manish Agrawal, Emily Manetta (2026). \textit{Developing Methods for Observing Awe Narration in Psilocybin-Assisted Therapy}. Healthcare. [published; OpenAlex]. \href{https://doi.org/10.3390/healthcare14111589}{doi:10.3390/healthcare14111589}.
\item Myfanwy Graham, Yimin Ge, Rosalie Liccardo Pacula, Seema Choksy Pessar, Chris Wilkins, Wayne Hall, David Hammond (2026). \textit{A cross-national comparison of nonmedical and medical use of psychedelic drugs in the international cannabis policy study}. International Journal of Drug Policy. [published; OpenAlex]. \href{https://doi.org/10.1016/j.drugpo.2026.105348}{doi:10.1016/j.drugpo.2026.105348}.
\item Kevin F. Boehnke, Niloufar Pouyan, Jacob S. Aday (2026). \textit{Classic Psychedelics for Chronic Pain: A Critical Review of the Literature and Practical Advice for Clinicians}. Drugs. [published; OpenAlex]. \href{https://doi.org/10.1007/s40265-026-02339-5}{doi:10.1007/s40265-026-02339-5}.
\item Cecelia Kelly, Mathieu Fradet, Catherine M. Bostian, Anna Donnelly, Sara Ellis, Michael Ostacher, Scott Aaronson, Trisha Suppes (2026). \textit{Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression}. Journal of Affective Disorders. [published; OpenAlex]. \href{https://doi.org/10.1016/j.jad.2026.122063}{doi:10.1016/j.jad.2026.122063}.
\item University of Calgary (2026). \textit{The Role of the Subjective Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using Risperidone in Healthy Adults}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06768944}{source link}.
\item Gaurav Uppal, Naima Gul, Asha Dhandapani, Sathyan Soundararajan, Khushboo Kansal (2026). \textit{From Altered States to Altered Trajectories and From Molecules to Meaning: A Network Meta Analysis Mapping Comparative Efficacy of Psychedelic Assisted Therapies in Modern Psychiatry}. BJPsych Open. [published; OpenAlex]. \href{https://doi.org/10.1192/bjo.2026.11141}{doi:10.1192/bjo.2026.11141}.
\item Centre for Addiction and Mental Health (2026). \textit{Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06512220}{source link}.
\item Jenna Houff, Andrew Williams, Obie Allen, Barbara Gisabella, Harry Pantazopoulos, Alberto Del Arco (2026). \textit{Psilocybin Decreases Preference for Large Rewards Accompanied by Increased Activity of Parvalbumin Neurons With Perineuronal Nets in the Medial Prefrontal Cortex}. European Journal of Neuroscience. [published; OpenAlex]. \href{https://doi.org/10.1111/ejn.70574}{doi:10.1111/ejn.70574}.
\item C. Poppe, Liisa Lyck, Laura Bechtold, Dimitris Repantis (2026). \textit{Expectations and Motivations for Participation in Clinical Trials Utilizing Psychedelics for Treatment-Resistant Depression: A Qualitative Study}. Brain and Behavior. [published; OpenAlex]. \href{https://doi.org/10.1002/brb3.71544}{doi:10.1002/brb3.71544}.
\item University of Washington (2026). \textit{A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07336238}{source link}.
\item Valerie A. Canady (2026). \textit{Psilocybin shows rapid relief for depression symptoms}. Mental Health Weekly. [published; OpenAlex]. \href{https://doi.org/10.1002/mhw.34890}{doi:10.1002/mhw.34890}.
\item Unknown authors (2026). \textit{Psilocybin shows mixed results for patients with treatment-resistant depression}. The Brown University Psychopharmacology Update. [published; OpenAlex]. \href{https://doi.org/10.1002/pu.31461}{doi:10.1002/pu.31461}.
\item Alex Hood, Gary ELKINS (2026). \textit{Effect of psilocybin-assisted psychotherapy on anxiety symptoms: A systematic review and meta-analysis}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2026.00507}{doi:10.1556/2054.2026.00507}.
\item Elliot Hampsey, Kirsty Martin, Michail Kalfas, Louis Benson, Sirid Wihlborg, Luke Jelen, Allan H. Young, James Rucker (2026). \textit{A systematic review of the pharmacokinetics of classical serotonergic psychedelic compounds in healthy adult subjects}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811261453938}{doi:10.1177/02698811261453938}.
\item L Belinger, N M Rieser, E J E Engeli, L Becciolini, M Clamote, M Pribis, F Saissi, G.A. Florineth, N L Hehl, M Herdener, K H Preller (2026). \textit{Blinding integrity in psychedelic research: Evidence from a comparative randomized controlled trial of psilocybin, MDMA, and methylphenidate in healthy volunteers.}. Open Access CRIS of the University of Bern. [published; OpenAlex]. \href{https://doi.org/10.48620/98266}{doi:10.48620/98266}.
\item Mazen A. Atiq, Eli Weisman, Rodrigo B. Guerra, Luis Luna Martinez, David B. Yaden, Frederick S. Barrett, Sandeep Nayak, Ceyda Sayalı (2026). \textit{Psilocybin-induced neurocardiogenic syncope: a case report}. Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1007/s00213-026-07079-8}{doi:10.1007/s00213-026-07079-8}.
\item Lea J. Mertens, Felix Betzler, Manuela Brand, Ricarda Evens, Andrea Jungaberle, Henrik Jungaberle, Laura Kärtner, Tomislav Majić, Christian N. Schmitz, Andreas Ströhle, Dennis Scharf, Moritz Spangemacher, Max Wolff, Zahra Assadi, Scharif Bahri, Lilith Becher, Luca V. Färber, Henry Harder, Niklas Kirchen, Eugenia Kulakova, Linda C. Kunz, Andy Meijer, Barbara Rohrmoser, Stefan Wellek, Moritz M. Berger, Michael Koslowski, Gerhard Gründer (2026). \textit{Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression (EPIsoDE): 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial}. Psychotherapy and Psychosomatics. [published; OpenAlex]. \href{https://doi.org/10.1159/000552272}{doi:10.1159/000552272}.
\item Laursen DRT, Salazar J, Jürgens G, Hróbjartsson A. (2026). \textit{Active placebo control interventions in pharmacological trials: a scoping review of the development process and a terminological analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jclinepi.2026.112345}{doi:10.1016/j.jclinepi.2026.112345}.
\item Dallas T Mason (2026). \textit{Psilocybin for Treatment-Resistant Depression: A Comprehensive Review of Mechanisms and Therapeutic Potential}. Digital Showcase Research, Scholarship, \& Creative Works (University of Lynchburg). [published; OpenAlex]. \href{https://digitalshowcase.lynchburg.edu/dmscjournal/vol8/iss1/6}{source link}.
\item Rachel N Clark (2026). \textit{The Use of Psilocybin for Managing Refractory Behavioral Health Conditions: A New and Promising Approach}. Digital Showcase Research, Scholarship, \& Creative Works (University of Lynchburg). [published; OpenAlex]. \href{https://digitalshowcase.lynchburg.edu/cgi/viewcontent.cgi?article=3694\&context=dmscjournal}{source link}.
\item University of New Mexico (2026). \textit{Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07506395}{source link}.
\item Washington University School of Medicine (2026). \textit{A Pilot Mechanistic Study of Psilocybin-Assisted Therapy as a Treatment for Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07582120}{source link}.
\item Centre for Addiction and Mental Health (2026). \textit{Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06299319}{source link}.
\item Hampus Yngwe, Pontus Plavén-Sigray, Carl Johan Ekman, Eva Henje, Anders Berglund, Mikael Tiger, Maria Beckman, J O Lundberg (2026). \textit{Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression}. JAMA Network Open. [published; OpenAlex]. \href{https://doi.org/10.1001/jamanetworkopen.2026.12589}{doi:10.1001/jamanetworkopen.2026.12589}.
\item Alan Davis (2026). \textit{Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07216404}{source link}.
\item Unknown authors (2026). \textit{Low doses of psilocybin as adjunct pharmacological treatment to virtual reality exposure therapy for social anxiety disorder: A study protocol for a double-blind randomized controlled trial.}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/3b9fx\_v1}{source link}.
\item Christina Chwyl, Alissa Bazinet, Adrianne R. Wilson-Poe, Kim Hoffman, Kellie Pertl, R. Cameron Wolf, P. Todd Korthuis, Jason B. Luoma (2026). \textit{Ethical Complexities and Best Practices in Informed Consent Processes for Psilocybin Services: A Qualitative Study}. Neuroethics. [published; OpenAlex]. \href{https://doi.org/10.1007/s12152-026-09645-5}{doi:10.1007/s12152-026-09645-5}.
\item COMPASS Pathways (2026). \textit{A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07570654}{source link}.
\item Bartłomiej Kosiarski, Anna Skrzypek, Patrycja Markowicz, Mikołaj Zbrożek, Krzysztof Biłyk, Maciej Hutkowski, Zuzanna Chwostek, Hanna Maruchniak, Wiktoria Marzec, Paulina Biedroń (2026). \textit{Rapid-acting interventions in treatment-resistant depression - a comparative review of esketamine and psilocybin}. Journal of Pre-Clinical and Clinical Research. [published; OpenAlex]. \href{https://doi.org/10.26444/jpccr/221219}{doi:10.26444/jpccr/221219}.
\item Andrew van der Vaart, Jeffrey LaPratt, Kimberly Swartz, Audrey Shoultz, Margo Lauterbach, Trisha Suppes, Harold A. Sackeïm, Scott T. Aaronson (2026). \textit{Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation}. The Journal of Clinical Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.4088/jcp.26m16338}{doi:10.4088/jcp.26m16338}.
\item Walters CK, Chetty S, Rants’o TA, Gossayn S, Lerotholi LJ. (2026). \textit{Safety and Efficacy of Psilocybin in the Management of Treatment-Resistant Depression: A Systematic Review}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-9283280/v1}{doi:10.21203/rs.3.rs-9283280/v1}.
\item Jessie Kim, Liam Lochhead, Cory R. Weissman (2026). \textit{From Trials to Clinics: Considerations for Implementing Psychedelic-Assisted Therapy Into Clinical Practice}. Pharmacology Research \& Perspectives. [published; OpenAlex]. \href{https://doi.org/10.1002/prp2.70262}{doi:10.1002/prp2.70262}.
\item John R. Kelly, Christopher Sheridan, Patricia Iusan, Lisa Coakley, Lisa Burke, C. Brennan, Annie Annie MacDonald, Jo-Hanna Ivers, Dominic Trepel, Garrath Tormey, Martha Finnegan, Gareth W. Young, Andrew Harkin (2026). \textit{Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland}. The International Journal of Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1093/ijnp/pyag028}{doi:10.1093/ijnp/pyag028}.
\item University Medical Center Groningen (2026). \textit{The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06782724}{source link}.
\item Centre for Addiction and Mental Health (2026). \textit{Does Psilocybin Require Psychedelic Effects to Treat Depression? A4-Week, Double-Blind, Proof-of-Concept Randomized Controlled Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05710237}{source link}.
\item Kinga Zachar, Maksymilian Sito, Filip Jurkowski, Łukasz Wójcik, Natalia Gawron, Hubert Tomasz Bojanowski, Aleksandra Dobracka, Zuzanna Marczak, Monika Jarowicz, Jędrzej Czmyr (2026). \textit{Psilocybin-Assisted Therapy in Depressive Disorders: Efficacy, Safety, and Persistence of Clinical Effects - A Narrative Review}. Journal of Education Health and Sport. [published; OpenAlex]. \href{https://doi.org/10.12775/jehs.2026.91.70672}{doi:10.12775/jehs.2026.91.70672}.
\item Peter S. Hendricks, Sara Lappan, Richard C. Shelton, Adrienne C. Lahti, Karen L. Cropsey, Matthew W. Johnson, Melissa Bradley, Otto Simonsson, Lori L. Davis, Daniel H. Grossman, Cynthia E. Ortiz (2026). \textit{Psilocybin in the Treatment of Cocaine Use Disorder}. JAMA Network Open. [published; OpenAlex]. \href{https://doi.org/10.1001/jamanetworkopen.2026.11029}{doi:10.1001/jamanetworkopen.2026.11029}.
\item Sunstone Medical (2026). \textit{A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With Cancer}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05947383}{source link}.
\item University of North Carolina, Chapel Hill (2026). \textit{Induction Protocol for Psilocybin-Assisted Therapy in Treatment-Resistant Depression (TRD): A Pilot Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06303739}{source link}.
\item Stanford University (2026). \textit{A Phase 2 Randomized Study Examining the Safety, Feasibility, and Effectiveness of Masking Psilocybin Therapy With General Anesthesia in Major Depressive Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07479550}{source link}.
\item Usona Institute (2026). \textit{A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-Control}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04353921}{source link}.
\item University of Washington (2026). \textit{A Phase 2 Sequential Dose-Finding Study of Preparation for Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07565909}{source link}.
\item Kevin H. Yang, Nora Satybaldiyeva, Wayne Kepner, Joseph Friedman, Siyuan Ping, Eric C. Leas (2026). \textit{Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults}. American Journal of Preventive Medicine. [published; OpenAlex]. \href{https://doi.org/10.1016/j.amepre.2026.108381}{doi:10.1016/j.amepre.2026.108381}.
\item Erin Mauney, Juliana Zambrano, Jenna Clukey, Helen Burton-Murray, Michael Datko, Vitaly Napadow, Braden Kuo, Franklin King (2026). \textit{Sa1731 A PILOT STUDY OF OPEN-LABEL PSILOCYBIN-ASSISTED THERAPY IN TREATMENT-REFRACTORY IBS}. Gastrointestinal Endoscopy. [published; OpenAlex]. \href{https://doi.org/10.1016/s0016-5107(26)04363-4}{doi:10.1016/s0016-5107(26)04363-4}.
\item Matthew Reid, Eli Weisman, Luis Luna Martinez, William Coon, Frederick Barrett (2026). \textit{1080 Psilocybin Elicits Non-Linear Night to Night Changes in Sleep Spectral Power}. SLEEP. [published; OpenAlex]. \href{https://doi.org/10.1093/sleep/zsag091.1079}{doi:10.1093/sleep/zsag091.1079}.
\item Gyandev Gupta, Ravina Yadav (2026). \textit{Role of Psychological support in sustaining Antidepressants effects in Psilocybin - Assisted Clinical}. JOURNAL OF ADVANCE AND FUTURE RESEARCH. [published; OpenAlex]. \href{https://doi.org/10.56975/jaafr.v4i5.509087}{doi:10.56975/jaafr.v4i5.509087}.
\item Zeina Beidas, Anya Ragnhildstveit, Adam Blackman, Thomas Anderson, Emily Fewster, Omer A. Syed, Valentyne Sobolenko, Ismail Kaan Kanca, Tatiana Son, Norman Farb, Rotem Petranker (2026). \textit{Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial - CORRIGENDUM}. BJPsych Open. [published; OpenAlex]. \href{https://doi.org/10.1192/bjo.2026.12000}{doi:10.1192/bjo.2026.12000}.
\item Nayak SM, Sepeda ND, Dick MN, Tiwari P, Zahid Z, Sayalı C, Weiss BM, Yaden DB, Garcia-Romeu A, Barnett BS, Barrett FS. (2026). \textit{Acute Cardiovascular Effects of Psilocybin: A Pooled Analysis of 14 Studies with Safety Recommendations}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.64898/2026.04.28.26351625}{doi:10.64898/2026.04.28.26351625}.
\item University Hospital, Basel, Switzerland (2026). \textit{Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05883540}{source link}.
\item Ellen Bradley, D Parker Kelley, Martin Picard, Balazs Szigeti, Kimberly Sakai, Gisele Fernandes, Jill Ostrem, Caroline Tanner, Patrick Finley, Connie Ludwig, Katiah Llerena, Zach Busby, Amber McKernan, Jose Rafael Zuzuarregui, Meredith Bock, Aliss Wang, Andrew Penn, Josh Woolley, Aoife O'Donovan (2026). \textit{356. Psilocybin Therapy is Associated With Decreases in Markers of Mitochondrial Stress and Inflammation in an Open-Label Clinical Trial of Parkinson’s Disease}. Biological Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.biopsych.2026.03.590}{doi:10.1016/j.biopsych.2026.03.590}.
\item Low ZXB. (2026). \textit{Serotonergic psychedelics for Autism spectrum disorder: Neurobiological mechanisms and translational prospects.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.pnpbp.2026.111717}{doi:10.1016/j.pnpbp.2026.111717}.
\item Portland VA Research Foundation, Inc (2026). \textit{Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04982796}{source link}.
\item Kyle Greenway (2026). \textit{Toward Patient-Tailored Care for Treatment-Resistant Depression: A Pilot Patient-Preference Clinical Trial of Music and Mindfulness in Psilocybin-Assisted Psychotherapy}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07373535}{source link}.
\item Deivid Antonio Cahuasqui-Mendoza (2026). \textit{Psilocybin as an alternative to conventional treatments: A systematic review}. Gaceta Médica de Caracas. [published; OpenAlex]. \href{https://doi.org/10.47307/gmc.2026.134.s2.32}{doi:10.47307/gmc.2026.134.s2.32}.
\item University of Colorado, Denver (2026). \textit{Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence in Patients Diagnosed With Early-stage Breast Cancer and Ovarian Cancer in Remission}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06430541}{source link}.
\item Mohsen Khosravi, Domenico De Berardis, Massimo Tusconi (2026). \textit{The efficacy and safety of psilocybin-assisted therapy for major depressive disorder: a meta-analytic review of clinical outcomes}. Mental Wellness. [published; OpenAlex]. \href{https://doi.org/10.4081/mw.2026.40}{doi:10.4081/mw.2026.40}.
\item Siti Nashria Rusdhy, Andrian Fajar Kusumadewi, Carla Raymondalexas Marchira, Mustika Suci Mahardikaningrum, Teresa Lalita Wiryarini, Devira Ayu Wulandari (2026). \textit{Efficacy and Safety of Psilocybin-Assisted Therapy for Depression: A Meta-Analysis of Randomised Controlled Trials}. Open Access Indonesian Journal of Medical Reviews. [published; OpenAlex]. \href{https://doi.org/10.37275/oaijmr.v6i2.883}{doi:10.37275/oaijmr.v6i2.883}.
\item Bhagavan C, Dandash O, Carter O, Bryson A, Kanaan RA. (2026). \textit{Sustained Effects of Low-to-Moderate Doses of Psilocybin on Brain Connectivity}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.64898/2026.04.17.26351147}{doi:10.64898/2026.04.17.26351147}.
\item Christopher S. Gondi, Manu Gnanamony, Tarun P. Gondi, Lilyt Nersesyan, Lusine Demirkhanyan (2026). \textit{Psychedelics and Autism Therapy: A Review of Current Research and Future Directions}. Current Issues in Molecular Biology. [published; OpenAlex]. \href{https://doi.org/10.3390/cimb48040417}{doi:10.3390/cimb48040417}.
\item Klintefors P, Bhagavan C, Kanaan R, Bryson A, Berlowitz D, Attard Z, Carter O. (2026). \textit{Psilocybin’s Kinematic Effect on Manual Dexterity}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-9291780/v1}{doi:10.21203/rs.3.rs-9291780/v1}.
\item Anthony L. Back, Bonnie A. McGregor, Leslie L. Thorn, Kalin Harvey, Dianna Blom, George Callan, John Guy, Sameet Kumar, Rob Hershberg, Melissa Layer, Jackie Levin, Susanna Myers, Juliana Perez, Kathy Salmonson, Peter Thompson, Joseph Whinney (2026). \textit{A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experience}. Frontiers in Public Health. [published; OpenAlex]. \href{https://doi.org/10.3389/fpubh.2026.1810904}{doi:10.3389/fpubh.2026.1810904}.
\item Section for Affective Disorders; Northern Stockholm Psychiatry (2026). \textit{CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06319378}{source link}.
\item J. Morgan Penberthy, Fatma Wise, Nicholas P. Cherup, Evaline Mitchell, Madeline Burns, Oluwafunmilayo Akinlade, David Chung, Harshit Parmar, Jonathan Singer (2026). \textit{Psilocybin for Treatment of Prolonged Grief Disorder: An Open-Label Feasibility Study Protocol}. Psychoactives. [published; OpenAlex]. \href{https://doi.org/10.3390/psychoactives5020012}{doi:10.3390/psychoactives5020012}.
\item Nikita Sanati Morel, Dea Siggaard Stenbaek, Johan Lundberg, Maria Beckman (2026). \textit{Evaluation of a facilitator training program in a randomized controlled trial of psilocybin treatment for depression}. BMC Medical Education. [published; OpenAlex]. \href{https://doi.org/10.1186/s12909-026-09124-8}{doi:10.1186/s12909-026-09124-8}.
\item S. Parker Singleton, Brooke L. Sevchik, Analiese Lahey, Pim Cuijpers, Mathias Harrer, Megan T. Jones, Sandeep M. Nayak, Eric C. Strain, Simon Vandekar, Robert H. Dworkin, J. Cobb Scott, Theodore D. Satterthwaite (2026). \textit{A living systematic review, meta-analysis and open-data resource of randomized controlled trials of psilocybin treatment for symptoms of depression}. Nature Mental Health. [published; OpenAlex]. \href{https://doi.org/10.1038/s44220-026-00630-8}{doi:10.1038/s44220-026-00630-8}.
\item University of Wisconsin, Madison (2026). \textit{Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06692192}{source link}.
\item University of Wisconsin, Madison (2026). \textit{Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of Psilocybin}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05866471}{source link}.
\item University Hospital, Basel, Switzerland (2026). \textit{Acute Analgesic Effects of DMT on Experimentally Induced Acute Nociceptive Pain, Hyperalgesia and Allodynia in Healthy Participants}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06180759}{source link}.
\item Shakila Meshkat, Manish K. Jha, Venkat Bhat (2026). \textit{Therapeutic Potential of Psilocybin in Psychiatric Disorders: Mechanisms, Efficacy, and Clinical Implications}. FOCUS The Journal of Lifelong Learning in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.focus.20250043}{doi:10.1176/appi.focus.20250043}.
\item Jordana Kazdan, Karim S. Ladha, M. Ishrat Husain (2026). \textit{Psychedelic Therapies for Comorbid Major Depressive Disorder and Chronic Pain: A Review of Putative Mechanisms of Action}. Pharmacology Research \& Perspectives. [published; OpenAlex]. \href{https://doi.org/10.1002/prp2.70238}{doi:10.1002/prp2.70238}.
\item Jon E. Grant, Sophia Boutouis, Margaret O’Brien, Laurie Avila, Megha Neelapu, Dustin Ehsan (2026). \textit{An Open-Label Study of Single-Dose Psilocybin for Borderline Personality Disorder With Co-Occurring Major Depressive Disorder}. Clinical Neuropharmacology. [published; OpenAlex]. \href{https://doi.org/10.1097/wnf.0000000000000683}{doi:10.1097/wnf.0000000000000683}.
\item Kenji Hashimoto, Feyza Arıcıoğlu, Mesut Çetin (2026). \textit{Therapeutic Potential of Classical Psychedelics and NonHallucinogenic Psychoplastogens in Psychiatric Disorders}. Psychiatry and Clinical Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.65801/pcp.3512}{doi:10.65801/pcp.3512}.
\item Sunnybrook Health Sciences Centre (2026). \textit{Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06072898}{source link}.
\item Indiana University (2026). \textit{Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07499583}{source link}.
\item Linda M. Richmond (2026). \textit{MedCheck: FDA Approves Novel Antipsychotic Milsaperidone; Designates Psilocybin Analogue as Breakthrough Therapy for Postpartum Depression, and More!}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2026.04.4.3}{doi:10.1176/appi.pn.2026.04.4.3}.
\item Yves Martins Varela, Vagner Deuel de O Tavares, Luiza Macedo Delgado, Heitor Augusto Trindade de Faria, Lucas Queiroz Menezes, R. Z. H. Almeida, Pedro Moraes Dutra Agrícola, Bruna Santos de Carvalho, Bheatrix Bienemann, Marcelo Falchi-Carvalho, Patrícia Cavalcanti-Ribeiro, Fernanda Palhano-Fontes, Gisele Fernandes-Osterhold, Dráulio Barros de Araújo, Nicole Leite Galvão-Coelho (2026). \textit{Mapping cognitive-behavioral approach in psychedelic-assisted treatment: a systematic review across phases with classic and non-classic psychedelics}. European Archives of Psychiatry and Clinical Neuroscience. [published; OpenAlex]. \href{https://doi.org/10.1007/s00406-025-02188-5}{doi:10.1007/s00406-025-02188-5}.
\item Federal University of Latin American Integration (2026). \textit{Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06898606}{source link}.
\item Aly Shah Aziz (2026). \textit{Classic psychedelic medicines for adolescent refractory mental health disease}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2026.00452}{doi:10.1556/2054.2026.00452}.
\item Unknown authors (2026). \textit{Safety and Efficacy of Psilocybin-Assisted Therapy for Alcohol Use Disorder: Open-Label Extension of a Phase II Randomized Controlled Trial}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/7xfek\_v1}{source link}.
\item Piotr Skalski, Katarzyna Pękacka-Falkowska, Agnieszka Pluto-Prądzyńska, Michał K. Owecki (2026). \textit{Psilocybin in Neuropsychiatric Disorders: Seeking Valuable Evidence in History, Pure Science, Clinical Trials and Real-World Data (RWD)}. Brain Sciences. [published; OpenAlex]. \href{https://doi.org/10.3390/brainsci16040358}{doi:10.3390/brainsci16040358}.
\item Anders Fink-Jensen, MD, DMSci (2026). \textit{The QUANTUM Trip Trial - Psilocybin-assisted Therapy for Reducing Alcohol Intake in Patients With Alcohol Use Disorder: A Randomized, Double-blinded, Placebo-controlled Clinical Trial.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05416229}{source link}.
\item Medical University of Vienna (2026). \textit{Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects: A Randomized, Open-Label, Cross-Over Functional Magnetic Resonance Imaging Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07490353}{source link}.
\item Shivaputra A. Patil, Holly C. Hunsberger (2026). \textit{Psilocybin: Chemical Foundations and Emerging Therapeutic Potential}. Mini-Reviews in Medicinal Chemistry. [published; OpenAlex]. \href{https://doi.org/10.2174/0113895575429775260119043318}{doi:10.2174/0113895575429775260119043318}.
\item Donatella Marazziti, Matteo Gambini, Riccardo Gurrieri, Gerardo Russomanno, Giorgia Sità, Elena Pescini, FRANCESCA RITA DIGIUSEPPE, Federico Mucci (2026). \textit{Psychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations}. Expert Opinion on Pharmacotherapy. [published; OpenAlex]. \href{https://doi.org/10.1080/14656566.2026.2654682}{doi:10.1080/14656566.2026.2654682}.
\item Malkanthi Evans, Andrew Charrette (2026). \textit{Editorial: Psychedelic-assisted psychotherapies: from clinical trials to credibility}. Frontiers in Neuroscience. [published; OpenAlex]. \href{https://doi.org/10.3389/fnins.2026.1816932}{doi:10.3389/fnins.2026.1816932}.
\item Taro Kishi, Kenji Sakuma, Masakazu Hatano, Hiroyuki Uchida, Nakao Iwata (2026). \textit{Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysis}. Journal of Affective Disorders. [published; OpenAlex]. \href{https://doi.org/10.1016/j.jad.2026.121675}{doi:10.1016/j.jad.2026.121675}.
\item Centre for Addiction and Mental Health (2026). \textit{Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand Mechanism}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06731621}{source link}.
\item Bonnie Brusky, Katia M’Baïlara, François Alla, M. Barrault (2026). \textit{Psychological support in psychedelic-assisted therapy clinical trials: A systematic review}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811261424204}{doi:10.1177/02698811261424204}.
\item Anna Komarczewska, Michał Kociński, Patryk Iglewski, Michał Pietrasz, Jakub Idziński, Anna Lubomska (2026). \textit{PSILOCYBIN AS AN ADJUNCTIVE TREATMENT FOR DEPRESSION AND PSYCHOLOGICAL DISTRESS IN ONCOLOGY: CURRENT EVIDENCE AND CLINICAL IMPLICATIONS}. International Journal of Innovative Technologies in Social Science. [published; OpenAlex]. \href{https://doi.org/10.31435/ijitss.1(49).2026.5034}{doi:10.31435/ijitss.1(49).2026.5034}.
\item Gustavo Vazquez (2026). \textit{Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer: a Pilot Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06818994}{source link}.
\item Centre for Addiction and Mental Health (2026). \textit{Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07211438}{source link}.
\item Lea J. Mertens, Michael Koslowski, Felix Betzler, Manuela Brand, Ricarda Evens, Laura Kärtner, Andrea Jungaberle, Henrik Jungaberle, Tomislav Majić, Christian N. Schmitz, Andreas Ströhle, Dennis Scharf, Moritz Spangemacher, Max Wolff, Zahra Assadi, Scharif Bahri, Lilith Becher, Luca V. Färber, Niklas Kirchen, Eugenia Kulakova, Linda C. Kunz, Andy Meijer, Barbara Rohrmoser, Stefan Wellek, Moritz Berger, Gerhard Gründer (2026). \textit{Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression}. JAMA Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1001/jamapsychiatry.2026.0132}{doi:10.1001/jamapsychiatry.2026.0132}.
\item Alessandra Linardi, Ariadiny Lima Caetano, Rodrigo Portes Ureshino (2026). \textit{Editorial: Psychedelic substances and neurological diseases: from basics to clinical application}. Frontiers in Pharmacology. [published; OpenAlex]. \href{https://doi.org/10.3389/fphar.2026.1816812}{doi:10.3389/fphar.2026.1816812}.
\item Akey Sungheetha, R. Rajesh Sharma, Oluwasegun Julius Aroba, Sheila Mahapatra, P. D. Mahendhiran (2026). \textit{Explainable AI framework for psilocybin depression treatment optimization}. Frontiers in Computer Science. [published; OpenAlex]. \href{https://doi.org/10.3389/fcomp.2025.1652190}{doi:10.3389/fcomp.2025.1652190}.
\item Marc-Antoine Crocq, Philippe Auby (2026). \textit{The renaissance of research on psychedelics in child and adolescent psychopharmacology}. Child and Adolescent Psychiatry and Mental Health. [published; OpenAlex]. \href{https://doi.org/10.1186/s13034-026-01069-6}{doi:10.1186/s13034-026-01069-6}.
\item Francisco A. Moreno, Katja Ehrmann Allen, Christopher B. Wiegand, Rajan Dunne, James I. Prickett, Brian Bayze, John J. B. Allen (2026). \textit{A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorder}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811261424214}{doi:10.1177/02698811261424214}.
\item Yale University (2026). \textit{Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06442423}{source link}.
\item Gregorio GD, Basset S, Manmohan H, Nixon WC, Pogaku A, Zhou J, Sanderson DJ, Lengieza ML, Bocchio M. (2026). \textit{Age moderates the relationship between psychedelics use and mental health in naturalistic settings}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-9022170/v1}{doi:10.21203/rs.3.rs-9022170/v1}.
\item Vorawut Wongumpornpinit, K Ingkaninan, Prapapan Temkitthawon, Neti Waranuch, Rhannanda Copetti Pivetta, Jieyu Zuo, Gabriel Lima Barros de Araújo, Nádia Bou-Chacra, Vijay Somayaji, Raimar Löebenberg (2026). \textit{Impact of formulation variables on the quality attributes of psilocybin-loaded oral thin films for early-phase development}. Journal of Drug Delivery Science and Technology. [published; OpenAlex]. \href{https://doi.org/10.1016/j.jddst.2026.108228}{doi:10.1016/j.jddst.2026.108228}.
\item MW Johnson, Gideon P. Naudé, Peter S. Hendricks, Albert Garcia-Romeu (2026). \textit{Psilocybin or Nicotine Patch for Smoking Cessation}. JAMA Network Open. [published; OpenAlex]. \href{https://doi.org/10.1001/jamanetworkopen.2026.0972}{doi:10.1001/jamanetworkopen.2026.0972}.
\item Suzanne "Sue" Sisley MD (2026). \textit{An Open-Label, Phase 1 Study of the Safety Pharmacokinetic Profile, and Preliminary Efficacy, of Organic Whole Psilocybin-Containing Mushrooms in Patients Suffering From PTSD}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07275970}{source link}.
\item Region Skane (2026). \textit{The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young Adults}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07169747}{source link}.
\item Jennifer E. Thomas, Anna Dellarole, Joshua Caballero (2026). \textit{Efficacy and risks of psychedelics in the treatment of posttraumatic stress disorder: A systematic review}. American Journal of Health-System Pharmacy. [published; OpenAlex]. \href{https://doi.org/10.1093/ajhp/zxag062}{doi:10.1093/ajhp/zxag062}.
\item Psyence Australia Pty Ltd (2026). \textit{A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07072728}{source link}.
\item Bo Jarrett Wood, M. Frances Vest, Catharine Carfagno, Kyla Rose Bartley, Papori Sharma, Adam L. Halberstadt, Bruce E. Blough, Kevin S. Murnane (2026). \textit{Differential Effects of Acute and Chronic Fluoxetine on Psychedelic-Induced Behavior in Mice: Implications for Clinical Trials}. ACS Pharmacology \& Translational Science. [published; OpenAlex]. \href{https://doi.org/10.1021/acsptsci.5c00484}{doi:10.1021/acsptsci.5c00484}.
\item Samuel E. Williamson, Elise K. Burkhartzmeyer, Michael T. Faley, Rachel Friedman Ohana, Ilia A. Guzei, Mike Valley, James J. Cali, Alexander M. Sherwood (2026). \textit{Synthesis and Characterization of Psilocybin Metabolites and Deuterated Analogs}. ACS Chemical Neuroscience. [published; OpenAlex]. \href{https://doi.org/10.1021/acschemneuro.5c00879}{doi:10.1021/acschemneuro.5c00879}.
\item Ana Deutsch, Luis E. Contreras, Sarah Kratina, Leah M. Mayo (2026). \textit{A scoping review of mystical-type experiences and mood symptom outcomes in psychedelic therapy clinical trials: comparing life-threatening disease and depressive populations}. Therapeutic Advances in Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/20451253261433836}{doi:10.1177/20451253261433836}.
\item Alexander WB, Hansen ED, Anderson BT, Zarrabi AJ, Rogers AH, Loewen G, Ficarro ZR, Alexander MH, Schaefer D, Case AA (2026). \textit{Meaning and Psychedelics in Palliative Care: A Narrative Review.}. Journal of pain and symptom management. [published; PubMed]. \href{https://doi.org/10.1016/j.jpainsymman.2025.10.015}{doi:10.1016/j.jpainsymman.2025.10.015}.
\item Rosalind McAlpine, Magdalena Jaglinska, Krisztina Jedlovszky, Joanna Kuc, Ariel Castro, Alexandre Piot, Christopher Timmermann, Jeremy I Skipper, Matthew D Sacchet, Sunjeev K. Kamboj (2026). \textit{Digital Intervention for Psychedelic Preparation (DIPP): protocol for a randomised controlled feasibility trial comparing meditation- and music-based programmes in healthy volunteers}. BMJ Open. [published; OpenAlex]. \href{https://doi.org/10.1136/bmjopen-2025-107512}{doi:10.1136/bmjopen-2025-107512}.
\item C Faria, Diana Dias da Silva, João José Sousa (2026). \textit{Psilocybin-assisted therapy for major depressive disorder: implications for clinical effectiveness, health economics, and regulatory decision-making}. Instituto Politécnico do Porto. [published; OpenAlex]. \href{https://doi.org/10.26537/prpaeh.v4i3.7173}{doi:10.26537/prpaeh.v4i3.7173}.
\item Alex Gearin, Jennifer Docherty, Xiaofan Sun, Emmanuel Hei-Lok Cheung, Peter Tanuseputro (2026). \textit{Psychedelic therapy and cultural humility}. Translational Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1038/s41398-026-03913-x}{doi:10.1038/s41398-026-03913-x}.
\item Linda M. Richmond (2026). \textit{MedCheck: FDA Reviews NDA for Narcolepsy Drug, Green-Lights Psilocybin Trial for PTSD, and More}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2026.03.3.5}{doi:10.1176/appi.pn.2026.03.3.5}.
\item Kengo Yonezawa, M. Hirata, Hiroaki Takano, Keisuke Kusudo, Sota Tomiyama, Lisa Harada, Kota Suzuki, DJ Nutt, H. Uchida, Hideaki Tani (2026). \textit{Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations}. Psychiatry and Clinical Neurosciences. [published; OpenAlex]. \href{https://doi.org/10.1111/pcn.70042}{doi:10.1111/pcn.70042}.
\item Centre for Addiction and Mental Health (2026). \textit{Does Psilocybin Change Synaptic Density in the Brains of Patients With Amnestic Mild Cognitive Impairment}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06041152}{source link}.
\item Albert Garcia-Romeu, Gideon P. Naudé, Alison W. Rebman, Sara So, Abigail Yaffe, Ian Geithner, Erica A. Kozero, Ting Yang, Mark J. Soloski, John N. Aucott (2026). \textit{Pilot study of psilocybin in patients with post-treatment lyme disease}. Scientific Reports. [published; OpenAlex]. \href{https://doi.org/10.1038/s41598-026-38091-9}{doi:10.1038/s41598-026-38091-9}.
\item van der Meer PB, Schukking N, Dik M, van Reemst A, Fuentes JJ, Kaptein AA, Schoones JW, Verboeket S, de Waal MM, Goudriaan AE, Kramers C, Schellekens A, Bossong MG, Somers M, Batalla A. (2026). \textit{Efficacy and Safety of Psychoactive Tryptamines in Addiction: A Systematic Review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/28314425251364182}{doi:10.1177/28314425251364182}.
\item Johns Hopkins University (2026). \textit{Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06005662}{source link}.
\item Petranker R, Farb N, Syed O, Li E, Shore D, Anderson T, Blackman A. (2026). \textit{Safety and Efficacy of Microdosing Psilocybin over 8 Weeks for Major Depressive Disorder: A Randomized Clinical Trial}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-8319478/v1}{doi:10.21203/rs.3.rs-8319478/v1}.
\item Edward Jacobs, Zarmeen Zahid, Jared T. Hinkle, Sandeep M. Nayak, David B Yaden (2026). \textit{Psychedelic medicine: mechanisms, evidence, and translation to practice}. BMJ. [published; OpenAlex]. \href{https://doi.org/10.1136/bmj-2024-081723}{doi:10.1136/bmj-2024-081723}.
\item Unknown authors (2026). \textit{Ethical Complexities and Best Practices in Informed Consent for Psychedelic Services: A Qualitative Study on Expert Perspectives}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/mdz73\_v2}{source link}.
\item Jordan McDowell, Jada Middleton, Alanna Bluett, Alisa Kozachenko, Bayan Attar, Yuvraj Singh Saini, Jennifer Burke, Cayden McPhee, Mutahera Mutahera, Talya Ahmed, Nabila Ibrahim, Gilbert Atukwatsibwe, Sulabha Adhikari, Mohammad Esmaili, Jean-Vital Yambayamba (2026). \textit{Effects of Psilocybin and Select Pharmaceutical Interactions}. MacEwan University Student eJournal. [published; OpenAlex]. \href{https://doi.org/10.31542/bcek6t76}{doi:10.31542/bcek6t76}.
\item Zaynab Khan, Sterre Weaver, Rachael V. Dando, Anne Katrin Schlag, Joanna C. Neill, Verity Wainwright (2026). \textit{Sense-Making Around Psilocybin in UK Women Experiencing Cancer-Related Existential Distress: An Interpretative Phenomenological Analysis}. Qualitative Health Research. [published; OpenAlex]. \href{https://doi.org/10.1177/10497323261419338}{doi:10.1177/10497323261419338}.
\item Unknown authors (2026). \textit{Mindfulness-Based Psilocybin-Assisted Therapy (MB-PAT) for cancer-related demoralization in Canada: the case for a hybrid group-based delivery model}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/yrgkf\_v1}{source link}.
\item Zeina Beidas, Anya Ragnhildstveit, Adam Blackman, Thomas Anderson, Emily C. Fewster, Omer A. Syed, Valentyne Sobolenko, Ismail Kaan Kanca, Magdalena Jaglinska, Tatiana Son, Norman Farb, Rotem Petranker (2026). \textit{Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial}. BJPsych Open. [published; OpenAlex]. \href{https://doi.org/10.1192/bjo.2025.10968}{doi:10.1192/bjo.2025.10968}.
\item Marc J. Weintraub, Jessica Jeffrey, Megan Ichinose, R. Lindsey Bergman, Benjamin Shapiro, Gregory Barnett, Hewa Artin, Marc Lynn, Anabel Salimian, Shelby Grody, Rahul Ramesh, Lauren Eales, Charles S. Grob, David J. Miklowitz (2026). \textit{Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial}. Journal of Affective Disorders. [published; OpenAlex]. \href{https://doi.org/10.1016/j.jad.2026.121423}{doi:10.1016/j.jad.2026.121423}.
\item MycoMedica Life Sciences PBC (2026). \textit{A Phase 1 Translational Study to Assess Brain Activity Using Functional Magnetic Resonance Imaging (fMRI) and to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07050368}{source link}.
\item Johns Hopkins University (2026). \textit{Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07053917}{source link}.
\item Sean P. Goldy, Nathan D. Sepeda, Samantha Hilbert, Bilal A. Bari, Albert Garcia-Romeu, Natalie Gukasyan, Frederick S. Barrett, David B. Yaden, Sandeep M. Nayak (2026). \textit{Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones}. Psychiatry Research. [published; OpenAlex]. \href{https://doi.org/10.1016/j.psychres.2026.117010}{doi:10.1016/j.psychres.2026.117010}.
\item Amanda L. Elyse (2026). \textit{Psilocybin and Animal Testing: Charting an End to the Use of Animals in Drug Development Research}. Digital Commons at University of Maryland Carey Law (University of Maryland Francis King Carey School of Law). [published; OpenAlex]. \href{https://digitalcommons.law.umaryland.edu/cgi/viewcontent.cgi?article=1002\&context=jhclp\_online\_issue}{source link}.
\item Rafael Lancelotta, Paul Nagib, Stacey B. Armstrong, Adam W. Levin, A. B. Davis (2026). \textit{Development and assessment of a psychedelic-assisted therapy music playlist for clinical trials: Theory, intentionality, and metrics}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2026.00462}{doi:10.1556/2054.2026.00462}.
\item Trent Emerick (2026). \textit{Single Dose Psilocybin for a Post-surgical Trauma Inpatient Population for Pain, Mood, and Opioid Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07406828}{source link}.
\item Centre for Addiction and Mental Health (2026). \textit{Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder: A Pilot Randomized Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07405606}{source link}.
\item Matthew Hicks, Olivia Hicks, Ryan Bradley, Heather Zwickey (2026). \textit{Low-income group psilocybin assisted therapy for depression: An Oregon feasibility study}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2026.00485}{doi:10.1556/2054.2026.00485}.
\item Johnston J, Jones G, Peng S, Yuan P, Yavi M, Kadriu B, Henter I, Quintanilla B, Elkahloun AG, Moaddel R, Schulmann A, Akula N, Kvarta M, McMahon F, Zarate C. (2026). \textit{Time-Dependent Effects of Rapid-Acting Antidepressants in iPSC-Derived Neurons from Treatment-Resistant Depression and Healthy Volunteers}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-8733841/v1}{doi:10.21203/rs.3.rs-8733841/v1}.
\item Ziping He, Yijie Wang, Jie Chen, Junzhe Cheng, Yuxin Feng, Shuliang Niu, J. Yan (2026). \textit{Therapeutic effects of psilocybin in major depressive disorder: a systematic review and meta-analysis exploring dose effects}. European Archives of Psychiatry and Clinical Neuroscience. [published; OpenAlex]. \href{https://doi.org/10.1007/s00406-025-02165-y}{doi:10.1007/s00406-025-02165-y}.
\item Erica Kaczmarek, Nelson B. Rodrigues, Noah Chisamore, Zoe Doyle, Shakila Meshkat, Marc G. Blainey, Ryan M. Brudner, Shaun Ali, Kayla M. Teopiz, Roger S. McIntyre, Joshua D. Rosenblat (2026). \textit{Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression}. Journal of Affective Disorders. [published; OpenAlex]. \href{https://doi.org/10.1016/j.jad.2026.121385}{doi:10.1016/j.jad.2026.121385}.
\item Chiranth Bhagavan, Olivia P. Carter, Alexander Bryson, Orwa Dandash, Richard Kanaan (2026). \textit{Psychedelics in functional disorders: A scoping review}. Progress in Neuro-Psychopharmacology and Biological Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.pnpbp.2026.111642}{doi:10.1016/j.pnpbp.2026.111642}.
\item Hadassah Medical Organization (2026). \textit{Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07079930}{source link}.
\item TRYP Therapeutics (2026). \textit{A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Oral Psilocybin (TRP-8802) Administration in Concert With Psychotherapy Among Adult Patients With Irritable Bowel Syndrome: A Randomized Delayed Treatment Control Design}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06206265}{source link}.
\item Nantes University Hospital (2026). \textit{Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER: a Pilot Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07391332}{source link}.
\item Benjamin R. Lewis, M. Carrington Reid, Andrew M. Novick, Kevin Byrne, Mark J. Niciu, Gregory A. Fonzo, Thomas D. Meyer, David Feifel, Rif S. El-Mallakh, Jair Soares, Trisha Suppes, Frederick S. Barrett (2026). \textit{Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers’ task group on psychedelics and related compounds}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811251413490}{doi:10.1177/02698811251413490}.
\item Junhong Liu, Y. Lynn Wang, Ke Xia, Jia-Bin Wu, Danhao Zheng, Aoling Cai, Haitao Yan, Ruibin Su (2026). \textit{Acute psilocin increased cortical activity in rat}. Frontiers in Neuroscience. [published; OpenAlex]. \href{https://doi.org/10.3389/fnins.2026.1593703}{doi:10.3389/fnins.2026.1593703}.
\item Swainson J, Brietzke E, Khullar A, McIntyre RS, Soares CN (2026). \textit{Ketamine, Psychedelics, and Psychotherapy: Reframing, Redefining, Renaming Treatment Models.}. Canadian journal of psychiatry. Revue canadienne de psychiatrie. [published; PubMed]. \href{https://doi.org/10.1177/07067437251389090}{doi:10.1177/07067437251389090}.
\item Rachel Ham, John Gardner, Adrian Carter, Paul Liknaitzky (2026). \textit{Participant Experiences of Therapeutic Touch in Psilocybin-Assisted Therapy}. Brain and Behavior. [published; OpenAlex]. \href{https://doi.org/10.1002/brb3.71262}{doi:10.1002/brb3.71262}.
\item Anna Maria Komarczewska, Filip Matusiak, Klaudia Brzoza, Michał Kociński, Patryk Iglewski, Michał Pietrasz (2026). \textit{Psilocybin-Induced Neuroplasticity and Sustained Antidepressant Effects}. Quality in Sport. [published; OpenAlex]. \href{https://doi.org/10.12775/qs.2026.51.68216}{doi:10.12775/qs.2026.51.68216}.
\item James Downar, Julie Lapenskie, Koby Anderson, Gaelle Parsons, Nadia Polskaia, Genevieve Lalumiere, Peter G. Lawlor (2026). \textit{PSilocybin for psYCHological and existential distress in PALliative care (PSYCHED-PAL): A single arm unblinded clinical trial}. Palliative Medicine. [published; OpenAlex]. \href{https://doi.org/10.1177/02692163261416269}{doi:10.1177/02692163261416269}.
\item Łukasz Deska, Cezary Kosmecki, Dawid Głaz, Natalia Kamińska, Wojciech Sołtys, Magdalena Stolarczyk, Maksymilian Głaz, Mateusz Stronczyński, Aleksandra Jagura-Sukiennik, Julia Wawerska (2026). \textit{PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION}. International Journal of Innovative Technologies in Social Science. [published; OpenAlex]. \href{https://doi.org/10.31435/ijitss.1(49).2026.4711}{doi:10.31435/ijitss.1(49).2026.4711}.
\item Rayyan Raja Zafar, Patrick Kleine, Danielle L. Kurtin, Matthew B. Wall, David Erritzoe (2026). \textit{High hopes? Precision psychedelic addiction medicine}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2025.1681795}{doi:10.3389/fpsyt.2025.1681795}.
\item Mohsin Raza, Jasleen Kaur (2026). \textit{A Promise Without Panacea: Psychedelic-Assisted Therapies in Modern Psychiatry}. Cureus. [published; OpenAlex]. \href{https://doi.org/10.7759/cureus.102421}{doi:10.7759/cureus.102421}.
\item Cheng-Teng Ip, Sebastian Olbrich, Mateo de Bardeci, Anna Monn, Andres Ort, John W. Smallridge, Franz Vollenweider (2026). \textit{Psilocybin-induced alterations in EEG power, connectivity and network dynamics in healthy subjects: Correlations with subjective experience and implications for therapeutic applications}. Progress in Neuro-Psychopharmacology and Biological Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.pnpbp.2026.111626}{doi:10.1016/j.pnpbp.2026.111626}.
\item Adam Wolski, Ewa Szplit, Mikołaj Franciszek Patalong, Roman Cemaga, Mateusz Kubicki, Przemysław Kołodziej, Natalia Bruska, Bartłomiej Błaszkowski, Andrii Bilyk, Katarzyna Więckowska (2026). \textit{Psychedelics in psychiatric treatment: a literature review}. Quality in Sport. [published; OpenAlex]. \href{https://doi.org/10.12775/qs.2026.50.68013}{doi:10.12775/qs.2026.50.68013}.
\item Fernando Mora López, Johynny Solís Solís, Ekaterina Daniela Hernández Baker, Olger Herrera Barboza, David Diaz Polo, Daniela Consumi Cordero (2026). \textit{The therapeutic efficacy of psilocybin in major depressive disorder: A review of recent clinical and mechanistic evidence}. Zenodo (CERN European Organization for Nuclear Research). [published; OpenAlex]. \href{https://doi.org/10.5281/zenodo.18375715}{doi:10.5281/zenodo.18375715}.
\item Rishika Scott, James Smith (2026). \textit{The Evaluation of the Efficacy and Safety of the Use of Psilocybin in the Treatment of Adults with Treatment-Resistant Depression}. Emerging Minds Journal for Student Research. [published; OpenAlex]. \href{https://doi.org/10.59973/emjsr.317}{doi:10.59973/emjsr.317}.
\item Omer A. Syed, Benjamin Tsang, Sean M. Nestor, Nir Lipsman, Muhammad Ishrat Husain, Fahad Alam, Peter Giacobbe (2026). \textit{Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis}. Neuroscience \& Biobehavioral Reviews. [published; OpenAlex]. \href{https://doi.org/10.1016/j.neubiorev.2026.106573}{doi:10.1016/j.neubiorev.2026.106573}.
\item NYU Langone Health (2026). \textit{A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone Treatment}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06796062}{source link}.
\item Jakub Klepacz, Radosław Swędrak, Marzena Swojnóg, Zuzanna Dobrakowska (2026). \textit{THE PSYCHEDELIC RENAISSANCE: A SYSTEMATIC REVIEW OF PSILOCYBIN AND LSD IN THE TREATMENT OF PSYCHIATRIC DISORDERS}. International Journal of Innovative Technologies in Social Science. [published; OpenAlex]. \href{https://doi.org/10.31435/ijitss.1(49).2026.4582}{doi:10.31435/ijitss.1(49).2026.4582}.
\item Marija Franka Žuljević, Antonija Mijatović, Renata Orhanović, Glenn Goasdoué, Diana Gujinović (2026). \textit{Consistency of protocol and safety data reporting in clinical trial registrations and corresponding publications of interventions involving MDMA and psilocybin}. Journal of Clinical Epidemiology. [published; OpenAlex]. \href{https://doi.org/10.1016/j.jclinepi.2026.112170}{doi:10.1016/j.jclinepi.2026.112170}.
\item Tripdatabase (2026). \textit{Is psilocybin only effective as part of psychotherapy?}. Zenodo (CERN European Organization for Nuclear Research). [published; OpenAlex]. \href{https://doi.org/10.5281/zenodo.18339347}{doi:10.5281/zenodo.18339347}.
\item Florineth, Gianluca Andri, Klima, Isabell, Boeker, Anna Laura, Catzeflis, Polina, Wopfner, Alexander, Denier, Niklaus, Bracht, Tobias, Adorjan, Kristina, Pfammatter, Mario, Müller, Felix, Soravia, Leila Maria (2026). \textit{Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy: A Systematic Review and Meta-Analysis.}. Open Access CRIS of the University of Bern. [published; OpenAlex]. \href{https://doi.org/10.48620/94398}{doi:10.48620/94398}.
\item Gianluca Andri Florineth, Isabell Klima, Anna Laura Boeker, Polina Catzeflis, Alexander Wopfner, Niklaus Denier, Tobias Bracht, Kristina Adorjan, Mario Pfammatter, Felix Müller, Leila Maria Soravia (2026). \textit{Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy}. JAMA Network Open. [published; OpenAlex]. \href{https://doi.org/10.1001/jamanetworkopen.2025.54843}{doi:10.1001/jamanetworkopen.2025.54843}.
\item Zoe Doyle, Noah Chisamore, Erica Kaczmarek, Danica E. Johnson, Ryan M. Brudner, Geneva Weiglein, Marc G. Blainey, Jordan Bawks, Jeremy Riva-Cambrin, Rickinder Sethi, Roger S. McIntyre, Joshua D. Rosenblat (2026). \textit{Early response to psilocybin in adults with treatment-resistant depression as a predictor for antidepressant efficacy}. General Hospital Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.genhosppsych.2026.01.001}{doi:10.1016/j.genhosppsych.2026.01.001}.
\item Anthony L. Back, Bonnie A. McGregor, Leslie Lazar Thorn, Kelsey K. Baker, T. Gooley, Mendel Kaelen, Kalin Harvey, John M. Guy, Susanna Myers, Juliana Pérez, Peter Thompson, Lindsay Billingsley, Cheryl Sesnon (2026). \textit{Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 Study}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1177/28314425251413856}{doi:10.1177/28314425251413856}.
\item Damian Świeczkowski, Aleksander Kwaśny, Krzysztof Sadko, Wiesław Jerzy Cubała (2026). \textit{Bridging the reporting gap: Application of the ReSPCT guidelines in psilocybin clinical trial protocols}. European Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1016/j.euroneuro.2025.112746}{doi:10.1016/j.euroneuro.2025.112746}.
\item Unknown authors (2026). \textit{Psilocybin for Treatment-Resistant OCD: A Randomized Controlled Trial}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/atfum\_v1}{source link}.
\item Celia Faye Jacobsen, Dea Siggaard Stenbæk, Stig Poulsen, Sophia Armand (2026). \textit{The Psychological Support Model in Psilocybin Research: Psychotherapy in Disguise?}. Psychiatric Research and Clinical Practice. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.prcp.20250113}{doi:10.1176/appi.prcp.20250113}.
\item COMPASS Pathways (2026). \textit{A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05711940}{source link}.
\item Zaynab Khan, Sterre Weaver, Rachael V. Dando, Anne Katrin Schlag, Joanna; id\_orcid 0000-0002-2717-9739 Neill, Verity; id\_orcid 0000-0002-9876-250X Wainwright (2026). \textit{Sense-making around psilocybin in UK women experiencing cancer-related existential distress: An Interpretative Phenomenological Analysis}. Research Explorer (The University of Manchester). [published; OpenAlex]. \href{https://research.manchester.ac.uk/en/publications/6f070f13-96c6-4cc4-9e40-f2837bdb79b3}{source link}.
\item Matheus G. Marques, Liliana Patarroyo-Rodríguez, Balwinder Singh (2026). \textit{Psilocybin and Bipolar Depression: Promise and Prudence}. CNS Drugs. [published; OpenAlex]. \href{https://doi.org/10.1007/s40263-025-01255-8}{doi:10.1007/s40263-025-01255-8}.
\item Reza Moshfeghinia, Sara Mostafavi, Kimia Jazi, Amir Reza Ghasemi, Yasamin Khosravaninezhad, Santhosshi Narayanan, Jamshid Ahmadi, Mehdi Pasalar (2026). \textit{The effects of psilocybin on psychological distress in cancer patients: a systematic review and meta-analysis}. BMC Psychology. [published; OpenAlex]. \href{https://doi.org/10.1186/s40359-025-03935-y}{doi:10.1186/s40359-025-03935-y}.
\item Marta Gómez Álvarez, Javier Calleja-Conde, Víctor Echeverry-Alzate (2025). \textit{Psychedelics and Mental Health: Psilocybin and Depression. A Sistematic Review}. Open Science Framework. [published; OpenAlex]. \href{https://doi.org/10.17605/osf.io/yu3n9}{doi:10.17605/osf.io/yu3n9}.
\item E. Lopez, J O Lundberg, F. Hieronymus, M. Beckman, H. Yngwe, C.J. Ekman, M. Tiger, N. Edvall (2025). \textit{Symptom-level antidepressant response to psilocybin: exploratory outcomes comparing psilocybin treatment to niacin}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2026.106904}{doi:10.1016/j.nsa.2026.106904}.
\item Yosr Ziadi, Taehwan Park (2025). \textit{Cost-Effectiveness of Psilocybin-Assisted Therapy (PAT) for Patients with Treatment-Resistant Depression}. Open MIND. [published; OpenAlex]. \href{https://doi.org/10.17605/osf.io/nrt59}{doi:10.17605/osf.io/nrt59}.
\item Stefan Jerotić, Olga Čolović, Nađa Marić (2025). \textit{Psychedelic-assisted psychotherapy: Clarifying the role of the "psychotherapy"}. Medicinska istrazivanja. [published; OpenAlex]. \href{https://doi.org/10.5937/medi0-62051}{doi:10.5937/medi0-62051}.
\item Hannah Whitmore, Maria Mangini, Heather Leutwyler, Brian Anderson (2025). \textit{Facing Mortality Together: A Constructivist Grounded Theory Analysis of Group Psilocybin Therapy Among Older Long-Term AIDS Survivor Gay Men}. Palliative Medicine Reports. [published; OpenAlex]. \href{https://doi.org/10.1177/26892820251401798}{doi:10.1177/26892820251401798}.
\item Unknown authors (2025). \textit{Psilocybin-Therapie vorteilhaft für Stimmungsstörungen von Parkinsonkranken}. Fortschritte der Neurologie · Psychiatrie. [published; OpenAlex]. \href{https://doi.org/10.1055/a-2700-8978}{doi:10.1055/a-2700-8978}.
\item L.J. Mertens, M. Koslowski, F. Betzler, M. Brand, R. Evens, L. Krätner, A. Jungaberle, H. Jungaberle, T. Majić, C.N. Schmitz, A. Ströhle, D. Scharf, M. Spangemacher, M. Wolff, Z. Assadi, B. Scharif, L. Becher, L.V. Färber, N. Kirchen, E. Kulakova, L. Kunz, A. Meijer, B. Rohrmoser, S. Wellek, M. Berger, G. Gründer (2025). \textit{Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE): Results of a randomized active placebo-controlled trial}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2025.105779}{doi:10.1016/j.nsa.2025.105779}.
\item L. Marwood, M. Young, J. Chai-Rees, S. Mistry, S. Maxwell, G.M. Goodwin (2025). \textit{The impact of COMP360 psilocybin on anhedonia: post-hoc analyses from a phase IIb randomised controlled trial}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2025.106572}{doi:10.1016/j.nsa.2025.106572}.
\item N. Mcgowan, J. Rucker, R. Yehuda, M. Agrawal, H. Simmons, S. Das, G. Goodwin (2025). \textit{An open-label study of single-dose COMP360 psilocybin for post-traumatic stress disorder: safety, tolerability, and secondary efficacy outcomes}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2025.106821}{doi:10.1016/j.nsa.2025.106821}.
\item Jensen, Hailey A (2025). \textit{Psilocybin Treatment for Refractory Depression: A Clinical Review}. Digital Commons - Gardner-Webb University (Gardner-Webb University). [published; OpenAlex]. \href{https://digitalcommons.gardner-webb.edu/pa-department-journal-of-medical-science/63}{source link}.
\item Brunno Freitas da Costa, Paula Hartmann, Daniel Pagnin (2025). \textit{Pharmacological Management of Anxiety in End-of-Life Care: A Systematic Review of Benzodiazepines, Opioids, and Psilocybin}. Human Psychopharmacology Clinical and Experimental. [published; OpenAlex]. \href{https://doi.org/10.1002/hup.70032}{doi:10.1002/hup.70032}.
\item Spiti A, Caldirola D, Perna G. (2025). \textit{New Antidepressant Development in the Treatment of Depression.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/978-981-95-6872-7\_23}{doi:10.1007/978-981-95-6872-7\_23}.
\item Joshua Mitchell, Logan Neitzke-Spruill, David S. Mathai, Jill O. Robinson, Zuzana Kavan, Lynnette A Averil, Amy L McGuire (2025). \textit{From trials to clinics: investigators’ perspectives on translating psychedelic research into clinical care}. Translational Behavioral Medicine. [published; OpenAlex]. \href{https://doi.org/10.1093/tbm/ibag027}{doi:10.1093/tbm/ibag027}.
\item Petr Scholle, Štěpán Wenke, Tereza Nekovářová, Yulia Zaytseva, Filip Tylš, Martin Brunovský, Jiřı́ Horáček, Veronika Andrashko, Vlastimil Koudelka, Michaela Viktorinová, Vojtěch Viktorin, Kateřina Hájková, Martin Kuchař, T. Páleníček (2025). \textit{The effects of psilocybin on time perception in humans: A comparative analysis of subjective and objective measures}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811251389552}{doi:10.1177/02698811251389552}.
\item Rotem Petranker (2025). \textit{Microdosing Psychedelics to Improve Mood}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05259943}{source link}.
\item Sophie Weiser, Sidney Jung, Bettina Bardl, Johann E. Kufs, Slavica Janevska, Vito Valiante, Dirk Hoffmeister, Lars Regestein (2025). \textit{Psilocybin Production With Genetically Modified Aspergillus nidulans Under Pressurized Conditions}. Biotechnology and Bioengineering. [published; OpenAlex]. \href{https://doi.org/10.1002/bit.70137}{doi:10.1002/bit.70137}.
\item Miguel Benjamín Cervera-Sánchez, Daniel San-Juan, Roberto Díaz-Peregrino, Evelin Zulema Camacho-Castillo, Sthefany Anahi Bringas-Ortiz, Christian Padilla-Cabezutd (2025). \textit{Psilocybin as a Serotonergic Therapy in Epilepsy: Narrative Review of Therapeutic Potentials and Seizure Risks}. Unknown journal. [published; OpenAlex]. \href{https://doi.org/10.22541/au.176701186.65064859/v1}{doi:10.22541/au.176701186.65064859/v1}.
\item Monika Dominiak, Adam Gędek, Szymon Modrzejewski, Agnieszka Permoda-Osip, Anna Zofia Antosik (2025). \textit{Efficacy and Safety of Psychedelics in Mental Disorder Cases: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials}. Journal of Clinical Medicine. [published; OpenAlex]. \href{https://doi.org/10.3390/jcm15010253}{doi:10.3390/jcm15010253}.
\item Emmanuelle A. D. Schindler, Christopher Gottschalk, Brian Pittman, Deepak D'Souza (2025). \textit{Comparing single- and repeat-dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial}. Headache The Journal of Head and Face Pain. [published; OpenAlex]. \href{https://doi.org/10.1111/head.70024}{doi:10.1111/head.70024}.
\item Manasicha Wongpaiboon, Jackson L. Shelton, Eric Delgado Rendon, Maddison Vail (2025). \textit{A Systematic Review of the efficacy, safety, and Tolerability of Psychedelics in the Treatment of post-traumatic Stress Disorder}. Current Treatment Options in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1007/s40501-025-00373-w}{doi:10.1007/s40501-025-00373-w}.
\item Houff J, Williams A, Allen O, Gisabella B, Pantazopoulos H, Del Arco A. (2025). \textit{Psilocybin decreases reward-seeking behavior accompanied by increased activity of parvalbumin neurons with perineuronal nets in the medial prefrontal cortex}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.64898/2025.12.22.696123}{doi:10.64898/2025.12.22.696123}.
\item Sahba Afsharnia, Vivian Liang, Yona Lunsky, A Orsini, Ami Tint, Hsiang-yuan Lin (2025). \textit{Knowledge, perceptions, and use of psychedelics for mental health among autistic adults: An online survey}. PLOS mental health.. [published; OpenAlex]. \href{https://doi.org/10.1371/journal.pmen.0000514}{doi:10.1371/journal.pmen.0000514}.
\item Bhagavan C, Carter O, Nielsen G, Berlowitz D, Issak S, Braat S, Zaloumis S, Attard Z, Oliver G, Mayne D, Rucker J, Butler M, Dandash O, Bryson A, Kanaan RA. (2025). \textit{A Randomised, Triple-Blind, Dose-Finding Study of the Impact of Psilocybin on Motor Function in Healthy Participants}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.64898/2025.12.22.25342874}{doi:10.64898/2025.12.22.25342874}.
\item Anthony L. Back, Bonnie A. McGregor, Lindsay Billingsley, Dianna Blom, George Callan, Susanna Myers, John Guy, Sameet Kumar, Melissa Layer, Jackie Levin, Juliana Pérez, Peter Thompson, Kathy Salmonson, Joseph Whinney, Leslie Lazar Thorn (2025). \textit{Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1177/28314425251404460}{doi:10.1177/28314425251404460}.
\item Paweł Liszka, Agata Ogórek, Klaudia M Olejnik-Chlewicka, Konrad Puchalski, Marta Zasiadła, Klaudia M Patrzykąt, Jakub Perediatkiewicz, Wojciech Urbański, Paweł M Łuczak, Jakub Brodowski (2025). \textit{Psychedelics as a Therapeutic Opportunity or Threat: A Narrative Review}. Cureus. [published; OpenAlex]. \href{https://doi.org/10.7759/cureus.99942}{doi:10.7759/cureus.99942}.
\item NYU Langone Health (2025). \textit{Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07296328}{source link}.
\item Carlson LE, Richardson H, Shore R, Albertyn CP, Balneaves LG, Bates A, Burnell M, Chochinov HM, Clements D, Deleemans J, Horlock H, Mathews J, McKenzie M, Savard C, Soares CN, Tu W, Williams M (2025). \textit{The CAnadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT): A Multi-Phase Program Overview.}. Current oncology (Toronto, Ont.). [published; PubMed]. \href{https://doi.org/10.3390/curroncol33010007}{doi:10.3390/curroncol33010007}.
\item Qinqing Chen, Peiyuan Chen, Tao Wei, Sunita Chamyuang, Bai-Xiong Chen (2025). \textit{From fungi to pharmacy: Applied technologies in psilocybin production and its therapeutic applications}. Creative Science. [published; OpenAlex]. \href{https://doi.org/10.55674/cs.v18i1.264689}{doi:10.55674/cs.v18i1.264689}.
\item COMPASS Pathways (2025). \textit{A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05624268}{source link}.
\item Gurjot Brar, T. R. JUN. BURKE, Andrew Gribben, Colm Harrington, Guillaume Thuery, John R. Kelly (2025). \textit{Psilocybin reporting in media (PRiMe) for the treatment of depression}. Irish Journal of Psychological Medicine. [published; OpenAlex]. \href{https://doi.org/10.1017/ipm.2025.10142}{doi:10.1017/ipm.2025.10142}.
\item Matos ARS, Silva AC, Rego L, Fernandes R, Gonçalves S. (2025). \textit{Psilocybin-assisted therapy for individuals with palliative care needs: A systematic review of safety and efficacy.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/02692163251383335}{doi:10.1177/02692163251383335}.
\item Megan Dutton, Paul Schwenn, Jules Mitchell, Per Hoffmann, Neil W. Bailey, Paul B. Fitzgerald, Jim Lagopoulos, Adem Can (2025). \textit{Psilocybin in the real world: Regulatory, ethical, and operational challenges in Australia’s clinical landscape}. Australian \& New Zealand Journal of Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1177/00048674251398677}{doi:10.1177/00048674251398677}.
\item M. H. M. Wickramasekara, G. D. M. C. Gonapaladeniya (2025). \textit{Psychedelic-Assisted Therapy (Pat): A New Frontier in Mental Health Treatment}. The journal of desk research review and analysis.. [published; OpenAlex]. \href{https://doi.org/10.4038/jdrra.v3i2.87}{doi:10.4038/jdrra.v3i2.87}.
\item Yvan Beaussant, MD, MSci (2025). \textit{Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced Cancer}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06001749}{source link}.
\item Nicole Ledwos, Jenna Baer, Muhammad Ishrat Husain, Daniel M. Blumberger, Rachel Patterson, Elizabeth Hollingdrake, Ezmond S.L. Cheung, Colin Hawco, Christoph Zrenner, Brigitte Zrenner, Jamie D. Feusner, Susan L. Rossell, David Castle, Gwyneth Zai (2025). \textit{Psilocybin-assisted psychotherapy for treatment-resistant obsessive-compulsive disorder: protocol for an open-label pilot study}. BJPsych Open. [published; OpenAlex]. \href{https://doi.org/10.1192/bjo.2025.10895}{doi:10.1192/bjo.2025.10895}.
\item Pedro Rodrigues, Weliton Rodrigues dos Santos Júnior, Ivan de Sousa Araújo, Leonardo Maia Leony, Fernanda Adélia Almeida Custódio Pires Gomes, Tairone Matos de Lima Junior, Luís Felipe Freitas Moreira, Rafael Telles Santana, Manoel Carlos Matos Santos, R. Silva (2025). \textit{COMPARATIVE EFFICACY AND ACCEPTABILITY OF PSILOCYBIN-KETAMINE AND TYPICAL ANTIDEPRESSANTS FOR MAJOR DEPRESSIVE DISORDER MANAGEMENT: A NETWORK META-ANALYSIS}. Unknown journal. [published; OpenAlex]. \href{https://doi.org/10.55905/edicon.978-65-83115-47-8\_8}{doi:10.55905/edicon.978-65-83115-47-8\_8}.
\item Jungwirth J, Westenhöfer S, Aicher H, Provaznikova B, Kronenberg G, Seifritz E, Prinz S, Olbrich S. (2025). \textit{Real-World Psilocybin Therapy for Treatment-Resistant Depression: a Retrospective Observational Study}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-8079137/v1}{doi:10.21203/rs.3.rs-8079137/v1}.
\item T. H. W. Ching, B. Stahnke, S. Shnayder, G. Agin-Liebes, T. G. Adams, L. Amoroso, O. Baiz, A. Belser, C. Bohner, M. Burke, E. D’Amico, G. DePalmer, J. Eilbott, G. Fram, R. Grazioplene, J. Hokanson, A. Jankovsky, S. A. Kichuk, B. Martins, P. Purohit, H. Schaer, Y. P. Sierra, C. Witherow, C. Pittenger, B. Kelmendi (2025). \textit{Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2025.1726818}{doi:10.3389/fpsyt.2025.1726818}.
\item Justin Dwyer, Robert B. Johnston, Clare O’Callaghan, Margaret Ross (2025). \textit{Stepping back into life: How Psychedelic Assisted Psychotherapy transforms the way of life of the terminally ill}. General Hospital Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.genhosppsych.2025.12.002}{doi:10.1016/j.genhosppsych.2025.12.002}.
\item Suspène J, Huet S, Berteina-Raboin S, Benyamina A, Baril P, Morisset-Lopez S, Serreau R. (2025). \textit{Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacy: A Scoping Review}. Qeios. [preprint; Europe PMC]. \href{https://doi.org/10.32388/xcfsag.2}{doi:10.32388/xcfsag.2}.
\item Gerasimos Konstantinou, Joshua D. Rosenblat, Sarah Hales, Muhammad Ishrat Husain, Daniel M. Blumberger (2025). \textit{Psilocybin in late-life mental health: Addressing depression, loneliness, and existential anxiety}. General Hospital Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.genhosppsych.2025.12.005}{doi:10.1016/j.genhosppsych.2025.12.005}.
\item Namik Kirlić, Merve Atli, Sunil Mistry, Michael Gold, Guy M. Goodwin (2025). \textit{The Relationship Between Participant Pretreatment Clinical Presentation and the Quality of Psilocybin Experience}. Journal of Clinical Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1097/jcp.0000000000002119}{doi:10.1097/jcp.0000000000002119}.
\item Reid MR, Song J, Boehnke KF, Buchanan NT, Aday JS. (2025). \textit{Disengaged: A systematic review of community engagement in psychedelic-assisted therapy research.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.neubiorev.2025.106516}{doi:10.1016/j.neubiorev.2025.106516}.
\item NYU Langone Health (2025). \textit{A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced Cancer}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05398484}{source link}.
\item Spohn, Kyle (2025). \textit{Magic Mushrooms as Medicine: What the United States Can Learn from Jamaica’s Unregulated Psilocybin Industry as FDA Approval Nears}. eYLS (Yale Law School). [published; OpenAlex]. \href{https://repository.law.miami.edu/umialr/vol57/iss1/7}{source link}.
\item Philip Garrity, Alicia Danforth, Brian Anderson, Jason M. Thompson (2025). \textit{Meaning and Purpose Therapy Modified for Psilocybin (P-MaP): A Treatment Model for Palliative Care Patients}. Journal of Health Service Psychology. [published; OpenAlex]. \href{https://doi.org/10.1007/s42843-025-00145-3}{doi:10.1007/s42843-025-00145-3}.
\item Bjørn Holmøy, Kristoffer Andreas Aamodt Andersen (2025). \textit{Persistent Altered States: Psychological Treatment of Psychedelic Adverse Effects}. Tidsskrift for Norsk psykologforening. [published; OpenAlex]. \href{https://doi.org/10.52734/hgsn7664}{doi:10.52734/hgsn7664}.
\item Nadav Liam Modlin, Victoria Williamson, Guy M. Goodwin, Ekaterina Malievskaia, Merve Atli, Zsofia Elek, Alice Gaillard, Don Koelpin, Anthony J. Cleare, Manish Agrawal, Rachel Yehuda, Namik Kirlić, James Rucker (2025). \textit{Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment}. EClinicalMedicine. [published; OpenAlex]. \href{https://doi.org/10.1016/j.eclinm.2025.103692}{doi:10.1016/j.eclinm.2025.103692}.
\item University of Texas at Austin (2025). \textit{Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06132178}{source link}.
\item Małgorzata Domżalska, Joanna Kwiatkowska, Iwona Cichoń, Ewa Sokołowska (2025). \textit{A comparative assessment of the antidepressant efficacy of ketamine, psilocybin, and fluoxetine in a chronic stress model}. Scientific Reports. [published; OpenAlex]. \href{https://doi.org/10.1038/s41598-025-29642-7}{doi:10.1038/s41598-025-29642-7}.
\item Van Ameringen M, Patel V, Patterson B, Hopkinson P, Rahat M. (2025). \textit{New treatments for OCD? Evidence for cannabinoids and psychedelics.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jpsychires.2025.11.021}{doi:10.1016/j.jpsychires.2025.11.021}.
\item Charles S. Grob, M.D. (2025). \textit{Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of Life}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05403086}{source link}.
\item Daniel J. Kruger, Gina Mersereau, Ashley F. Sullivan, Julie Barron, Moss Herberholz, Niloufar Pouyan, Jacob S. Aday, Kevin F. Boehnke (2025). \textit{Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community}. Harm Reduction Journal. [published; OpenAlex]. \href{https://doi.org/10.1186/s12954-025-01337-2}{doi:10.1186/s12954-025-01337-2}.
\item Suspène J, Huet S, Berteina-Raboin S, Benyamina A, Baril P, Morisset-Lopez S, Serreau R. (2025). \textit{Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacy: A Scoping Review}. Qeios. [preprint; Europe PMC]. \href{https://doi.org/10.32388/xcfsag}{doi:10.32388/xcfsag}.
\item Silvia Natoli, Arturo Cuomo, Maurizio Marchesini, Livio Luongo, Giuliano Lo Bianco, Vittorio Guardamagna, Shigeki Yamaguchi (2025). \textit{Psilocybin and Chronic Pain: A New Perspective for Future Pain Therapists?}. Medical Sciences. [published; OpenAlex]. \href{https://doi.org/10.3390/medsci13040277}{doi:10.3390/medsci13040277}.
\item Beersheva Mental Health Center (2025). \textit{A Double-blind, Phase II Feasibility Study to Assess the Safety and Efficacy of Psilocybin Microdosing Combined With Psychotherapy in Treatment-resistant Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07183748}{source link}.
\item Beersheva Mental Health Center (2025). \textit{Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04882839}{source link}.
\item Unknown authors (2025). \textit{Microdosing Psilocybin for Major Depressive Disorder: Study Protocol for a Phase II Double-Blind Placebo-Controlled Randomized Partial Crossover Trial}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/hmnsw\_v1}{source link}.
\item Marieke Martens, Bruna Giribaldi Cunha, David Erritzøe, David Nutt, Robin Carhart-Harris, Catherine J. Harmer (2025). \textit{Negative affective bias in depression following treatment with psilocybin or escitalopram - a secondary analysis from a randomized trial}. Translational Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1038/s41398-025-03693-w}{doi:10.1038/s41398-025-03693-w}.
\item Højlund M, Kafali HY, Kırmızı B, Fusar-Poli P, Correll CU, Cortese S, Sabé M, Fiedorowicz J, Saraf G, Zein J, Berk M, Husain MI, Rosenblat JD, Rubaiyat R, Corace K, Wong S, Hatcher S, Kaluzienski M, Yatham LN, Cipriani A, Gosling CJ, Carhart-Harris R, Tanuseputro P, Myran DT, Fabiano N, Moher D, Mayo LM, Nicholls SG, White T, Prisco M, Radua J, Vieta E, Ladha KS, Katz J, Veroniki AA, Solmi M. (2025). \textit{Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.euroneuro.2025.09.011}{doi:10.1016/j.euroneuro.2025.09.011}.
\item Aisling McGuigan (2025). \textit{Classic psychedelics may treat depressive disorders, but more evidence and legislative changes are required}. Drugs \& Therapy Perspectives. [published; OpenAlex]. \href{https://doi.org/10.1007/s40267-025-01199-5}{doi:10.1007/s40267-025-01199-5}.
\item University of Washington (2025). \textit{A Phase 1/2 Study of a Group Model of Psilocybin-Assisted Therapy for Cancer-Related Anxiety in Patients With Metastatic Cancer}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05847686}{source link}.
\item Kent E. Hutchison, Jake F. Hooper, Hollis C. Karoly (2025). \textit{Psilocybin Outside the Clinic}. JAMA Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1001/jamapsychiatry.2025.3038}{doi:10.1001/jamapsychiatry.2025.3038}.
\item Chiranth Bhagavan, Alexander Bryson, Olivia Carter, Glenn Nielsen, David J. Berlowitz, Sara Issak, Sabine Braat, Sophie Zaloumis, Zachary Attard, Dina Eleftheriadis, Georgina Oliver, Deanne Mayne, Greg Roebuck, James Rucker, Matthew Butler, Richard Kanaan (2025). \textit{Psilocybin-assisted physiotherapy for refractory motor functional neurological disorder: protocol for a randomised dose-comparison pilot study}. Acta Neuropsychiatrica. [published; OpenAlex]. \href{https://doi.org/10.1017/neu.2025.10042}{doi:10.1017/neu.2025.10042}.
\item Luisa Prochazkova, Josephine Marschall, Michiel van Elk, Ben David Rifkin, Neil R Schon, Donatella Fiacchino, George Fejer, Martin Kuchař, Bernhard Hommel (2025). \textit{Microdosing psilocybin and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials}. Neuropharmacology. [published; OpenAlex]. \href{https://doi.org/10.1016/j.neuropharm.2025.110732}{doi:10.1016/j.neuropharm.2025.110732}.
\item Jonathon Marinis, Sarah Clarke, Alexandre A. Guerin, Adam J. Guastella, Gillinder Bedi (2025). \textit{Reporting of side-effects in clinical trials of psilocybin-assisted psychotherapy for psychiatric conditions: systematic review}. BJPsych Open. [published; OpenAlex]. \href{https://doi.org/10.1192/bjo.2025.10847}{doi:10.1192/bjo.2025.10847}.
\item André Leão Dantas, Lara Moreira Jalles Milani, Saulo Gabriel Moreira Falci, João Américo da Silveira, Cristina Pereira Isolan, Lia Dietrich (2025). \textit{Use of psilocybin for chronic pain: a scoping review with current evidence and prospection of literature and technology for future applications}. Caderno Pedagógico. [published; OpenAlex]. \href{https://doi.org/10.54033/cadpedv22n12-345}{doi:10.54033/cadpedv22n12-345}.
\item d'Andrea G, Chiappini S, Ciavoni L, Tucci R, Martino F, Semeraro FM, Di Battista D, Mosca A, Miuli A, Di Carlo F, Russo M, Di Petta G, Fornaro M, Pettorruso M, Sensi SL, Martinotti G. (2025). \textit{Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1038/s41398-025-03654-3}{doi:10.1038/s41398-025-03654-3}.
\item Do A, Cloutier L, Hébert-Tremblay L, Thauvin C. (2025). \textit{Psilocybin use in bipolar disorder: A comprehensive review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jad.2025.120485}{doi:10.1016/j.jad.2025.120485}.
\item Anna Rose Childress, Ph.D. (2025). \textit{A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)?}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06786325}{source link}.
\item James J Gattuso, Bilgenur Bezcioglu, Carey Wilson, Kato Havaux, Anthony J. Hannan, Thibault Renoir (2025). \textit{Psilocybin's effects on obsessive-compulsive behaviors: A systematic review of preclinical and clinical evidence}. Psychedelics.. [published; OpenAlex]. \href{https://doi.org/10.61373/pp025i.0044}{doi:10.61373/pp025i.0044}.
\item Candice Richardson, Cindy Chan, Emily Macgregor, Crystal Hare, Breffni Hannon, SarahRose Black, Evan E. Schneider, Daniel Z. Buchman, Stella Wang, Valeria E. Rac, Lusine Abrahamyan, Ella Huszti, Rinat Nissim, Madeline Li, Camilla Zimmermann, Emma Hapke, Daniel M. Rosenbaum, Sarah Hales (2025). \textit{Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy for patients with advanced cancer: protocol for a multi-method feasibility trial}. Pilot and Feasibility Studies. [published; OpenAlex]. \href{https://doi.org/10.1186/s40814-025-01706-5}{doi:10.1186/s40814-025-01706-5}.
\item David A. Bender, Sandeep M. Nayak, Joshua S. Siegel, David J. Hellerstein, Barış Erçal, Eric J. Lenze (2025). \textit{Provider perspectives on challenges in treatment during psychedelic therapy}. Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1007/s00213-025-06907-7}{doi:10.1007/s00213-025-06907-7}.
\item Keighley EE, Abo Hamza E, Bedewy DA, Nalla S, Moustafa AA. (2025). \textit{A Systematic Review and Meta-Analysis Investigating the Efficacy of Various Psychedelic Drugs for the Treatment of Substance Use Disorder.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3390/healthcare13212668}{doi:10.3390/healthcare13212668}.
\item Bukovsky D, Amaev A, Song J, Kyte S, Carmona-Torres E, Ueno F, Deluca V, Strafella AP, Husain MI, Graff-Guerrero A, Gerretsen P. (2025). \textit{Adverse event reporting and management in psilocybin therapy clinical trials: A systematic review to guide clinical and research protocol development.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.pnpbp.2025.111541}{doi:10.1016/j.pnpbp.2025.111541}.
\item Uyar A, Forbrich L, Lueken U, Evens R. (2025). \textit{Landscape analysis of pre-registered clinical trials involving classical psychedelics.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811251371690}{doi:10.1177/02698811251371690}.
\item special to C EN Mara Johnson-Groh (2025). \textit{Is there more to magic mushrooms than psilocybin?}. C\&EN Global Enterprise. [published; OpenAlex]. \href{https://doi.org/10.1021/cen-10322-feature2}{doi:10.1021/cen-10322-feature2}.
\item Suspene J, Huet S, Berteina-Raboin S, Benyamina A, Baril P, Morisset-Lopez S, Serreau R. (2025). \textit{Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacity: A Scoping Review}. Preprints.org. [preprint; Europe PMC]. \href{https://doi.org/10.20944/preprints202510.1355.v1}{doi:10.20944/preprints202510.1355.v1}.
\item Vale LN, Ibrahim M, Fávaro-Pereira L, Soares JC, Meyer TD. (2025). \textit{Contemplating versus having used psychedelics in bipolar disorder - What makes the difference?}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jad.2025.120437}{doi:10.1016/j.jad.2025.120437}.
\item Luisa Prochazkova, Josephine Marschall, Dominique P. Lippelt, Neil R Schon, Martin Kuchař, Bernhard Hommel (2025). \textit{Cognitive and subjective effects of psilocybin microdosing: Results from two double-blind placebo-controlled longitudinal trials}. Neuropharmacology. [published; OpenAlex]. \href{https://doi.org/10.1016/j.neuropharm.2025.110722}{doi:10.1016/j.neuropharm.2025.110722}.
\item Wong S, Jones BDM, Thiyagarajah MT, Sabbah SG, Thompson C, Solmi M, Umer M, Zrenner C, Voineskos D, Rosenblat JD, Mulsant BH, Blumberger DM, Husain MI. (2025). \textit{Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/20451253251384513}{doi:10.1177/20451253251384513}.
\item David J. Heal, Jane Gosden, Sharon L. Smith (2025). \textit{Mind the gap! Addressing unresolved aspects of abuse potential evaluation and scheduling of classic and novel psychedelic drugs}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811251382147}{doi:10.1177/02698811251382147}.
\item Gerard J. Marek, Soma Makai-Bölöni, Daniel Umbricht, Edward P. Christian, Jason Winters, Dino Dvořák, Shane Raines, Zoë A. Hughes, Eric W. Austin, Adam K. Klein, William Leong, Fas J. Krol, Anne J. van der Graaf, Maria J. Juachon, Marije E. Otto, Laura Borghans, Gabriël E. Jacobs, Andrew C. Kruegel, Jonathan Sporn (2025). \textit{A novel psychedelic 5-HT2A receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811251378512}{doi:10.1177/02698811251378512}.
\item University of Washington (2025). \textit{A Phase 1 Study of a Second Psilocybin Group Retreat for Partial Responders With Anxiety Associated With Metastatic Cancer}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06644170}{source link}.
\item Unknown authors (2025). \textit{Control group improvement lower in psilocybin trials for depression}. The Brown University Psychopharmacology Update. [published; OpenAlex]. \href{https://doi.org/10.1002/pu.31371}{doi:10.1002/pu.31371}.
\item Centre Hospitalier St Anne (2025). \textit{Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07210112}{source link}.
\item M Loganathan, A Saravanakumar, P. Parthiban, G Anandharaj, S Gobika, D Dharshana, Mohamed Safir Ali (2025). \textit{Neurobiological and Therapeutic Potential of Psilocybin in Psychiatric Disorders}. Journal of Pharma Insights and Research.. [published; OpenAlex]. \href{https://doi.org/10.69613/thv1dn30}{doi:10.69613/thv1dn30}.
\item Mohamad Chweikh (2025). \textit{Legal and Regulatory Barriers to Medical Psilocybin Use: An International Overview}. Unknown journal. [published; OpenAlex]. \href{https://doi.org/10.31219/osf.io/dy5cu\_v1}{doi:10.31219/osf.io/dy5cu\_v1}.
\item Anneliese McConnell, Wei He, Harry McConnell, Sandro Sprendei, Paul F. Sowman (2025). \textit{3642 Down the rabbit hole: case reports of a hallucinogen-induced disorder of neuroperception}. Unknown journal. [published; OpenAlex]. \href{https://doi.org/10.1136/bmjno-2025-anzan.170}{doi:10.1136/bmjno-2025-anzan.170}.
\item Michel Sabé, Federico Seragnoli, Louise Penzenstadler, Gabriel Thorens (2025). \textit{[Role of psychedelics in psychiatry: a true therapeutic revolution or a trend?]}. PubMed. [published; OpenAlex]. \href{https://pubmed.ncbi.nlm.nih.gov/41575100}{source link}.
\item Egger, Klemens, Meling, Daniel, Polat, Firuze, Seifritz, Erich, Avram, Mihai, Scheidegger, Milan (2025). \textit{Meditation, psychedelics, and brain connectivity: A randomized controlled resting-state fMRI study of N,N-dimethyltryptamine and harmine in a meditation retreat}. Universität Zürich, ZORA. [published; OpenAlex]. \href{https://doi.org/10.5167/uzh-280470}{doi:10.5167/uzh-280470}.
\item Caporuscio C, Poppe C, Gieselmann A, Repantis D. (2025). \textit{Ethical issues with psychedelic-assisted treatments in psychiatry: A systematic scoping review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1017/s0033291725101761}{doi:10.1017/s0033291725101761}.
\item University of Southern California (2025). \textit{An Exploratory Study of Feasibility, Efficacy, and Mechanisms of Mindfulness-Assisted Psychedelic Therapy}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06233344}{source link}.
\item Unknown authors (2025). \textit{“So many relationships in the room”: Participant perspectives on the affordances and challenges of co-therapy in psychedelic assisted therapy}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/4cn5r\_v1}{source link}.
\item Healing Advocacy Fund (2025). \textit{Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07189988}{source link}.
\item Keshen A, Touyz S, Lacroix E, Hay P, McElroy SL. (2025). \textit{Innovative Pharmacological Approaches to Eating Disorder Treatment.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.psc.2025.08.014}{doi:10.1016/j.psc.2025.08.014}.
\item Matthew Halma, R. Levy, Joseph Varón (2025). \textit{With great power comes great responsibility: Promise and caution in the new psychedelic renaissance}. Brain Disorders. [published; OpenAlex]. \href{https://doi.org/10.1016/j.dscb.2025.100286}{doi:10.1016/j.dscb.2025.100286}.
\item Elizabeth Knock, Krista J. Siefried, Gillinder Bedi, Steven M. Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett (2025). \textit{Psilocybin-assisted psychotherapy for methamphetamine use disorder: A pilot open-label safety and feasibility study}. Addiction. [published; OpenAlex]. \href{https://doi.org/10.1111/add.70187}{doi:10.1111/add.70187}.
\item Benjamin R. Lewis (22279166), John Hendrick (22279169), Kevin Byrne (1610821), Madeleine Odette (22279172), Chaorong Wu (8444343), Eric L. Garland (4666660) (2025). \textit{S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial}. Figshare. [published; OpenAlex]. \href{https://doi.org/10.1371/journal.pmed.1004519.s001}{doi:10.1371/journal.pmed.1004519.s001}.
\item Benjamin R. Lewis, John Hendrick, Kevin Byrne, Madeleine Odette, Chaorong Wu, Eric L. Garland (2025). \textit{Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial}. PLoS Medicine. [published; OpenAlex]. \href{https://doi.org/10.1371/journal.pmed.1004519}{doi:10.1371/journal.pmed.1004519}.
\item Anastasia Calin, Ana Flavia Burlec, Cornelia Mircea, Irina Macovei, Monica Hăncianu, Andreia Corciovă (2025). \textit{Evolution and Comparative Analysis of Clinical Trials on Psilocybin in the Treatment of Psychopathologies: Trends in the EU and the US}. Journal of Clinical Medicine. [published; OpenAlex]. \href{https://doi.org/10.3390/jcm14186613}{doi:10.3390/jcm14186613}.
\item Johns Hopkins University (2025). \textit{PRoMiSS: Psilocybin and the Role of Music in Set and Setting}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07180108}{source link}.
\item Lopez, Alissa A, Salloum, Ihsan, Lopez-Alvarenga, Juan C (2025). \textit{Efficacy of Psychedelics Therapy Across Psychiatric Disorders: An Umbrella Review of Meta-Analyses}. ScholarWorks @ UTRGV (The University of Texas Rio Grande Valley). [published; OpenAlex]. \href{https://scholarworks.utrgv.edu/colloquium/2025/talks/1}{source link}.
\item Zhifan He, Rui Tang, Min Feng, Xiaohui Li, Changhong Zhang, Jing Li (2025). \textit{Dynamic myocardial injury and variable hallucination latency in Psilocybe keralensis poisoning: a molecularly confirmed case series from China}. Clinical Toxicology. [published; OpenAlex]. \href{https://doi.org/10.1080/15563650.2025.2552438}{doi:10.1080/15563650.2025.2552438}.
\item John A. Razidlo, Noelle Cataldo, Cody J. Wenthur (2025). \textit{Psilocybin Enhances Cued Fear Extinction and Extinction Recall in Stress-Naïve, Acutely Stressed, and Chronically Stressed Mice}. ACS Pharmacology \& Translational Science. [published; OpenAlex]. \href{https://doi.org/10.1021/acsptsci.5c00462}{doi:10.1021/acsptsci.5c00462}.
\item King's College London (2025). \textit{Measurement of Serum Cytokine Levels in Samples Collected as Part of a Clinical Trial of Psilocybin for Treatment-resistant Depression.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07164755}{source link}.
\item Georgios Mikellides, Marios Kyriazis (2025). \textit{Psychedelics and mental health: reimagining care through science, insight, and compassion}. Frontiers in Pharmacology. [published; OpenAlex]. \href{https://doi.org/10.3389/fphar.2025.1649929}{doi:10.3389/fphar.2025.1649929}.
\item Khyber Medical University Peshawar (2025). \textit{Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers: a Randomized Controlled Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06746441}{source link}.
\item Anna Blazhkova, Magdalena Czaja, Hanna Sitka, Sven Solisch, Anna Susłow, Ewa Szczęsna (2025). \textit{PSYCHEDELICS IN PSYCHIATRY - OVERVIEW OF PSILOCYBIN RESEARCH}. International Journal of Innovative Technologies in Social Science. [published; OpenAlex]. \href{https://doi.org/10.31435/ijitss.3(47).2025.3650}{doi:10.31435/ijitss.3(47).2025.3650}.
\item David Nutt, David Erritzøe, Anne Katrin Schlag, David Luke, Deborah C. Mash, Hiroyuki Uchida, Jacob S. Aday, James Rucker, Liliana Galindo, Mark Sweeney, Matthew X. Lowe, Oliver Davis, Plinio Ferreira, Rayyan Zafar, Robin Carhart-Harris, Tadeusz Hawrot, Joanna C. Neill (2025). \textit{A lexicon for psychedelic research and treatment}. Drug Science Policy and Law. [published; OpenAlex]. \href{https://doi.org/10.1177/20503245251380511}{doi:10.1177/20503245251380511}.
\item Sally Meikle, Olivia Carter, Paul Liknaitzky, Lauren Johansen, Ravi Iyer, Nigel Strauss, M.L. Williams, David Castle, Susan L. Rossell (2025). \textit{Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial}. Therapeutic Advances in Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/20451253251377187}{doi:10.1177/20451253251377187}.
\item Niall M. McGowan, James Rucker, Rachel Yehuda, Manish Agrawal, Nadav Liam Modlin, Hollie Simmons, Agata Tofil-Kaluza, Shriya Das, Guy M. Goodwin (2025). \textit{Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811251362390}{doi:10.1177/02698811251362390}.
\item Nathan Brashares Sackett (2025). \textit{A Phase 2 Single-site, Double-blind, Placebo-controlled, Randomized Clinical Trial With an Open-label Extension Phase to Examine the Safety, Subjective Experiences, Acute Effects, and Suitability of Psilocybin Combined With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06853912}{source link}.
\item Fernandes-Nascimento MH, Viana-Ferreira K, Negrão AB. (2025). \textit{Overview and Specificity of Psilocybin Use in the Treatment of Mental Disorders: A Scientometric Analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1089/psymed.2024.0031}{doi:10.1089/psymed.2024.0031}.
\item Samir A Nader (2025). \textit{Psychedelic minimalism: the case against music in psychedelic therapy settings}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2025.1652568}{doi:10.3389/fpsyt.2025.1652568}.
\item Elise C. Tarbi, Skye A. Miner, Kabir Nigam, Zachary Sager, Justin J. Sanders, Michael Ljuslin, Benjamin Guérin, Kimberly Roddy, James A. Tulsky, Manish Agrawal, Yvan Beaussant (2025). \textit{“To Have the Encounter with Our Own Finiteness in that Existential Way”: Descriptions of Existential Experience in Patients with Cancer and Major Depression Participating in Psilocybin-Assisted Group Therapy}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1177/28314425251370303}{doi:10.1177/28314425251370303}.
\item Zeifman R, Danias G, Agin-Liebes G, Pagni B, Kettner H, Bhat V, Ross S, Erritzoe D, Carhart-Harris R. (2025). \textit{Psychedelic Therapy, Positive Emotional Experiences, and the Central Role of Self-Compassion}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-7420529/v1}{doi:10.21203/rs.3.rs-7420529/v1}.
\item Bilenker D, Avena NM. (2025). \textit{Psychedelics and the Serotonin Hypothesis of Eating Disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3390/brainsci15080893}{doi:10.3390/brainsci15080893}.
\item COMPASS Pathways (2025). \textit{A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05733546}{source link}.
\item Li Y, Li H, Wang H, Wang X. (2025). \textit{Exploring the therapeutic potential of psychedelics in treating substance use disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1038/s41380-025-03168-w}{doi:10.1038/s41380-025-03168-w}.
\item Singleton SP, Sevchik BL, Lahey A, Cuijpers P, Harrer M, Jones MT, Nayak SM, Strain EC, Vandekar SN, Dworkin RH, Scott JC, Satterthwaite TD. (2025). \textit{Psilocybin treatment for symptoms of depression: a living systematic review, meta-analysis, and data resource}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2025.08.13.25333530}{doi:10.1101/2025.08.13.25333530}.
\item Nadav Liam Modlin, Jessica L. Maples-Keller, Maria Sarang, Lucie Siebenaler, Carolina Maggio, Susannah Pick, Victoria Williamson, Anthony J. Cleare, James Rucker (2025). \textit{Perspectives on Trauma Treatment, Self-Management Strategies, and Attitudes Toward Psychedelic Therapies in Individuals with Psychological Trauma Symptoms}. Psychiatry and Clinical Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.5152/pcp.2025.24934}{doi:10.5152/pcp.2025.24934}.
\item Kimberley Foster, Isaac Morrison, Shemar Daniel, Johann M.R. Antoine, Babumon M. Thankappan, Winston De La Haye, Marshall Tyler, Charles N. Grant, Rupika Delgoda (2025). \textit{Toward Standardized Products Containing Biomass of Psilocybe Cubensis Fungi}. Journal of AOAC International. [published; OpenAlex]. \href{https://doi.org/10.1093/jaoacint/qsaf072}{doi:10.1093/jaoacint/qsaf072}.
\item Margaret Ross, Ravi Iyer, M.L. Williams, Mark Boughey, Clare O’Callaghan, Richard Hiscock, Justin Dwyer (2025). \textit{Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial}. General Hospital Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.genhosppsych.2025.08.001}{doi:10.1016/j.genhosppsych.2025.08.001}.
\item Silczuk A, Madejek RJ, Koweszko T, Mularczyk-Tomczewska P, Adamska E, Gujski M, Szulc A. (2025). \textit{Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.12659/msm.948302}{doi:10.12659/msm.948302}.
\item Harsha S. Krishna (2025). \textit{Intersecting Psychedelic Pharmacology and Gut-Brain Axis Signaling in Neurodegenerative Disorders}. JUNIOR RESEARCHERS. [published; OpenAlex]. \href{https://doi.org/10.52340/jr.2025.03.03.09}{doi:10.52340/jr.2025.03.03.09}.
\item Meredith C. Meacham, Maha N. Mian, Ralph C. Wang, Allison R. Coker, B. Anderson, Juan Carlos C. Montoy (2025). \textit{Latent Classes of Lifetime Use of Seven Hallucinogens in the United States}. Journal of Psychoactive Drugs. [published; OpenAlex]. \href{https://doi.org/10.1080/02791072.2025.2537040}{doi:10.1080/02791072.2025.2537040}.
\item Małgorzata Wierzbicka, Renata Kopczyk, Aleksandra Gerlach, Joanna Rymaszewska (2025). \textit{Therapeutic and legal aspects of psilocybin in cancer-related depression}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2025.1591864}{doi:10.3389/fpsyt.2025.1591864}.
\item Hiroe Tani (2025). \textit{577. CLINICAL EVIDENCE AND APPLICATIONS OF PSYCHEDELICS FOR MENTAL ILLNESSES}. The International Journal of Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1093/ijnp/pyaf052.377}{doi:10.1093/ijnp/pyaf052.377}.
\item Unknown authors (2025). \textit{229. PSILOCYBIN WITH PSYCHOTHERAPEUTIC SUPPORT FOR TREATMENT-RESISTANT DEPRESSION: A PILOT CLINICAL TRIAL}. Unknown journal. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC12359778}{source link}.
\item Adebo M, Bonnet M, Laouej O, Defaix C, McGowan JC, Butlen-Ducuing F, David DJ, Poupon E, Tritschler L, Gardier AM. (2025). \textit{Psilocybin as Transformative Fast-Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1111/fcp.70038}{doi:10.1111/fcp.70038}.
\item Heidi Allen, B. Stott (2025). \textit{Preparing Social Work for Psychedelic-Assisted Therapy}. Social Work. [published; OpenAlex]. \href{https://doi.org/10.1093/sw/swaf031}{doi:10.1093/sw/swaf031}.
\item Rosa WE, Napolitano S, McAndrew N, Jenkins B, Lichtenthal WG, Applebaum AJ, Breitbart W, Agrawal M. (2025). \textit{Meaning-Centered Psychotherapy for Psilocybin-Assisted Therapy Among Patients with Advanced Cancer and Depression: Rationale and Preliminary Evaluation of MCP-PSIL.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/28314425251363983}{doi:10.1177/28314425251363983}.
\item Bevione F, Lacidogna MC, Lavalle R, Abbate Daga G, Preti A. (2025). \textit{Psilocybin in the treatment of eating disorders: a systematic review of the literature and registered clinical trials.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s40519-025-01771-y}{doi:10.1007/s40519-025-01771-y}.
\item Johns Hopkins University (2025). \textit{Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06067737}{source link}.
\item King's College London (2025). \textit{Modulation of Serotonin Pathways Using Psilocybin in Adults With and Without Autism Spectrum Disorder (ASD)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05651126}{source link}.
\item Yale University (2025). \textit{Mechanistic Studies of Psilocybin in Headache Disorders}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06464367}{source link}.
\item Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul A. Rochefort, Thibault Mura, Felix Sergent (2025). \textit{Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial}. Addiction. [published; OpenAlex]. \href{https://doi.org/10.1111/add.70152}{doi:10.1111/add.70152}.
\item Sarah-Catherine Rodan, Noah Meez, Sophie Lloyd-Hurwitz, Miguel A. Bedoya-Pérez, Anastasia Suraev, Natasha Sommer, Kayla Greenstien, Sarah Maguire, Iain S. McGregor (2025). \textit{Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey}. Journal of Eating Disorders. [published; OpenAlex]. \href{https://doi.org/10.1186/s40337-025-01328-5}{doi:10.1186/s40337-025-01328-5}.
\item Emory University (2025). \textit{The Safety, Feasibility, and Acceptability of Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain (P-PC)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05506982}{source link}.
\item The University of Texas Health Science Center, Houston (2025). \textit{Acceptability \& Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06706232}{source link}.
\item Kittur ME, Burgos M LA, Jones BDM, Blumberger DM, Mulsant BH, Rosenblat JD, Husain MI. (2025). \textit{Mapping psilocybin therapy: A systematic review of therapeutic frameworks, adaptations, and standardization across contemporary clinical trials.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jad.2025.119952}{doi:10.1016/j.jad.2025.119952}.
\item Katherine Cheung, Caleigh Propes, Marianna Graziosi, Kyle Patch, David B. Yaden (2025). \textit{Informed Consent Documents from Psychedelic Clinical Trials: A Descriptive Ethical Analysis}. AJOB Empirical Bioethics. [published; OpenAlex]. \href{https://doi.org/10.1080/23294515.2025.2526339}{doi:10.1080/23294515.2025.2526339}.
\item Cohen ZZ, Blest-Hopley G (2025). \textit{Females in Psychedelic Research: A Perspective for Advancing Research and Practice.}. ACS pharmacology \& translational science. [published; PubMed]. \href{https://doi.org/10.1021/acsptsci.5c00255}{doi:10.1021/acsptsci.5c00255}.
\item Damian Świeczkowski, Aleksander Kwaśny, Patrycja Ciurkowska, Michał Pruc, Łukasz Szarpak, Wiesław Jerzy Cubała (2025). \textit{Unequal representation? A cross-sectional analysis of age, sex, race, and ethnicity in clinical trials of classic psychedelics}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811251353250}{doi:10.1177/02698811251353250}.
\item Miller EA, Capone C, Eaton E, Swift RM, Haass-Koffler CL. (2025). \textit{Psychedelics for Alcohol Use Disorder: A Narrative Review with Candidate Mechanisms of Action.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s40263-025-01199-z}{doi:10.1007/s40263-025-01199-z}.
\item Khaleel Rajwani, Melanie Almonte, F. Feroz, Jamila Hokanson, Edward Jacobs, Julian Savulescu, Ilina Singh, David B. Yaden, Brian D. Earp (2025). \textit{Clinical Psychedelic Therapy Research Involving Adolescents: Protocol for a Scoping Review of Intervention Studies}. Wellcome Open Research. [published; OpenAlex]. \href{https://doi.org/10.12688/wellcomeopenres.24181.1}{doi:10.12688/wellcomeopenres.24181.1}.
\item Joga R, Yerram S, Patnam JD, Choudhary KK, Varpe P, Raghuvanshi RS, Srivastava S. (2025). \textit{Unraveling the policies, legislations, and regulations of psychedelics in Australia, Canada, Netherlands, New Zealand, and India.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.healthpol.2025.105392}{doi:10.1016/j.healthpol.2025.105392}.
\item Tolle HM, Luppi AI, Lawn T, Roseman L, Nutt D, Carhart-Harris RL, Mediano PAM. (2025). \textit{Accurate and Interpretable Prediction of Antidepressant Treatment Response from Receptor-informed Neuroimaging}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2025.07.02.662710}{doi:10.1101/2025.07.02.662710}.
\item Luca Pellegrini, Naomi Fineberg, Sorcha O'Connor, Ana Maria Frota Lisbôa Pereira de Souza, Kate Godfrey, Sara Reed, Joseph Peill, Mairead Healy, Cyrus Rohani-Shukla, Hakjun Lee, Robin Carhart-Harris, Trevor W. Robbins, David Nutt, David Erritzøe (2025). \textit{Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study}. Comprehensive Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.comppsych.2025.152619}{doi:10.1016/j.comppsych.2025.152619}.
\item Atiq MA, Baker MR, Voort JLV, Vargas MV, Choi DS (2025). \textit{Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-024-06599-5}{doi:10.1007/s00213-024-06599-5}.
\item Hieronymus F, López E, Werin Sjögren H, Lundberg J. (2025). \textit{Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression: A Meta-Analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1001/jamanetworkopen.2025.24119}{doi:10.1001/jamanetworkopen.2025.24119}.
\item Mathieu Fradet (2025). \textit{Increasing the Evaluation and Reporting Rigor of Psychotherapy Interventions in Treatments Involving Psychedelics}. Psychoactives. [published; OpenAlex]. \href{https://doi.org/10.3390/psychoactives4030021}{doi:10.3390/psychoactives4030021}.
\item Carvalho LC, Encantado J, Kettner H, Timmermann C, Veiga D, Teixeira PJ. (2025). \textit{A Scoping Review of Research in Naturalistic Studies with Psychedelics.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/02791072.2025.2520221}{doi:10.1080/02791072.2025.2520221}.
\item Mathew A, Dongre R, Kim SH, Turner J, Mathew A, Cherryholmes E, Mehrinfar M, Kamprath S. (2025). \textit{The Clinical Applications of Psilocybin Therapies and Post-COVID Syndrome: A Comprehensive Narrative Review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.7759/cureus.86659}{doi:10.7759/cureus.86659}.
\item Kyle T. Greenway, Nicolas Garel, Lê-Anh Dinh-Williams, Julien Thibault Lévesque, Mendel Kaelen, Vincent Dagenais-Beaulé, Sara de la Salle, David Erritzøe, Karl Looper, Gustavo Turecki, Soham Rej, Stéphane Richard-Devantoy (2025). \textit{The Music for Subanesthetic Infusions of Ketamine randomised clinical trial: ketamine as a psychedelic treatment for highly refractory depression}. The British Journal of Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1192/bjp.2025.102}{doi:10.1192/bjp.2025.102}.
\item Manish Agrawal, Kim Roddy, Betsy Jenkins, Celia Leeks, Ezekiel Emanuel (2025). \textit{Long-term benefits of single-dose psilocybin in depressed patients with cancer}. Cancer. [published; OpenAlex]. \href{https://doi.org/10.1002/cncr.35889}{doi:10.1002/cncr.35889}.
\item Ines Erkizia-Santamaría, Igor Horrillo, Nerea Martínez-Álvarez, Daniel Pérez-Martínez, Guadalupe Rivero, Amaia M. Erdozain, J. Javier Meana, Jorge E. Ortega (2025). \textit{Evaluation of behavioural and neurochemical effects of psilocybin in mice subjected to chronic unpredictable mild stress}. Translational Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1038/s41398-025-03421-4}{doi:10.1038/s41398-025-03421-4}.
\item MycoMedica Life Sciences PBC (2025). \textit{A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Participants}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06643637}{source link}.
\item Stephen Ross (2025). \textit{Stephen Ross: Psychedelic-assisted therapies for difficult-to-treat psychiatric and medical disorders}. Psychedelics.. [published; OpenAlex]. \href{https://doi.org/10.61373/pp025k.0017}{doi:10.61373/pp025k.0017}.
\item Sara Ellis, Catherine Bostian, Anna J. Donnelly, Wendy Feng, Katherine Eisen, Melanie Lean, Elizabeth Conlan, Michael J. Ostacher, Scott T. Aaronson, Trisha Suppes (2025). \textit{Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - 12-month data from an open-label pilot study}. Journal of Affective Disorders. [published; OpenAlex]. \href{https://doi.org/10.1016/j.jad.2025.119655}{doi:10.1016/j.jad.2025.119655}.
\item William Roseby, Hannes Kettner, Leor Roseman, Meg J. Spriggs, Taylor Lyons, Joe Peill, Bruna Giribaldi, David Erritzøe, David Nutt, Robin Carhart-Harris (2025). \textit{Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies}. Frontiers in Psychology. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyg.2025.1580663}{doi:10.3389/fpsyg.2025.1580663}.
\item Czopek A, Jończyk J, Fryc M, Kluzik D, Zagórska A. (2025). \textit{Classic Psychedelics in Pain Modulation: Mechanisms, Clinical Evidence, and Future Perspectives.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1021/acschemneuro.5c00152}{doi:10.1021/acschemneuro.5c00152}.
\item Matthew Hicks (2025). \textit{Low-Income Group Psilocybin Assisted Therapy for Depression: A Feasibility Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06372197}{source link}.
\item National University of Natural Medicine (2025). \textit{Optimizing Microdosing and Meditation}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06560658}{source link}.
\item Subha Subramanian, Travis Rick Reneau, Demetrius Perry, Ravi V. Chacko, Timothy O. Laumann, Karin Flavin, Christine Horan, Julia Schweiger, Nicholas V. Metcalf, Eric J. Lenze, Abraham Z. Snyder, Nico U.F. Dosenbach, Ginger E. Nicol, Joshua S. Siegel (2025). \textit{Psilocybin’s acute and persistent brain effects: a precision imaging drug trial}. Scientific Data. [published; OpenAlex]. \href{https://doi.org/10.1038/s41597-025-05189-0}{doi:10.1038/s41597-025-05189-0}.
\item Berkovitch L, Fauvel B, Preller KH, Gaillard R. (2025). \textit{Neurocognitive effects of psilocybin: A systematic and comprehensive review of neuroimaging studies in humans.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.neubiorev.2025.106239}{doi:10.1016/j.neubiorev.2025.106239}.
\item Fitzgerald PB, Webb SL, Denning NC, Dowie T, Schweickle MM, Modak A, Chan G, Knight J, Waldron M, Gainsford K, Hawkes H, Zammit S, Sutanto NC, Fitzgibbon BM, Bailey NW. (2025). \textit{Understanding the Psychological Effects of Psilocybin and 3,4-Methylenedioxymethamphetamine in a Non-Clinical Population}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2025.05.28.25328532}{doi:10.1101/2025.05.28.25328532}.
\item Anders A. Jensen, Cláudia R. Cecchi, Meghan Hibicke, Astrid H. Bach, Erik Kaadt, Emil Märcher-Rørsted, Charles D. Nichols, Betina Elfving, Jesper L. Kristensen (2025). \textit{The Selective Serotonin 5-HT2A Receptor Agonist (S)-3-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)piperidine (LPH-5) Induces Persistent and Robust Antidepressant-Like Effects in Rodents}. ACS Pharmacology \& Translational Science. [published; OpenAlex]. \href{https://doi.org/10.1021/acsptsci.5c00208}{doi:10.1021/acsptsci.5c00208}.
\item Palmer C, Ferber AT, Greenwald BD. (2025). \textit{The Potential Role of Psilocybin in Traumatic Brain Injury Recovery: A Narrative Review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3390/brainsci15060572}{doi:10.3390/brainsci15060572}.
\item Vogt SB, Liechti ME. (2025). \textit{Clinical pharmacology.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/bs.irn.2025.02.003}{doi:10.1016/bs.irn.2025.02.003}.
\item Swieczkowski D, Kwaśny A, Sadko K, Pruc M, Gaca Z, Szarpak L, Cubała WJ. (2025). \textit{Lessons learned from the regulatory alignment in ketamine, esketamine and arketamine clinical trials: A cross-sectional analysis of protocols from ClinicalTrials.gov.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.psychres.2025.116559}{doi:10.1016/j.psychres.2025.116559}.
\item Wingert AM, Agnorelli C, Peill J, Reed S, Nutt DJ, Erritzoe D. (2025). \textit{Serotonergic psychedelics for depression: A comprehensive overview.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/bs.irn.2025.04.009}{doi:10.1016/bs.irn.2025.04.009}.
\item Queen's University (2025). \textit{A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06969170}{source link}.
\item Estric C, Duron T, Kabani S, Lopez-Castroman J. (2025). \textit{Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811251338214}{doi:10.1177/02698811251338214}.
\item Chen MJQ, Chen-Li D, Chisamore N, Husain MI, Di Vincenzo JD, Mansur RB, Phan L, Johnson D, McIntyre RS, Rosenblat JD. (2025). \textit{Non-hallucinogenic psychedelics for mood and anxiety disorders: A systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.psychres.2025.116532}{doi:10.1016/j.psychres.2025.116532}.
\item Weintraub MJ, Miklowitz DJ, Jeffrey JK. (2025). \textit{Divergent Effects of Psilocybin for 2 Patients Participating in a Psilocybin-assisted Cognitive Behavioral Therapy Trial for Major Depressive Disorder.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1097/pra.0000000000000853}{doi:10.1097/pra.0000000000000853}.
\item Saara Susan Sevander, Marja-Liisa Rissanen (2025). \textit{The benefits and harm of psychedelics in the treatment of patients with mental health and substance abuse disorders: an integrative literature review}. Unknown journal. [published; OpenAlex]. \href{https://doi.org/10.59476/hesdia.v0i1.700}{doi:10.59476/hesdia.v0i1.700}.
\item Unknown authors (2025). \textit{Psilocybin-assisted therapy shows range of benefits in cancer patients}. The Brown University Psychopharmacology Update. [published; OpenAlex]. \href{https://doi.org/10.1002/pu.31316}{doi:10.1002/pu.31316}.
\item Centre for Addiction and Mental Health (2025). \textit{Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06518720}{source link}.
\item Louise Penzenstadler, Sandra Baudois, Alma Lingenberg, Sabina Catalano Chiuvé, Emilie Tomkova, Vanessa Fleury (2025). \textit{[Treatment with psychedelics: potential benefits in Parkinson's disease].}. PubMed. [published; OpenAlex]. \href{https://doi.org/10.53738/revmed.2025.21.915.47180}{doi:10.53738/revmed.2025.21.915.47180}.
\item Cummins BR, Billac GB, Nichols DE, Nichols CD. (2025). \textit{5-HT2A receptors: Pharmacology and functional selectivity.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.pharmr.2025.100059}{doi:10.1016/j.pharmr.2025.100059}.
\item Falchi-Carvalho M, Palhano-Fontes F, Wießner I, Barros H, Bolcont R, Laborde S, Ruschi B Silva S, Montanini D, C Barbosa D, Teixeira E, Florence-Vilela R, Almeida R, K A de Macedo R, Arichelle F, J Pantrigo É, V Costa-Macedo J, da Cruz Nunes JA, de Araújo Costa Neto LA, Nunes Ferreira LF, Dantas Corrêa L, da Costa Bezerra RB, Arcoverde E, Galvão-Coelho N, B Araujo D. (2025). \textit{Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1038/s41386-025-02091-6}{doi:10.1038/s41386-025-02091-6}.
\item DuPont CM, Johnson MW. (2025). \textit{Psychedelics and substance use disorder treatment.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/bs.irn.2025.03.005}{doi:10.1016/bs.irn.2025.03.005}.
\item Nilubon Thaoboonruang, Ornrat Lohitnavy, Kimheang Ya, Manupat Lohitnavy (2025). \textit{Development of a PBPK model of psilocybin/psilocin from Psilocybe cubensis (magic mushroom) in mice, rats, and humans}. Scientific Reports. [published; OpenAlex]. \href{https://doi.org/10.1038/s41598-025-98202-w}{doi:10.1038/s41598-025-98202-w}.
\item Mimms C, Sotelo K, Khaliq AS. (2025). \textit{Comparative Efficacy and Functional Outcomes of Psychedelic-Assisted Therapies in Treatment-Resistant Depression: A Systematic Review of Recent Clinical Trials.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.7759/cureus.82532}{doi:10.7759/cureus.82532}.
\item Damian Świeczkowski, Aleksander Kwaśny, Michał Pruc, Zuzanna Gaca, Łukasz Szarpak, Wiesław Jerzy Cubała (2025). \textit{Regulatory Alignment of Psilocybin Clinical Trials in Major Depressive Disorder on ClinicalTrials.gov: A Cross-Sectional Analysis}. Pharmacopsychiatry. [published; OpenAlex]. \href{https://doi.org/10.1055/a-2529-7029}{doi:10.1055/a-2529-7029}.
\item Kevin Boehnke (2025). \textit{A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Psilocybin Administration in Concert With Psychotherapy Among Adult Patients With Fibromyalgia}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05128162}{source link}.
\item Meshkat S, Malik G, Zeifman RJ, Swainson J, Balachandra K, Reichelt AC, Zhang Y, Burback L, Winkler O, Greenshaw A, Vermetten E, Mayo LM, Tanguay R, Jetly R, Bhat V. (2025). \textit{Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.neubiorev.2025.106163}{doi:10.1016/j.neubiorev.2025.106163}.
\item Umbacia MA, Leon MX, Quintero JM, Castro LM, Paez V, Dodd S, Bustos RH. (2025). \textit{Exploring psilocybin's role in mental health and palliative medicine: a path to improved well-being.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/14728214.2025.2488786}{doi:10.1080/14728214.2025.2488786}.
\item Erica Kaczmarek, Nelson B. Rodrigues, Noah Chisamore, Zoe Doyle, Roger S. McIntyre, Rodrigo B. Mansur, Joshua D. Rosenblat (2025). \textit{187. Changes in Symptoms of Anhedonia With Psilocybin-Assisted Psychotherapy: A Secondary Analysis of a Randomized Clinical Trial for Treatment-Resistant Depression}. Biological Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.biopsych.2025.02.424}{doi:10.1016/j.biopsych.2025.02.424}.
\item University of Otago (2025). \textit{Psilocybin-assisted Interpersonal Therapy for Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05581797}{source link}.
\item Omidian H, Omidian A. (2025). \textit{The Emergence of Psilocybin in Psychiatry and Neuroscience.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3390/ph18040555}{doi:10.3390/ph18040555}.
\item Tim Schäfer, Alexander M. Sherwood, Thomas A. Kirkland, Thomas Krüger, Jakob Worbs, Olaf Kniemeyer, Markus Gressler, Dirk Hoffmeister (2025). \textit{In Vitro Psilocybin Synthesis by Co-Immobilized Enzymes}. Chemistry - A European Journal. [published; OpenAlex]. \href{https://doi.org/10.1002/chem.202501037}{doi:10.1002/chem.202501037}.
\item Jennifer Jones (2025). \textit{Harnessing neuroplasticity with psychoplastogens: the essential role of psychotherapy in psychedelic treatment optimization}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2025.1565852}{doi:10.3389/fpsyt.2025.1565852}.
\item Emmanuelle A. D. Schindler, Christopher Gottschalk, Deepak Cyril D’Souza (2025). \textit{Psilocybin’s Effects on Headache Frequency are Not Related to Acute Psychedelic Effects or Measures of Mental Health: Secondary Analysis of Clinical Trials in Migraine and Cluster Headache (P7-12.001)}. Neurology. [published; OpenAlex]. \href{https://doi.org/10.1212/wnl.0000000000210945}{doi:10.1212/wnl.0000000000210945}.
\item Totomanova I, Haijen ECHM, Hurks PPM, Ramaekers JG, Kuypers KPC. (2025). \textit{Potential therapeutic effects of psychedelics in small doses: Is there a role for microdosing in psychiatry?}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/bs.irn.2025.03.002}{doi:10.1016/bs.irn.2025.03.002}.
\item Nathalie M. Rieser, Raoul Bitar, Simon Halm, Christina Rossgoderer, Ladina P Gubser, Maeva Thévenaz, Yara Kreis, Robin von Rotz, Carlos Nordt, Monika Visentini, Flora Moujaes, Etna Engeli, Andres Ort, Erich Seifritz, Franz Xaver Vollenweider, Marcus Herdener, Katrin H. Preller (2025). \textit{Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial}. Universität Zürich, ZORA. [published; OpenAlex]. \href{https://doi.org/10.5167/uzh-284304}{doi:10.5167/uzh-284304}.
\item Ioana A. Cristea, G Tomei, Jazmín Freddi, A. Bonessio (2025). \textit{Selective outcome reporting and non-reporting in trials of psychedelic drugs for mental disorders}. European Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1192/j.eurpsy.2025.393}{doi:10.1192/j.eurpsy.2025.393}.
\item Jenna Matsukubo, Sarah Dickson, Jennifer Xiao, Erik Loewen Friesen, Marco Solmi, Jess G. Fiedorowicz, Benedikt Fischer, Daniel T. Myran (2025). \textit{Psilocybin Dispensaries and Online Health Claims in Canada}. JAMA Network Open. [published; OpenAlex]. \href{https://doi.org/10.1001/jamanetworkopen.2025.2853}{doi:10.1001/jamanetworkopen.2025.2853}.
\item Vanessa L. Beesley, Tom Kennedy, Fiona Maccallum, Margaret Ross, Renee Harvey, Susan L. Rossell, Jerome Sarris, Daniel Perkins, Rachel Ε. Neale, James Bennett-Levy, Shevaugn Johnson, Hanna Beebe, Natalie Roset, Jörg Strobel, Stephen Parker (2025). \textit{Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief (PARTING) trial: protocol for an open-label pilot trial for cancer-related bereavement}. BMJ Open. [published; OpenAlex]. \href{https://doi.org/10.1136/bmjopen-2024-095992}{doi:10.1136/bmjopen-2024-095992}.
\item Unity Health Toronto (2025). \textit{Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06731335}{source link}.
\item Bires J. (2025). \textit{Existing evidence for the use of psychedelics in patients with cancer and other serious illness: A narrative review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/07347332.2025.2482917}{doi:10.1080/07347332.2025.2482917}.
\item Noah Chisamore, Erica Kaczmarek, Zoe Doyle, Danica E. Johnson, Geneva Weiglein, Shakila Meshkat, Ryan M. Brudner, Marc G. Blainey, Jeremy Riva-Cambrin, Roger S. McIntyre, Joshua D. Rosenblat (2025). \textit{Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l’étude}. The Canadian Journal of Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1177/07067437251328316}{doi:10.1177/07067437251328316}.
\item McMaster University (2025). \textit{An 8-week Phase 2 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-assisted-psychotherapy in Adults With Cannabis Use Disorder: A Proof-of-Concept Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06225232}{source link}.
\item Centre Hospitalier Universitaire de Nīmes (2025). \textit{Psilocybin in Alcohol Use Disorder With Comorbid Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06235411}{source link}.
\item Repple J, Bayas M, Möser C, Kobayashi NF, Reif A. (2025). \textit{Current Evidence for the Role of Rapid-Acting Antidepressants in Bipolar Depression: A Perspective and Plan for Action.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.biopsych.2025.02.903}{doi:10.1016/j.biopsych.2025.02.903}.
\item University Hospital, Basel, Switzerland (2025). \textit{Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05523401}{source link}.
\item Aicher HD, Müller F, Gasser P. (2025). \textit{Further education in psychedelic-assisted therapy - experiences from Switzerland.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1186/s12909-025-06871-y}{doi:10.1186/s12909-025-06871-y}.
\item Craig, Danny R, Blalock, Eric M. (2025). \textit{Could psilocin rescue chronic, stress-accelerated, transcriptional aging in brain?}. UKnowledge (University of Kentucky). [published; OpenAlex]. \href{https://uknowledge.uky.edu/jpns/vol2/iss1/1}{source link}.
\item Unknown authors (2025). \textit{Psilocybin therapy might help frontline pandemic workers}. The Brown University Psychopharmacology Update. [published; OpenAlex]. \href{https://doi.org/10.1002/pu.31292}{doi:10.1002/pu.31292}.
\item Belitzky E, Ravani Carvalho LV, Taylor M, Ortiz CN, Baum L, Fiellin DA, Lustberg MB. (2025). \textit{Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1002/cam4.70586}{doi:10.1002/cam4.70586}.
\item Petrovitch D, Hosford S, Littlefield AK, Austin-Robillard H. (2025). \textit{Sociodemographic and mental-health characteristics of psychedelic-assisted therapy participants: Latent class analysis of a cross-sectional, purposive online sample}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/26tz7\_v1}{doi:10.31234/osf.io/26tz7\_v1}.
\item Unknown authors (2025). \textit{Sociodemographic and mental-health characteristics of psychedelic-assisted therapy participants: Latent class analysis of a cross-sectional, purposive online sample}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/26tz7\_v1}{source link}.
\item Michel Bourin (2025). \textit{Psychedelics are Bringing a new wind to the Pharmacopoeia}. Neuroscience and Neurological Surgery. [published; OpenAlex]. \href{https://doi.org/10.31579/2578-8868/360}{doi:10.31579/2578-8868/360}.
\item Silva F, Butlen-Ducuing F, Guizzaro L, Balabanov P. (2025). \textit{A review of psychedelics trials completed in depression, informed by European regulatory perspectives.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.nsa.2025.105516}{doi:10.1016/j.nsa.2025.105516}.
\item Ari Brouwer, Joshua K. Brown, Earth Erowid, Fire Erowid, Sylvia Thyssen, Charles L. Raison, Robin Carhart-Harris (2025). \textit{A qualitative analysis of the psychedelic mushroom come-up and come-down}. npj Mental Health Research. [published; OpenAlex]. \href{https://doi.org/10.1038/s44184-024-00095-6}{doi:10.1038/s44184-024-00095-6}.
\item Lucido MJ, Dunlop BW. (2025). \textit{Emerging Medications for Treatment-Resistant Depression: A Review with Perspective on Mechanisms and Challenges.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3390/brainsci15020161}{doi:10.3390/brainsci15020161}.
\item Hogea L, Tabugan DC, Costea I, Albai O, Nussbaum L, Cojocaru A, Corsaro L, Anghel T. (2025). \textit{The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3390/medicina61020278}{doi:10.3390/medicina61020278}.
\item David A. Bender, Sandeep M. Nayak, Joshua S. Siegel, David J. Hellerstein, Barış Erçal, Eric J. Lenze (2025). \textit{Psychological Support Approaches in Psychedelic Therapy}. The Journal of Clinical Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.4088/jcp.24m15521}{doi:10.4088/jcp.24m15521}.
\item Joseph A. Zamaria, Gisele Fernandes-Osterhold, Jonathan Shedler, Rachel Yehuda (2025). \textit{Psychedelics assisting therapy, or therapy assisting psychedelics? The importance of psychotherapy in psychedelic-assisted therapy}. Frontiers in Psychology. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyg.2025.1505894}{doi:10.3389/fpsyg.2025.1505894}.
\item de Miranda AS, C B Toscano E, Venna VR, Graeff FG, Teixeira AL. (2025). \textit{Investigating novel pharmacological strategies for treatment-resistant depression: focus on new mechanisms and approaches.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/17460441.2025.2460674}{doi:10.1080/17460441.2025.2460674}.
\item Matthew Weirick Johnson (2025). \textit{Clinical Trial Comparing Psilocybin to Nicotine Patch for Tobacco Addiction}. Drug and Alcohol Dependence. [published; OpenAlex]. \href{https://doi.org/10.1016/j.drugalcdep.2024.112187}{doi:10.1016/j.drugalcdep.2024.112187}.
\item Piper T, Small F, Brown S, Kelleher M, Mitcheson L, Rucker J, Young AH, Marsden J. (2025). \textit{Psychedelic-assisted treatment for substance use disorder: A narrative systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1111/add.16762}{doi:10.1111/add.16762}.
\item Carrie Cuttler, Amanda Stueber, Jonathan J. Simone, Leah M. Mayo (2025). \textit{Down the Rabbit Hole: A Large-Scale Survey of Psychedelic Users’ Patterns of Use and Perceived Effects}. Journal of Psychoactive Drugs. [published; OpenAlex]. \href{https://doi.org/10.1080/02791072.2025.2452226}{doi:10.1080/02791072.2025.2452226}.
\item Central Institute of Mental Health, Mannheim (2025). \textit{A Phase II Randomized, Double-blind, Active Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Psilocybin in Treatment-resistant Major Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04670081}{source link}.
\item Liebnau J, Betzler F, Kerber A. (2025). \textit{Catalyst for change: Psilocybin's antidepressant mechanisms-A systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811241312866}{doi:10.1177/02698811241312866}.
\item Melani A, Bonaso M, Biso L, Zucchini B, Conversano C, Scarselli M. (2025). \textit{Uncovering Psychedelics: From Neural Circuits to Therapeutic Applications.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3390/ph18010130}{doi:10.3390/ph18010130}.
\item Roman Palitsky, Jessica L. Maples-Keller, Caroline Peacock, Boadie W. Dunlop, Tanja Mletzko, George H. Grant, Charles L. Raison, Sam Chao, Isabelle Shub, Michal Mendelbaum-Kweller, Liam Smolyar, Deanna M. Kaplan, Barbara O. Rothbaum, Ali John Zarrabi (2025). \textit{A critical evaluation of psilocybin-assisted therapy protocol components from clinical trial patients, facilitators, and caregivers.}. Psychotherapy. [published; OpenAlex]. \href{https://doi.org/10.1037/pst0000551}{doi:10.1037/pst0000551}.
\item Haft SL, Downey AE, Raymond-Flesch M, Fernandes-Osterhold G, Bradley ER, O'Donovan A, Woolley J. (2025). \textit{A systematic review of participant diversity in psychedelic-assisted psychotherapy trials.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.psychres.2025.116359}{doi:10.1016/j.psychres.2025.116359}.
\item Constantino JL, van Dalfsen JH, Massetti S, Kamphuis J, Schoevers RA. (2025). \textit{Neurobiological mechanisms of antidepressant properties of psilocybin: A systematic review of blood biomarkers.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.pnpbp.2025.111251}{doi:10.1016/j.pnpbp.2025.111251}.
\item Erkizia-Santamaría I, Horrillo I, Meana JJ, Ortega JE. (2025). \textit{Clinical and preclinical evidence of psilocybin as antidepressant. A narrative review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.pnpbp.2025.111249}{doi:10.1016/j.pnpbp.2025.111249}.
\item Chen J, Wang Z, Yong CY, Goh EML, Moy HY, Chan ECY. (2025). \textit{Elucidating the Phase I metabolism of psilocin in vitro.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s00204-024-03952-7}{doi:10.1007/s00204-024-03952-7}.
\item Socoró Garrigosa M, Sanz Perl Y, Kringelbach ML, Carhart-Harris R, Vohryzek J, Deco G. (2025). \textit{Perturbing whole-brain models of brain hierarchy: an application for depression following pharmacological treatment}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2025.01.01.631011}{doi:10.1101/2025.01.01.631011}.
\item Muniz, John Marco D.F. (2024). \textit{Comparative Efficacy of Hallucinogens in Treating Mood Disorders Through a Meta-Analysis of Symptom Reduction, Dosage, and Duration}. Journal of International Crisis and Risk Communication Research. [published; OpenAlex]. \href{https://stars.library.ucf.edu/hut2024/268}{source link}.
\item Hancock, Mackenzie, Shambhu Prasad Adhikari, Getz, Nicole (2024). \textit{Psilocybin-Assisted Therapy for Trauma-Related Disorders: A Scoping Review of a Depression-Dominated Evidence Base with Implications for Intimate Partner Violence-Related PTSD}. Open Science Framework. [published; OpenAlex]. \href{https://doi.org/10.17605/osf.io/ar2s4}{doi:10.17605/osf.io/ar2s4}.
\item Henrique Tofoli Vieira Machado, GEOVANA MENDES DE SEIXAS, L. Silva, Mariana Duarte Garcia Brito, Gabriella Assink de Castro (2024). \textit{Alternative therapy for neurological and psychiatric disorders using psilocybin}. Unknown journal. [published; OpenAlex]. \href{https://doi.org/10.5327/1516-3180.cpn.1123}{doi:10.5327/1516-3180.cpn.1123}.
\item Unknown authors (2024). \textit{Supplemental Material for A Critical Evaluation of Psilocybin-Assisted Therapy Protocol Components From Clinical Trial Patients, Facilitators, and Caregivers}. Psychotherapy. [published; OpenAlex]. \href{https://doi.org/10.1037/pst0000551.supp}{doi:10.1037/pst0000551.supp}.
\item Barnett BS, Vest MF, Delatte MS, King Iv F, Mauney EE, Coulson AJ, Nayak SM, Hendricks PS, Greer GR, Murnane KS (2024). \textit{Practical considerations in the establishment of psychedelic research programs.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-024-06722-6}{doi:10.1007/s00213-024-06722-6}.
\item Namik Kirlić, Molly Lennard-Jones, Merve Atli, Ekaterina Malievskaia, Nadav Liam Modlin, Stéphanie Knatz Peck, Alice Gaillard, Guy M. Goodwin, Don Koelpin (2024). \textit{Compass Psychological Support Model for COMP360 Psilocybin Treatment of Serious Mental Health Conditions}. American Journal of Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.ajp.20230884}{doi:10.1176/appi.ajp.20230884}.
\item Fonzo GA, Wolfgang AS, Barksdale BR, Krystal JH, Carpenter LL, Kraguljac NV, Grzenda A, McDonald WM, Widge AS, Rodriguez CI, Nemeroff CB. (2024). \textit{Psilocybin: From Psychiatric Pariah to Perceived Panacea.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1176/appi.ajp.20230682}{doi:10.1176/appi.ajp.20230682}.
\item Ramaekers JG, Reckweg JT, Mason NL. (2024). \textit{Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1176/appi.ajp.20230890}{doi:10.1176/appi.ajp.20230890}.
\item Scott T. Aaronson, Andrew van der Vaart, Tammy Miller, Jeffrey LaPratt, Kimberly Swartz, Audrey Shoultz, Margo Lauterbach, Trisha Suppes, Harold A. Sackeïm (2024). \textit{Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial}. American Journal of Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.ajp.20231063}{doi:10.1176/appi.ajp.20231063}.
\item Broc A. Pagni, Richard J. Zeifman, Sarah E. Mennenga, Brennan M. Carrithers, Noam Goldway, Snehal Bhatt, Kelley C. O’Donnell, Stephen Ross, Michael P. Bogenschutz (2024). \textit{Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial}. American Journal of Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.ajp.20230887}{doi:10.1176/appi.ajp.20230887}.
\item Manzano-Nunez R, Gomez DA, Toledo-Mendoza C, Perez-Otero M, Matilla IL, Prats C, Perez-Lopez E, Pardo H, Díaz-Pellicer P, De La Torre-Fornell R, Aldea AM. (2024). \textit{Exploring Psychedelics Pharmacology: A Scoping Review Charting the Course of Psilocybin Pharmacokinetics.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1097/wnf.0000000000000617}{doi:10.1097/wnf.0000000000000617}.
\item Lewis BR, Hendrick J, Byrne K, Odette M, Wu C, Garland EL. (2024). \textit{Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical Trial}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2024.12.31.24319806}{doi:10.1101/2024.12.31.24319806}.
\item Bostoen T, Tap S, Breeksema J, Schoevers R (2024). \textit{Post-traumatic stress disorder in psychedelic research.}. International review of neurobiology. [published; PubMed]. \href{https://doi.org/10.1016/bs.irn.2025.02.004}{doi:10.1016/bs.irn.2025.02.004}.
\item Katherine Cheung, Maxwell Brodie, Sue-Ling Chang, P. Deschamps, Jean-Sébastien Fallu, Houman Farzin, Johanne Hébert, Jean-François Stephan, Michel Dorval, Yann Joly, for the P3A Study Group (2024). \textit{Psychedelic Treatment with Psilocybin: Addressing Medical Malpractice Risk and Physicians’ Concerns}. The Journal of Law Medicine \& Ethics. [published; OpenAlex]. \href{https://doi.org/10.1017/jme.2025.10109}{doi:10.1017/jme.2025.10109}.
\item McHerron D, Barber M, Ham R, Liknaitzky P, Carter A, Gardner J (2024). \textit{The ethical use of therapeutic touch in psychedelic-assisted therapy: a qualitative study of researcher perspectives and experiences.}. Therapeutic advances in psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1177/20451253251377191}{doi:10.1177/20451253251377191}.
\item Papp N, Gonda X. (2024). \textit{[Psychedelics and pyschodelic-associated psychotherapies - Who is PAP for after all?]}. Unknown journal. [published; Europe PMC]. \href{https://europepmc.org/article/MED/42412648}{source link}.
\item Khalaud Naseeb Alhajry, Zahra Mohammed Sukairi, Hamidah Abdullah Lajami, Safiah Anber Bin Ali Ibrahim, Nawal Obaid Alanazi, Eman Ali Alsafwani, Ashwag Saad Hnif Albishi, Nada Naser Alomi, Zahrh Ahmed Ali Al-Hamadah, Anwar Mehdaf Akash Alrowaly (2024). \textit{Psychedelic-Assisted Therapy: The Emerging Role of the Psychiatric-Mental Health Nurse}. Saudi Journal of Medicine and Public Health. [published; OpenAlex]. \href{https://doi.org/10.64483/20251153}{doi:10.64483/20251153}.
\item Mohammad Ali, Urbah Viqar (2024). \textit{Treatment-Resistant Depression: A Comprehensive Insight of Ketamine Infusion Therapy, Transcranial Magnetic Stimulation (TMS), and Psychedelic-Assisted Psychotherapy}. Annals of Punjab Medical College. [published; OpenAlex]. \href{https://doi.org/10.29054/apmc/2024.1658}{doi:10.29054/apmc/2024.1658}.
\item Swieczkowski D, Kwaśny A, Pruc M, Gaca Z, Szarpak L, Cubała WJ. (2024). \textit{Efficacy and safety of psilocybin in the treatment of Major Depressive Disorder (MDD): A dose-response network meta-analysis of randomized placebo-controlled clinical trials.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.psychres.2024.116337}{doi:10.1016/j.psychres.2024.116337}.
\item Geller J, Whitney E. (2024). \textit{Therapeutic Potential of MDMA- and Psychedelic-Assisted Psychotherapy for Adolescent Depression and Trauma.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s11920-024-01577-2}{doi:10.1007/s11920-024-01577-2}.
\item Barnett JH, Todd KT, Benetatos J, Rabichow BE, Gibson KA, Olney KC, Fryer JD. (2024). \textit{Psilocybin causes sex, time, and dose dependent alterations in brain signaling pathways}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2024.12.16.628764}{doi:10.1101/2024.12.16.628764}.
\item Christina M. Andrews, Wayne Hall, Keith Humphreys, John Marsden (2024). \textit{Disentangling debate about therapeutic and recreational use of psychedelics}. Addiction. [published; OpenAlex]. \href{https://doi.org/10.1111/add.16744}{doi:10.1111/add.16744}.
\item Freitas RR, Gotsis ES, Gallo AT, Fitzgibbon BM, Bailey NW, Fitzgerald PB. (2024). \textit{The safety of psilocybin-assisted psychotherapy: A systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/00048674241289024}{doi:10.1177/00048674241289024}.
\item Meyer TD, Ibrahim M, Vale LN, Soares JC. (2024). \textit{Psychedelic use and bipolar disorder - An investigation of recreational use and its impact on mental health.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jad.2024.12.044}{doi:10.1016/j.jad.2024.12.044}.
\item Ethan G. Dutcher, Andrew D. Krystal (2024). \textit{Treatment Expectancies and Psilocybin vs Escitalopram for Depression}. JAMA Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1001/jamapsychiatry.2024.4387}{doi:10.1001/jamapsychiatry.2024.4387}.
\item Jonathan Brett, Elizabeth Knock, Kathy Watson, Steven M. Albert, Krista J. Siefried, Jeffrey Guss (2024). \textit{Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2024.1490907}{doi:10.3389/fpsyt.2024.1490907}.
\item Anthony L. Back, Timara K. Freeman-Young, Ladybird Morgan, Tanmeet Sethi, Kelsey K. Baker, Susanna Myers, Bonnie A. McGregor, Kalin Harvey, Marlene Tai, Austin Kollefrath, Brandon J. Thomas, Dennis Sorta, Mendel Kaelen, Benjamin Kelmendi, Ted Gooley (2024). \textit{Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic}. JAMA Network Open. [published; OpenAlex]. \href{https://doi.org/10.1001/jamanetworkopen.2024.49026}{doi:10.1001/jamanetworkopen.2024.49026}.
\item Juan Scuro (2024). \textit{God hasn’t died, it has merely been encapsulated - Psilocybin and ayahuasca in the psychedelic renaissance: Intersections between religion, indigenous cosmologies, spirituality, and science}. Social Compass. [published; OpenAlex]. \href{https://doi.org/10.1177/00377686241301923}{doi:10.1177/00377686241301923}.
\item Spangemacher M, Mertens LJ, Färber LV, Jungaberle A, Jungaberle H, Gründer G. (2024). \textit{Psilocybin as a Disease-Modifying Drug-A Salutogenic Approach in Psychiatry.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3238/arztebl.m2024.0224}{doi:10.3238/arztebl.m2024.0224}.
\item Sabé M, Sulstarova A, Glangetas A, De Pieri M, Mallet L, Curtis L, Richard-Lepouriel H, Penzenstadler L, Seragnoli F, Thorens G, Zullino D, Preller K, Böge K, Leucht S, Correll CU, Solmi M, Kaiser S, Kirschner M. (2024). \textit{Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1038/s41380-024-02800-5}{doi:10.1038/s41380-024-02800-5}.
\item Nadav Liam Modlin, Tyler McPhee, Nira Zazon, Maria Sarang, Rebecca Hignett, Susannah Pick, Anthony J. Cleare, Victoria Williamson, James Rucker (2024). \textit{Participants’ Experience of Psychedelic Integration Groups and Processes: A Qualitative Thematic Analysis}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1089/psymed.2024.0027}{doi:10.1089/psymed.2024.0027}.
\item Noah D. Gold, Broc A. Pagni, Petros Petridis, Michael P. Bogenschutz (2024). \textit{Psilocybin-Assisted Therapy May Enhance Conservation Values in Patients with Alcohol Use Disorder}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1089/psymed.2024.0030}{doi:10.1089/psymed.2024.0030}.
\item Yale University (2024). \textit{Psilocybin Treatment in Obsessive-Compulsive Disorder: a Preliminary Efficacy Study and Exploratory Investigation of Neural Correlates.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT03356483}{source link}.
\item TRYP Therapeutics (2024). \textit{A Phase 2a Safety and Feasibility Study Evaluating Psilocybin (TRP-8802) Administration in Concert With Psychotherapy in the Treatment of Binge Eating Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05035927}{source link}.
\item Reid MJ, Kettner H, Blanken TF, Weiss B, Carhart-Harris R. (2024). \textit{Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s11920-024-01539-8}{doi:10.1007/s11920-024-01539-8}.
\item Stéphanie Knatz Peck, Hannah M. Fisher, Jessie Kim, Samantha Shao, Julie Trim, Walter H. Kaye (2024). \textit{Psychedelic treatment for anorexia nervosa: A first-hand view of how psilocybin treatment did and did not help}. Psychedelics.. [published; OpenAlex]. \href{https://doi.org/10.61373/pp024e.0034}{doi:10.61373/pp024e.0034}.
\item Aday JS, McAfee J, Conroy DA, Hosanagar A, Tarnal V, Weston C, Scott K, Horowitz D, Harte SE, Pouyan N, Glynos NG, Baker AK, Guss J, Davis AK, Burgess HJ, Mashour GA, Clauw DJ, Boehnke KF. (2024). \textit{Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, pilot clinical trial}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/j8zb5}{doi:10.31234/osf.io/j8zb5}.
\item Unknown authors (2024). \textit{Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, pilot clinical trial}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/j8zb5\_v1}{source link}.
\item Mourad Wahba, Caroline Hayes, Maartje Kletter, R. Hamish McAllister-Williams (2024). \textit{Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: case report and thematic analysis of one participant's experience}. BJPsych Open. [published; OpenAlex]. \href{https://doi.org/10.1192/bjo.2024.768}{doi:10.1192/bjo.2024.768}.
\item Mourad Wahba, Caroline Hayes, Maartje Kletter, R. Hamish McAllister-Williams (2024). \textit{Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: case report and thematic analysis of one participant's experience}. BJPsych Open. [published; OpenAlex]. \href{https://doi.org/10.1192/bjo.2024.768}{source link}.
\item Luoma JB, Wilson-Poe A, Pertl K, Hoffman K, Bazinet A, Stauffer C, McCarty D, Korthuis P. (2024). \textit{Personal Psychedelic Experience as a Training Qualification for Facilitators: A Thematic Analysis of Qualitative Interviews with Psilocybin Experts}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/dwhcu\_v1}{doi:10.31234/osf.io/dwhcu\_v1}.
\item Unknown authors (2024). \textit{Personal Psychedelic Experience as a Training Qualification for Facilitators: A Thematic Analysis of Qualitative Interviews with Psilocybin Experts}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/dwhcu\_v1}{source link}.
\item Sepehr Aghajanian, Arman Shafiee, Samira Parvizi Omran, Aida Rezaei Nejad, Kyana Jafarabady, Omid Kohandel Gargari, Shahryar Rajai Firouzabadi, Ida Mohammadi, Touran Bahrami Babaheidari, Mahmood Bakhtiyari (2024). \textit{Psilocybin for major depressive disorder: An updated systematic review and meta-analysis of randomized clinical trials}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811241287542}{doi:10.1177/02698811241287542}.
\item Filament Health Corp. (2024). \textit{A Registered Clinical Trial of PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06666010}{source link}.
\item Min H, Park SY, Park J, Na S, Lee HS, Kim T, Ham J, Park YT. (2024). \textit{A narrative exploration of psilocybin's potential in mental health.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3389/fpsyt.2024.1429373}{doi:10.3389/fpsyt.2024.1429373}.
\item Pamela Kryskow, Paul Stamets, Joseph La Torre, Kathy Sattler, Vivian W. L. Tsang, Monnica T. Williams (2024). \textit{“The mushroom was more alive and vibrant”: Patient reports of synthetic versus organic forms of psilocybin}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2024.00379}{doi:10.1556/2054.2024.00379}.
\item Imperial College London (2024). \textit{Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT03429075}{source link}.
\item Perez Rosal SR, La Torre JT, Birnkammer S, Chernoloz O, Williams MT, Faber SC. (2024). \textit{Expert recommendations for Germany's integration of psychedelic-assisted therapy.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1186/s12909-024-06141-3}{doi:10.1186/s12909-024-06141-3}.
\item University Health Network, Toronto (2024). \textit{Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06506019}{source link}.
\item Danielle R. Adams, Heidi Allen, Ginger E. Nicol, Leopoldo J. Cabassa (2024). \textit{Moving psychedelic-assisted therapies from promising research into routine clinical practice: Lessons from the field of implementation science}. Translational Behavioral Medicine. [published; OpenAlex]. \href{https://doi.org/10.1093/tbm/ibae053}{doi:10.1093/tbm/ibae053}.
\item Kargbo RB. (2024). \textit{Expanding the Therapeutic Horizons of Psilocybin in Mental Health.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1021/acsmedchemlett.4c00488}{doi:10.1021/acsmedchemlett.4c00488}.
\item James Rucker, Matthew Butler, Sadie Hambleton, Catherine Bird, Mathieu Seynaeve, Sanjay Cheema, Kete Campbell-Coker, Carolina Maggio, Fiona Dunbar, Giorgio Lambru, Manjit Matharu (2024). \textit{Plain Language Summary Publication: Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: Results from an open-label phase Ib ascending dose study}. Headache The Journal of Head and Face Pain. [published; OpenAlex]. \href{https://doi.org/10.1111/head.14846}{doi:10.1111/head.14846}.
\item MycoMedica Life Sciences PBC (2024). \textit{A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 (psilocybin) in Healthy Participants}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06326606}{source link}.
\item Daniel Spinosa, Stacy M. Fischer, Richard J. Zeifman, Carolyn Lefkowits, Petros Petridis, Stephen Ross (2024). \textit{PR012/\#955 Psilocybin assisted psychotherapy for patients with ovarian caner: a subset analysis of a randomized, double-blind, placebo-controlled, phase II clinical trial}. International Journal of Gynecological Cancer. [published; OpenAlex]. \href{https://doi.org/10.1136/ijgc-2024-igcs.54}{doi:10.1136/ijgc-2024-igcs.54}.
\item Sarris J, Halman A, Urokohara A, Lehrner M, Perkins D (2024). \textit{Artificial intelligence and psychedelic medicine.}. Annals of the New York Academy of Sciences. [published; PubMed]. \href{https://doi.org/10.1111/nyas.15229}{doi:10.1111/nyas.15229}.
\item Elizabeth L. Fisher, Ryan Smith, Kyna-Anne Conn, Andrew W. Corcoran, Laura K Milton, Jakob Hohwy, Claire J. Foldi (2024). \textit{Psilocybin increases optimistic engagement over time: computational modelling of behaviour in rats}. Translational Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1038/s41398-024-03103-7}{doi:10.1038/s41398-024-03103-7}.
\item Western University, Canada (2024). \textit{The Effects of Psilocybin on Shared Experience in Film Processing}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06529939}{source link}.
\item Sara Ellis, Catherine Bostian, Wendy Feng, E. Grace Fischer, Garrett Schwartz, Katherine Eisen, Melanie Lean, Elizabeth Conlan, Michael J. Ostacher, Scott T. Aaronson, Trisha Suppes (2024). \textit{Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study}. Journal of Affective Disorders. [published; OpenAlex]. \href{https://doi.org/10.1016/j.jad.2024.09.133}{doi:10.1016/j.jad.2024.09.133}.
\item David Erritzøe, Tommaso Barba, Kyle T. Greenway, Roberta Murphy, Jonny Martell, Bruna Giribaldi, Christopher Timmermann, Ashleigh Murphy-Beiner, Michelle Baker Jones, David Nutt, Brandon Weiss, Robin Carhart-Harris (2024). \textit{Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial}. EClinicalMedicine. [published; OpenAlex]. \href{https://doi.org/10.1016/j.eclinm.2024.102799}{doi:10.1016/j.eclinm.2024.102799}.
\item James Rucker, Matthew Butler, Sadie Hambleton, Catherine Bird, Mathieu Seynaeve, Sanjay Cheema, Kete Campbell-Coker, Carolina Maggio, Fiona Dunbar, Giorgio Lambru, Manjit Matharu (2024). \textit{Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study}. Headache The Journal of Head and Face Pain. [published; OpenAlex]. \href{https://doi.org/10.1111/head.14837}{doi:10.1111/head.14837}.
\item Armstrong SB, Davis AK. (2024). \textit{Psychedelic research at a crossroads.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1126/science.adt1024}{doi:10.1126/science.adt1024}.
\item Danielle B Rodrigues (2024). \textit{Use of Psilocybin in the Treatment of Mental Disorders: Systematic Review of Clinal Trials}. Journal of Complementary Medicine \& Alternative Healthcare. [published; OpenAlex]. \href{https://doi.org/10.19080/jcmah.2024.13.555852}{doi:10.19080/jcmah.2024.13.555852}.
\item Li G, Facchini PJ. (2024). \textit{New frontiers in the biosynthesis of psychoactive specialized metabolites.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.pbi.2024.102626}{doi:10.1016/j.pbi.2024.102626}.
\item Thaoboonruang N, Lohitnavy M, Lohitnavy O. (2024). \textit{Pharmacokinetics of Psilocybin, a Tryptamine Alkaloid in Magic Mushroom (Psilocybe cubensis): A Systematic Review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/02791072.2024.2399128}{doi:10.1080/02791072.2024.2399128}.
\item Low ZXB, Ng WS, Lim ESY, Goh BH, Kumari Y. (2024). \textit{The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.pnpbp.2024.111139}{doi:10.1016/j.pnpbp.2024.111139}.
\item Cynthia Duan, Navid Farkhondehpay, Viana Safa, Emma Yuan (2024). \textit{Usage of Psilocybin to Treat Huntington's Disease: A Research Protocol}. Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal. [published; OpenAlex]. \href{https://doi.org/10.26685/urncst.644}{doi:10.26685/urncst.644}.
\item Smith CL, Sackett N, Stark BC, Dinh V, Romesburg EW, Roll J (2024). \textit{Understanding Psychedelic-Assisted Psychotherapy Providers' Perspective and Insights: A Qualitative Analysis.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2023.0074}{doi:10.1089/psymed.2023.0074}.
\item Najib J. (2024). \textit{The role of psilocybin in depressive disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/03007995.2024.2396536}{doi:10.1080/03007995.2024.2396536}.
\item Klučková T, Nikolič M, Tylš F, Viktorin V, Vejmola Č, Viktorinová M, Bravermanová A, Androvičová R, Andrashko V, Korčák J, Zach P, Hájková K, Kuchař M, Balíková M, Brunovský M, Horáček J, Páleníček T. (2024). \textit{The phenomenology of psilocybin’s experience mediates subsequent persistent psychological effects independently of sex, previous experience or setting}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2024.08.26.24311611}{doi:10.1101/2024.08.26.24311611}.
\item Jensen ME, Stenbæk DS, Messell CD, Poulsen ED, Varga TV, Fisher PM, Nielsen MKK, Johansen SS, Volkow ND, Knudsen GM, Fink-Jensen A. (2024). \textit{­­­­Single-Dose Psilocybin Therapy for Alcohol Use Disorder: Pharmacokinetics, Feasibility, Safety, and Efficacy in an Open-Label Study}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-4947184/v1}{doi:10.21203/rs.3.rs-4947184/v1}.
\item Lodetti G, de Bitencourt RM, Rico EP. (2024). \textit{Classic psychedelics and the treatment for alcoholism.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.pnpbp.2024.111129}{doi:10.1016/j.pnpbp.2024.111129}.
\item Hsu TW, Tsai CK, Kao YC, Thompson T, Carvalho AF, Yang FC, Tseng PT, Hsu CW, Yu CL, Tu YK, Liang CS. (2024). \textit{Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1136/bmj-2023-078607}{doi:10.1136/bmj-2023-078607}.
\item Kargbo RB. (2024). \textit{Current Trends in Psychedelic Science: Integrating Modified Lysergic Acid Derivatives and Psilocybin in Modern Medicine.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1021/acsmedchemlett.4c00414}{doi:10.1021/acsmedchemlett.4c00414}.
\item Alnagger NL, Cardone P, Martial C, Sanz Perl Y, Mindlin I, Sitt JD, Roseman L, Carhart-Harris R, Nutt D, Mallaroni P, Mason NL, Ramaekers JG, Bonhomme V, Laureys S, Deco G, Gosseries O, Nunez P, Annen J. (2024). \textit{A virtual clinical trial of psychedelics to treat patients with disorders of consciousness}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2024.08.16.608251}{doi:10.1101/2024.08.16.608251}.
\item Salvetti G, Saccenti D, Moro AS, Lamanna J, Ferro M. (2024). \textit{Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3390/brainsci14080829}{doi:10.3390/brainsci14080829}.
\item Kim A, Halton B, Shah A, Seecof OM, Ross S. (2024). \textit{Psilocybin-assisted psychotherapy for existential distress: practical considerations for therapeutic application-a review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.21037/apm-24-35}{doi:10.21037/apm-24-35}.
\item Clairvoyant Therapeutics (2024). \textit{A24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05646303}{source link}.
\item Chen MH, Cheng SL, Kao YC, Tseng PT, Hsu CW, Yu CL, Yang FC, Thompson T, Hsu TW, Liang CS. (2024). \textit{The association between diverse psychological protocols and the efficacy of psilocybin-assisted therapy for clinical depressive symptoms: a Bayesian meta-analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3389/fpsyt.2024.1439347}{doi:10.3389/fpsyt.2024.1439347}.
\item Michael P. Bogenschutz (2024). \textit{A clinical research perspective on the regulation of medical and non-medical use of psychedelic drugs}. Addiction. [published; OpenAlex]. \href{https://doi.org/10.1111/add.16647}{doi:10.1111/add.16647}.
\item Brugmann University Hospital (2024). \textit{Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy \& (Neuro)Cognitive Mechanisms}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06160232}{source link}.
\item Gustavo Deco, Yonatan Sanz Perl, Samuel Johnson, Niamh Bourke, Robin Carhart-Harris, Morten L. Kringelbach (2024). \textit{Different hierarchical reconfigurations in the brain by psilocybin and escitalopram for depression}. Nature Mental Health. [published; OpenAlex]. \href{https://doi.org/10.1038/s44220-024-00298-y}{doi:10.1038/s44220-024-00298-y}.
\item Nicky J. Mehtani, Mallory O. Johnson, Peter S. Hendricks, Jennifer Mitchell, B. Anderson (2024). \textit{Psilocybin-assisted therapy and HIV-related shame}. Scientific Reports. [published; OpenAlex]. \href{https://doi.org/10.1038/s41598-024-68908-4}{doi:10.1038/s41598-024-68908-4}.
\item Aday JS, Horton D, Fernandes-Osterhold G, O'Donovan A, Bradley ER, Rosen RC, Woolley JD (2024). \textit{Psychedelic-assisted psychotherapy: where is the psychotherapy research?}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-024-06620-x}{doi:10.1007/s00213-024-06620-x}.
\item Sara de la Salle, Hannes Kettner, Julien Thibault Lévesque, Nicolas Garel, Shannon Dames, Ryan Patchett-Marble, Soham Rej, Sara G. Gloeckler, David Erritzøe, Robin Carhart-Harris, Kyle T. Greenway (2024). \textit{Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy}. Scientific Reports. [published; OpenAlex]. \href{https://doi.org/10.1038/s41598-024-66817-0}{doi:10.1038/s41598-024-66817-0}.
\item André Do, Vanessa Michaud, Jean-François Stephan, Miltiadis Moreau, Élise Benoît, Felix-Antoine Berubé, Antoine Bibaud-De Serres, Alain Taillefer, Philippe Vincent (2024). \textit{Serotoninergic antidepressants combination in psilocybin-assisted psychotherapy: a case report}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2024.1394962}{doi:10.3389/fpsyt.2024.1394962}.
\item Kristoffer Andreas Aamodt Andersen, Bjørn Holmøy, Lowan H. Stewart (2024). \textit{Assessment of psychedelic--induced states: Norwegian translation and adaptation of the revised Mystical Experience Questionnaire (MEQ-30)}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2024.00346}{doi:10.1556/2054.2024.00346}.
\item Hussein El Bourji, Aziz Farhat, Zahi Hamdan, Ritvij Satodiya, Rashmi Shukla, Samer El Hayek (2024). \textit{Psilocybin in the Management of Substance Use Disorders: A Summary ofCurrent Evidence}. Current Psychopharmacologye. [published; OpenAlex]. \href{https://doi.org/10.2174/0122115560288779240628043307}{doi:10.2174/0122115560288779240628043307}.
\item Stéphanie Knatz Peck, Samantha Shao, Tessa Gruen, Kevin H. Yang, Alexandra Babakanian, Julie Trim, Daphna M. Finn, Walter H. Kaye (2024). \textit{Psilocybin Therapy for Females With Anorexia Nervosa: A Phase 1, Open-Label Feasibility Study}. FOCUS The Journal of Lifelong Learning in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.focus.24022013}{doi:10.1176/appi.focus.24022013}.
\item DeBattista C, Schatzberg AF. (2024). \textit{The Black Book of Psychotropic Dosing and Monitoring.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.64719/pb.4493}{doi:10.64719/pb.4493}.
\item Brownstien M, Lazar M, Botvinnik A, Shevakh C, Blakolmer K, Lerer L, Lifschytz T, Lerer B. (2024). \textit{Striking Long Term Beneficial Effects of Single Dose Psilocybin and Psychedelic Mushroom Extract in the SAPAP3 Rodent Model of OCD-Like Excessive Self-Grooming}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2024.06.25.600634}{doi:10.1101/2024.06.25.600634}.
\item Grant Jones, Jocelyn A. Ricard, Matthew K. Nock (2024). \textit{Race and ethnicity moderate the associations between lifetime psilocybin use and past year hypertension}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2024.1169686}{doi:10.3389/fpsyt.2024.1169686}.
\item Appiani FJ, Caroff SN. (2024). \textit{The cyclical revival of psychedelics in psychiatric treatment.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/03007995.2024.2368725}{doi:10.1080/03007995.2024.2368725}.
\item P. Todd Korthuis, Kim Hoffman, Adrianne R. Wilson-Poe, Jason B. Luoma, Alissa Bazinet, Kellie Pertl, David L. Morgan, Ryan Cook, Sarann Bielavitz, Renae Myers, R. Cameron Wolf, Dennis McCarty, Christopher S. Stauffer (2024). \textit{Developing the Open Psychedelic Evaluation Nexus consensus measures for assessment of supervised psilocybin services: An e-Delphi study}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811241257839}{doi:10.1177/02698811241257839}.
\item Torrado Pacheco A, Moghaddam B. (2024). \textit{Licit use of illicit drugs for treating depression: the pill and the process.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1172/jci180217}{doi:10.1172/jci180217}.
\item Downey AE, Bradley ER, Lerche AS, O'Donovan A, Krystal AD, Woolley J. (2024). \textit{A Plea for Nuance: Should People with a Family History of Bipolar Disorder Be Excluded from Clinical Trials of Psilocybin Therapy?}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1089/psymed.2023.0051}{doi:10.1089/psymed.2023.0051}.
\item P. Todd Korthuis, Adrianne R. Wilson-Poe, Joshua C. Black, Andrew A. Monte (2024). \textit{Commentary on Darkeet al.: Expanded psychedelic access requires new safety monitoring systems}. Addiction. [published; OpenAlex]. \href{https://doi.org/10.1111/add.16589}{doi:10.1111/add.16589}.
\item Linda M. Richmond (2024). \textit{Psychedelics’ Use as Medicine Hits Significant Roadblock}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2024.07.7.54}{doi:10.1176/appi.pn.2024.07.7.54}.
\item Sandra Szafoni, Piotr Gręblowski, Klaudia Grabowska, Gniewko Więckiewicz (2024). \textit{Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2024.1406888}{doi:10.3389/fpsyt.2024.1406888}.
\item Petrovitch D, Mitchell SM, Van Allen J, Littlefield AK. (2024). \textit{Who believes psychedelic-assisted therapies work? Risky cannabis use and other factors are associated with positive treatment-outcome expectancies}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/adnpg}{doi:10.31234/osf.io/adnpg}.
\item University of Sydney (2024). \textit{A Multi-centre, Double-blinded, Placebo-controlled, Randomised, Phase II Clinical Trial for Psilocybin-assisted Therapy for Alcohol Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06444243}{source link}.
\item Unknown authors (2024). \textit{Who believes psychedelic-assisted therapies work? Risky cannabis use and other factors are associated with positive treatment-outcome expectancies}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/adnpg\_v1}{source link}.
\item Chisamore N, Johnson D, Chen MJQ, Offman H, Chen-Li D, Kaczmarek ES, Doyle Z, McIntyre RS, Rosenblat JD. (2024). \textit{Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jpsychires.2024.05.051}{doi:10.1016/j.jpsychires.2024.05.051}.
\item Hoyer D. (2024). \textit{On serotonin, psychedelics, entactogens and psychoplastogens in depression, anxiety, post-traumatic stress, and related disorders.}. Authorea Preprints. [preprint; Europe PMC]. \href{https://doi.org/10.22541/au.171648613.31141136/v1}{doi:10.22541/au.171648613.31141136/v1}.
\item Ehrenkranz R, Agrawal M, Penberthy JK, Yaden DB. (2024). \textit{Narrative review of the potential for psychedelics to treat Prolonged Grief Disorder.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/09540261.2024.2357668}{doi:10.1080/09540261.2024.2357668}.
\item Fisher EL, Smith R, Corcoran AW, Milton LK, Conn K, Hohwy J, Foldi CJ. (2024). \textit{Psilocybin increases optimistic engagement over time: computational modelling of behavior in rats}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2024.05.16.594614}{doi:10.1101/2024.05.16.594614}.
\item Nathan Bryson, Robert Alexander, Aviva Asnis-Alibozek, Michael Ehlers (2024). \textit{RE104: Synthesis and Activity of a Novel Serotonergic Psychedelic Prodrug of 4-Hydroxy-N,N-diisopropyltryptamine}. ACS Chemical Neuroscience. [published; OpenAlex]. \href{https://doi.org/10.1021/acschemneuro.4c00058}{doi:10.1021/acschemneuro.4c00058}.
\item Shunichiro Ikeda, Toshihiko Kinoshita (2024). \textit{Psychedelic renaissance: A renewed focus on the clinical utility of hallucinogens}. Psychiatry and Clinical Neurosciences Reports. [published; OpenAlex]. \href{https://doi.org/10.1002/pcn5.196}{doi:10.1002/pcn5.196}.
\item Jeffrey JK, Weintraub MJ, Grob CS. (2024). \textit{Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jaac.2024.03.021}{doi:10.1016/j.jaac.2024.03.021}.
\item Anthony L. Back, Susanna Myers, John Guy, Juliana Pérez, Leslie Lazar Thorn, Bonnie A. McGregor (2024). \textit{Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted Therapy}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1089/psymed.2023.0069}{doi:10.1089/psymed.2023.0069}.
\item University of Calgary (2024). \textit{Mechanisms Supporting Psilocybin-assisted Psychotherapy for Alcohol Use Disorder: A Randomized, Controlled Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05995769}{source link}.
\item Stephen N. Xenakis, Scott Shannon (2024). \textit{What is needed for the roll-out of psychedelic treatments?}. Current Opinion in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1097/yco.0000000000000946}{doi:10.1097/yco.0000000000000946}.
\item British Medical Journal Publishing Group (2024). \textit{EXPRESSION OF CONCERN: Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis}. BMJ. [published; OpenAlex]. \href{https://doi.org/10.1136/bmj.q1025}{doi:10.1136/bmj.q1025}.
\item Hanna Brancaccio (2024). \textit{Efficacy of Psilocybin in the Treatment of Substance and Alcohol Use Disorders}. Unknown journal. [published; OpenAlex]. \href{https://doi.org/10.31986/issn.2689-0690\_rdw.stratford\_research\_day.149\_2024}{doi:10.31986/issn.2689-0690\_rdw.stratford\_research\_day.149\_2024}.
\item Claire Parker, Bethany Wood (2024). \textit{At the Forefront: Social Workers’ Role in Psilocybin Treatment for Depression and Substance Misuse}. Social Work. [published; OpenAlex]. \href{https://doi.org/10.1093/sw/swae019}{doi:10.1093/sw/swae019}.
\item Nicholas A Kerna, Kevin D. Pruitt, N.D. Victor Carsrud, Kyle Kadivi, Dabeluchi C. Ngwu, Hilary M. Holets, John V. Flores, Ijeoma Nnake, Cornelius I. Azi, Joseph Anderson, Fatimah A. Olunlade, Uzoamaka Nwokorie (2024). \textit{From Venerable Cultural Practices to Modern Psychological Solutions: Enter Entheogens into Mainstream Medicine}. European Journal of Arts Humanities and Social Sciences. [published; OpenAlex]. \href{https://doi.org/10.59324/ejahss.2024.1(3).10}{doi:10.59324/ejahss.2024.1(3).10}.
\item Metaxa AM, Clarke M. (2024). \textit{Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1136/bmj-2023-078084}{doi:10.1136/bmj-2023-078084}.
\item Jan Thomann, Karolina E. Kolaczynska, Oliver V Stoeckmann, Deborah Rudin, Patrick Vizeli, Marius C. Hoener, Christopher R. Pryce, Franz X. Vollenweider, Matthias E. Liechti, Urs Duthaler (2024). \textit{In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin}. Frontiers in Pharmacology. [published; OpenAlex]. \href{https://doi.org/10.3389/fphar.2024.1391689}{doi:10.3389/fphar.2024.1391689}.
\item Kyna-Anne Conn, Laura K Milton, Kaixin Huang, Hermany Munguba, Janika Ruuska, M. B. Lemus, Erin Greaves, Jihane Homman-Ludiye, Brian J. Oldfield, Claire J. Foldi (2024). \textit{Psilocybin restrains activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms}. Molecular Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1038/s41380-024-02575-9}{doi:10.1038/s41380-024-02575-9}.
\item Tobias P. Whelan, Eileen Daly, Nicolaas A.J. Puts, Paula Smith, Carrie Allison, Simon Baron-Cohen, Ekaterina Malievskaia, Declan Murphy, Gráinne McAlonan (2024). \textit{The ‘PSILAUT’ protocol: an experimental medicine study of autistic differences in the function of brain serotonin targets of psilocybin}. BMC Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1186/s12888-024-05768-2}{doi:10.1186/s12888-024-05768-2}.
\item Downey AE, Chaphekar AV, Woolley J, Raymond-Flesch M. (2024). \textit{Psilocybin therapy and anorexia nervosa: a narrative review of safety considerations for researchers and clinicians.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1186/s40337-024-01005-z}{doi:10.1186/s40337-024-01005-z}.
\item Terri D’Arrigo (2024). \textit{MedCheck: Psilocybin for Depression, LSD for Anxiety, Donanemab, LSD, and More}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2024.05.5.1}{doi:10.1176/appi.pn.2024.05.5.1}.
\item Jensen AA, Cecchi CR, Hibicke M, Bach AH, Kaadt E, Märcher-Rørsted E, Nichols CD, Elfving B, Kristensen JL. (2024). \textit{The selective 5-HT2A receptor agonist LPH-5 induces persistent and robust antidepressant-like effects in rodents}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2024.04.19.590212}{doi:10.1101/2024.04.19.590212}.
\item Emil Märcher-Rørsted, Anders A. Jensen, Gints Šmits, Karla Frydenvang, Jesper L. Kristensen (2024). \textit{Discovery and Structure-Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5-HT2A Receptor Agonists}. Journal of Medicinal Chemistry. [published; OpenAlex]. \href{https://doi.org/10.1021/acs.jmedchem.4c00082}{doi:10.1021/acs.jmedchem.4c00082}.
\item Section for Affective Disorders; Northern Stockholm Psychiatry (2024). \textit{The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density - A Single Dose Randomized, Double Blind, Placebo- Controlled Phase 2 Positron Emission Tomography Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04630964}{source link}.
\item Köhne S, Hillemacher T, Glahn A, Bach P. (2024). \textit{Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/14728214.2024.2342951}{doi:10.1080/14728214.2024.2342951}.
\item Jordan Sloshower, Richard J. Zeifman, Jeffrey Guss, Robert Krause, Hamideh Safi-Aghdam, Surbhi Pathania, Brian Pittman, Deepak Cyril D’Souza (2024). \textit{Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial}. Scientific Reports. [published; OpenAlex]. \href{https://doi.org/10.1038/s41598-024-58318-x}{doi:10.1038/s41598-024-58318-x}.
\item Valerie A. Canady (2024). \textit{Psychedelic therapists, pharma collaborate on clinical trial}. Mental Health Weekly. [published; OpenAlex]. \href{https://doi.org/10.1002/mhw.34009}{doi:10.1002/mhw.34009}.
\item Erika Dyck (2024). \textit{Who will staff the psychedelic resurgence?}. Open Access Government. [published; OpenAlex]. \href{https://doi.org/10.56367/oag-042-10690}{doi:10.56367/oag-042-10690}.
\item López E, Yngwe H, Beckman M, Tiger M, Hieronymus F, Lundberg J. (2024). \textit{[Psychedelic psychiatry].}. Unknown journal. [published; Europe PMC]. \href{https://europepmc.org/article/MED/38572715}{source link}.
\item Rachael Wilkes, Darren M. Roberts, Paul Liknaitzky, Jonathan Brett (2024). \textit{The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics}. Clinical Toxicology. [published; OpenAlex]. \href{https://doi.org/10.1080/15563650.2024.2346612}{doi:10.1080/15563650.2024.2346612}.
\item J. S. Seo (2024). \textit{Current situation regarding psychedelics and magic mushroom in Korea}. European Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1192/j.eurpsy.2024.1695}{doi:10.1192/j.eurpsy.2024.1695}.
\item Kim P. C. Kuypers (2024). \textit{Microdosing psychedelics in the treatment of ADHD and comorbid disorders}. European Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1192/j.eurpsy.2024.44}{doi:10.1192/j.eurpsy.2024.44}.
\item Yerubandi A, Thomas JE, Bhuiya NMMA, Harrington C, Villa Zapata L, Caballero J. (2024). \textit{Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1001/jamanetworkopen.2024.5960}{doi:10.1001/jamanetworkopen.2024.5960}.
\item Sarah A. Norring, Michael G. Spigarelli (2024). \textit{The Promise of Therapeutic Psilocybin: An Evaluation of the 134 Clinical Trials, 54 Potential Indications, and 0 Marketing Approvals on ClinicalTrials.gov}. Drug Design Development and Therapy. [published; OpenAlex]. \href{https://doi.org/10.2147/dddt.s443177}{doi:10.2147/dddt.s443177}.
\item Terri D’Arrigo (2024). \textit{MedCheck; Psilocybin, Roluperidone, Latozinemab, Lacosamide}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2024.04.4.1}{doi:10.1176/appi.pn.2024.04.4.1}.
\item David Erritzøe, Tommaso Barba, Meg J. Spriggs, Fernando E. Rosas, David Nutt, Robin Carhart-Harris (2024). \textit{Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811241237870}{doi:10.1177/02698811241237870}.
\item Adrian Preda (2024). \textit{Psychedelic Renaissance: Evidence and Culture}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2024.04.4.39}{doi:10.1176/appi.pn.2024.04.4.39}.
\item Ben Seal (2024). \textit{Psychedelic drugs and the law: What’s next?}. Knowable Magazine. [published; OpenAlex]. \href{https://doi.org/10.1146/knowable-031424-2}{doi:10.1146/knowable-031424-2}.
\item Adam W. Levin, Rafael Lancelotta, Nathan D. Sepeda, Natalie Gukasyan, Sandeep M. Nayak, Theodore L. Wagener, Frederick S. Barrett, Roland R. Griffiths, Alan K. Davis (2024). \textit{The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder}. PLoS ONE. [published; OpenAlex]. \href{https://doi.org/10.1371/journal.pone.0300501}{doi:10.1371/journal.pone.0300501}.
\item Brandon Weiss, Leor Roseman, Bruna Giribaldi, David Nutt, Robin Carhart-Harris, David Erritzøe (2024). \textit{Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder}. International Journal of Mental Health and Addiction. [published; OpenAlex]. \href{https://doi.org/10.1007/s11469-024-01253-9}{doi:10.1007/s11469-024-01253-9}.
\item Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas, Bryce D. Beutler, Kirsten Cherian, Viviana D. Evans, Chelsey Fasano, Owen S. Muir (2024). \textit{Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview}. American Journal of Therapeutics. [published; OpenAlex]. \href{https://doi.org/10.1097/mjt.0000000000001727}{doi:10.1097/mjt.0000000000001727}.
\item Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas, Bryce D. Beutler, Kirsten Cherian, Viviana D. Evans, Chelsey Fasano, Owen S. Muir (2024). \textit{Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin}. American Journal of Therapeutics. [published; OpenAlex]. \href{https://doi.org/10.1097/mjt.0000000000001724}{doi:10.1097/mjt.0000000000001724}.
\item Dana DiRenzo, Frederick S. Barrett, Jamie Perin, Erika Darrah, Lisa Christopher-Stine, Roland R. Griffiths (2024). \textit{Impact of Psilocybin on Peripheral Cytokine Production}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1089/psymed.2023.0039}{doi:10.1089/psymed.2023.0039}.
\item Hashimoto K. (2024). \textit{Are "mystical experiences" essential for antidepressant actions of ketamine and the classic psychedelics?}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s00406-024-01770-7}{doi:10.1007/s00406-024-01770-7}.
\item Brouwer A, Brown JK, Erowid E, Erowid F, Thyssen S, Raison CL, Carhart-Harris RL. (2024). \textit{The Temporal Trajectory of the Psychedelic Mushroom Experience Mimics the Narrative Arc of the Hero’s Journey}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-3941205/v1}{doi:10.21203/rs.3.rs-3941205/v1}.
\item Balázs Szigeti, Boris D. Heifets (2024). \textit{Expectancy Effects in Psychedelic Trials}. Biological Psychiatry Cognitive Neuroscience and Neuroimaging. [published; OpenAlex]. \href{https://doi.org/10.1016/j.bpsc.2024.02.004}{doi:10.1016/j.bpsc.2024.02.004}.
\item Fang S, Yang X, Zhang W. (2024). \textit{Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3389/fpsyt.2024.1359088}{doi:10.3389/fpsyt.2024.1359088}.
\item Joshua D. Rosenblat, Shakila Meshkat, Zoe Doyle, Erica Kaczmarek, Ryan M. Brudner, Kevin Kratiuk, Rodrigo B. Mansur, Christian Schulz, Rickinder Sethi, Amanda Abate, Shaun Ali, Jordan Bawks, Marc G. Blainey, Elisa Brietzke, Victoria Cronin, Jessica Danilewitz, Shalini Dhawan, Anthony Di Fonzo, M. Di Fonzo, Pawel Drzadzewski, William Dunlop, Hajnalka Fiszter, Fabiano A. Gomes, Smrita Grewal, Marisa Leon-Carlyle, Marilyn McCallum, Niki Mofidi, Hilary Offman, Jeremy Riva-Cambrin, Joel E. Schmidt, Mark E. Smolkin, Joan M. Quinn, Andrea Zumrova, Michelle Marlborough, Roger S. McIntyre (2024). \textit{Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin}. Med. [published; OpenAlex]. \href{https://doi.org/10.1016/j.medj.2024.01.005}{doi:10.1016/j.medj.2024.01.005}.
\item Broc A. Pagni, Petros Petridis, Samantha K. Podrebarac, Jack Grinband, Eric D. Claus, Michael P. Bogenschutz (2024). \textit{Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: an fMRI pilot study}. Scientific Reports. [published; OpenAlex]. \href{https://doi.org/10.1038/s41598-024-52967-8}{doi:10.1038/s41598-024-52967-8}.
\item Tommaso Barba, Hannes Kettner, Caterina Radu, Joseph Peill, Leor Roseman, David Nutt, David Erritzøe, Robin Carhart-Harris, Bruna Giribaldi (2024). \textit{Psychedelics and sexual functioning: a mixed-methods study}. Scientific Reports. [published; OpenAlex]. \href{https://doi.org/10.1038/s41598-023-49817-4}{doi:10.1038/s41598-023-49817-4}.
\item Joost J. Breeksema, Alistair Niemeijer, Erwin Krediet, T.L. Karsten, Jeanine Kamphuis, Eric Vermetten, Wim van den Brink, Robert A. Schoevers (2024). \textit{Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study}. Scientific Reports. [published; OpenAlex]. \href{https://doi.org/10.1038/s41598-024-53188-9}{doi:10.1038/s41598-024-53188-9}.
\item Phil Wolfson, Gita Vaid (2024). \textit{Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective-a new and evolving approach}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2024.1209419}{doi:10.3389/fpsyt.2024.1209419}.
\item Borissova A, Rucker JJ. (2024). \textit{The development of psilocybin therapy for treatment-resistant depression: an update.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1192/bjb.2023.25}{doi:10.1192/bjb.2023.25}.
\item Houman Farzin (2024). \textit{Psilocybin-assisted psychotherapy for cancer patients}. International Journal of Whole Person Care. [published; OpenAlex]. \href{https://doi.org/10.26443/ijwpc.v11i1.390}{doi:10.26443/ijwpc.v11i1.390}.
\item Bouchet L, Sager Z, Yrondi A, Nigam KB, Anderson BT, Ross S, Petridis PD, Beaussant Y. (2024). \textit{Older adults in psychedelic-assisted therapy trials: A systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811231215420}{doi:10.1177/02698811231215420}.
\item E-Wen McCulloch D, Liechti ME, Kuypers KP, Nutt D, Lundberg J, Stenbæk DS, Goodwin GM, Gründer G, Butlen-Ducuing F, Haberkamp M, Thirstrup S, Knudsen GM. (2024). \textit{Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.nsa.2024.103938}{doi:10.1016/j.nsa.2024.103938}.
\item Terence H. W. Ching, Lucia Amoroso, Calvin Bohner, Elizabeth J. D’Amico, Jeffrey Eilbott, Tara Entezar, Madison Fitzpatrick, Geena Fram, Rachael Grazioplene, Jamila Hokanson, Anastasia Jankovsky, Stephen A. Kichuk, Bradford Martins, Prerana Patel, Henry Schaer, Sarah Shnayder, Chelsea Witherow, Christopher Pittenger, Benjamin Kelmendi (2024). \textit{Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2023.1278823}{doi:10.3389/fpsyt.2023.1278823}.
\item Johns Hopkins University (2024). \textit{Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05562973}{source link}.
\item Devon Stoliker, Leonardo Novelli, Franz X. Vollenweider, Gary F. Egan, Katrin H. Preller, Adeel Razi (2024). \textit{Neural Mechanisms of Resting-State Networks and the Amygdala Underlying the Cognitive and Emotional Effects of Psilocybin}. Biological Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.biopsych.2024.01.002}{doi:10.1016/j.biopsych.2024.01.002}.
\item Vanderijst L, Hever F, Buot A, Dauré C, Benoit J, Hanak C, Veeser J, Morgiève M, Campanella S, Kornreich C, Mallet L, Leys C, Noël X. (2024). \textit{Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Protocol for a Double-Blind, Randomized, Placebo-Controlled, 7-month Parallel-Group Phase II Superiority Trial}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-3829237/v1}{doi:10.21203/rs.3.rs-3829237/v1}.
\item Prosenjit Ghosh, Avinash Desousa (2023). \textit{Psychedelics: The New Kid on the Block}. Annals of Indian Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.4103/aip.aip\_195\_23}{doi:10.4103/aip.aip\_195\_23}.
\item Jacobs E, Murphy-Beiner A, Rouiller I, Nutt D, Spriggs MJ (2023). \textit{When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research.}. Neuroethics. [published; PubMed]. \href{https://doi.org/10.1007/s12152-023-09536-z}{doi:10.1007/s12152-023-09536-z}.
\item M. Madsen, Anja Sofie Petersen, Dea Siggaard Stenbæk, Inger Marie Sørensen, Harald Schiønning, Tobias Fjeld, Charlotte H. Nykjær, Sara Marie Ulv Larsen, Maria Zofia Grzywacz, Tobias Mathiesen, Ida L. Klausen, Oliver Overgaard-Hansen, Kristoffer Brendstrup-Brix, Kristían Línnet, Sys Stybe Johansen, Patrick M. Fisher, Rigmor Jensen, Gitte M. Knudsen (2023). \textit{CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity}. Headache The Journal of Head and Face Pain. [published; OpenAlex]. \href{https://doi.org/10.1111/head.14656}{doi:10.1111/head.14656}.
\item Zaretsky TG, Jagodnik KM, Barsic R, Antonio JH, Bonanno PA, MacLeod C, Pierce C, Carney H, Morrison MT, Saylor C, Danias G, Lepow L, Yehuda R. (2023). \textit{The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.2174/1570159x22666231027111147}{doi:10.2174/1570159x22666231027111147}.
\item Thomas KL, Jesse R, Mehtani NJ, Mitchell JM, Anderson BT (2023). \textit{Commentary: Evidence-Informed Recommendation to Achieve Approximate Parity in the Allowed Number of Doses for Common Psychedelics.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2023.2201244}{doi:10.1080/02791072.2023.2201244}.
\item Verheijen Marcha C.T. (2023). \textit{Psilocybin Therapy for Depression: A Review of Current Molecular Knowledge}. Journal of the Netherlands Society of Toxicology. [published; Crossref]. \href{https://doi.org/10.61833/jnst.2024.0002}{doi:10.61833/jnst.2024.0002}.
\item Tabaac BJ, Shinozuka K, Arenas A, Beutler BD, Cherian K, Evans VD, Fasano C, Muir OS. (2023). \textit{Psychedelic Therapy: A Primer for Primary Care Clinicians - Part I. Historical Perspective and Overview}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/byms6}{doi:10.31234/osf.io/byms6}.
\item Tabaac BJ, Shinozuka K, Arenas A, Beutler BD, Cherian K, Evans VD, Fasano C, Muir OS. (2023). \textit{Psychedelic Therapy: A Primer for Primary Care Clinicians - Part IV. Psilocybin}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/a8xwk}{doi:10.31234/osf.io/a8xwk}.
\item Unknown authors (2023). \textit{Psychedelic Therapy: A Primer for Primary Care Clinicians - Part I. Historical Perspective and Overview}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/byms6\_v1}{source link}.
\item Unknown authors (2023). \textit{Psychedelic Therapy: A Primer for Primary Care Clinicians - Part IV. Psilocybin}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/a8xwk\_v1}{source link}.
\item Śladowska K, Kawalec P, Brzostek T, Pilc A. (2023). \textit{Potential use of psilocybin drugs in the treatment of depression.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/14728214.2023.2264180}{doi:10.1080/14728214.2023.2264180}.
\item Jingxuan Chen (2023). \textit{Application of psilocybin in mental health disorders}. Theoretical and Natural Science. [published; OpenAlex]. \href{https://doi.org/10.54254/2753-8818/21/20230859}{doi:10.54254/2753-8818/21/20230859}.
\item Lucas F. Borkel, Jaime Rojas-Hernández, Luis Alberto Henríquez-Hernández, Ángelo Santana, Domingo Jesús Quintana Hernández (2023). \textit{Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study}. Expert Review of Clinical Pharmacology. [published; OpenAlex]. \href{https://doi.org/10.1080/17512433.2023.2295997}{doi:10.1080/17512433.2023.2295997}.
\item Yvan Beaussant, Elise C. Tarbi, Kabir Nigam, Skye A. Miner, Zachary Sager, Justin J. Sanders, Michael Ljuslin, Benjamin Guérin, Paul Thambi, James A. Tulsky, Manish Agrawal (2023). \textit{Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis}. Cancer. [published; OpenAlex]. \href{https://doi.org/10.1002/cncr.35024}{doi:10.1002/cncr.35024}.
\item Manish Agrawal, William A. Richards, Yvan Beaussant, Sarah Shnayder, Rezvan Ameli, Kimberly Roddy, Norma Stevens, Brian D. Richards, Nick Schor, Heather Honstein, Betsy Jenkins, Mark Bates, Paul Thambi (2023). \textit{Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder}. Cancer. [published; OpenAlex]. \href{https://doi.org/10.1002/cncr.35010}{doi:10.1002/cncr.35010}.
\item Jonathan Reinwald, Christian N. Schmitz, Ivan Skorodumov, Martin Kuchař, Wolfgang Weber-Fahr, Rainer Spanagel, Marcus W. Meinhardt (2023). \textit{Psilocybin-induced default mode network hypoconnectivity is blunted in alcohol-dependent rats}. Translational Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1038/s41398-023-02690-1}{doi:10.1038/s41398-023-02690-1}.
\item Conn K, Milton L, Huang K, Munguba H, Ruuska J, Lemus M, Greaves E, Homman-Ludiye J, Oldfield B, Foldi C. (2023). \textit{Psilocybin prevents activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2023.12.12.571374}{doi:10.1101/2023.12.12.571374}.
\item Brennan W, Kelman AR, Belser AB. (2023). \textit{A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1089/psymed.2023.0007}{doi:10.1089/psymed.2023.0007}.
\item Ivana Turek (2023). \textit{Psychotropics: A scientific, regulatory, and public view on the medicinal uses of cannabinoids and psilocybin}. Medical Writing. [published; OpenAlex]. \href{https://doi.org/10.56012/tsen2260}{doi:10.56012/tsen2260}.
\item Duan W, Cao D, Wang S, Cheng J. (2023). \textit{Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1021/acs.chemrev.3c00375}{doi:10.1021/acs.chemrev.3c00375}.
\item Wang SM, Kim S, Choi WS, Lim HK, Woo YS, Pae CU, Bahk WM. (2023). \textit{Current Understanding on Psilocybin for Major Depressive Disorder: A Review Focusing on Clinical Trials.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.9758/cpn.23.1134}{doi:10.9758/cpn.23.1134}.
\item Tahlia R. Harrison (2023). \textit{Altered stakes: Identifying gaps in the informed consent process for psychedelic-assisted therapy trials}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2023.00267}{doi:10.1556/2054.2023.00267}.
\item Danelle Jones (2023). \textit{Psychedelic Integration: Psychotherapy for non-ordinary states of consciousness}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2023.00306}{doi:10.1556/2054.2023.00306}.
\item Hovmand OR, Poulsen ED, Arnfred S. (2023). \textit{Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811231200019}{doi:10.1177/02698811231200019}.
\item Tor-Morten Kvam, Malin V. Uthaug, Kristoffer Andreas Aamodt Andersen, Birk Berggrav Refsum, Paula Aarseth Tunstad, Lowan H. Stewart, Henrik Børsting Jacobsen, Cato Grønnerød (2023). \textit{Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2023.1287196}{doi:10.3389/fpsyt.2023.1287196}.
\item Wolinsky D, Barrett FS, Vandrey R. (2023). \textit{The psychedelic effects of cannabis: A review of the literature.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811231209194}{doi:10.1177/02698811231209194}.
\item Rhee TG, Davoudian PA, Sanacora G, Wilkinson ST. (2023). \textit{Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.drudis.2023.103818}{doi:10.1016/j.drudis.2023.103818}.
\item Unknown authors (2023). \textit{Single dose of psilocybin improves depressive symptoms in Phase 2 study}. The Brown University Psychopharmacology Update. [published; OpenAlex]. \href{https://doi.org/10.1002/pu.31093}{doi:10.1002/pu.31093}.
\item Kaminski D, Reinert JP. (2023). \textit{The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/10600280231205645}{doi:10.1177/10600280231205645}.
\item Wsół A. (2023). \textit{Cardiovascular safety of psychedelic medicine: current status and future directions.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s43440-023-00539-4}{doi:10.1007/s43440-023-00539-4}.
\item Haikazian S, Chen-Li DCJ, Johnson DE, Fancy F, Levinta A, Husain MI, Mansur RB, McIntyre RS, Rosenblat JD. (2023). \textit{Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.psychres.2023.115531}{doi:10.1016/j.psychres.2023.115531}.
\item Robert H. Dworkin, Michael McDermott, Sandeep M. Nayak, Eric C. Strain (2023). \textit{Psychedelics and Psychotherapy: Is the Whole Greater than the Sum of its Parts?}. Clinical Pharmacology \& Therapeutics. [published; OpenAlex]. \href{https://doi.org/10.1002/cpt.3050}{doi:10.1002/cpt.3050}.
\item C Donegan, Dimitri Daldegan-Bueno, Rachael L. Sumner, David B Menkes, William J. Evans, Nicholas Hoeh, Frederick Sundram, Lisa Reynolds, Rhys Ponton, Alana Cavadino, Todd Smith, Partha S. Roop, Nathan Allen, Binu Abeysinghe, Darren Svirskis, Anna Forsyth, Mahima Bansal, Suresh Muthukumaraswamy (2023). \textit{An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)}. Pilot and Feasibility Studies. [published; OpenAlex]. \href{https://doi.org/10.1186/s40814-023-01399-8}{doi:10.1186/s40814-023-01399-8}.
\item Unknown authors (2023). \textit{Psilocybin shows promising results in subjects continuing to use an antidepressant}. The Brown University Psychopharmacology Update. [published; OpenAlex]. \href{https://doi.org/10.1002/pu.31089}{doi:10.1002/pu.31089}.
\item Amanda E. Downey (2023). \textit{6.3 Psilocybin Therapy for the Treatment of Young Adults With Anorexia Nervosa: State of the Research}. Journal of the American Academy of Child \& Adolescent Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.jaac.2023.07.666}{doi:10.1016/j.jaac.2023.07.666}.
\item Gold ND, Mallard AJ, Hermann JC, Zeifman RJ, Pagni BA, Bogenschutz MP, Ross S (2023). \textit{Exploring the Potential Utility of Psychedelic Therapy for Patients With Amyotrophic Lateral Sclerosis.}. Journal of palliative medicine. [published; PubMed]. \href{https://doi.org/10.1089/jpm.2022.0604}{doi:10.1089/jpm.2022.0604}.
\item Goel A, Rai Y, Sivadas S, Diep C, Clarke H, Shanthanna H, Ladha KS. (2023). \textit{Use of Psychedelics for Pain: A Scoping Review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1097/aln.0000000000004673}{doi:10.1097/aln.0000000000004673}.
\item Kwonmok Ko, Ben Carter, Anthony J. Cleare, James Rucker (2023). \textit{Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis}. Neuropsychiatric Disease and Treatment. [published; OpenAlex]. \href{https://doi.org/10.2147/ndt.s426193}{doi:10.2147/ndt.s426193}.
\item Sierra Carter, Grace Packard, Callan Coghlan, Jamilah R. George, Ashanti J. Brown, Terence H. W. Ching, Jacob Julian, Jessica L. Maples-Keller (2023). \textit{Perceptions of psychedelic-assisted therapy among Black Americans}. Journal of Mood and Anxiety Disorders. [published; OpenAlex]. \href{https://doi.org/10.1016/j.xjmad.2023.100023}{doi:10.1016/j.xjmad.2023.100023}.
\item Schuitmaker Nicole (2023). \textit{Psilocybin-Assisted Therapy: A scoping review of participants’ and facilitators’ experiences in qualitative studies}. Research, Society and Development. [published; Crossref]. \href{https://doi.org/10.33448/rsd-v12i9.43308}{doi:10.33448/rsd-v12i9.43308}.
\item Mitch Earleywine, Maha N. Mian, Joseph A. De Leo (2023). \textit{Expectancies for Subjective and Antidepressant Effects in Psilocybin Users}. Journal of Humanistic Psychology. [published; OpenAlex]. \href{https://doi.org/10.1177/00221678231194798}{doi:10.1177/00221678231194798}.
\item University of Zurich (2023). \textit{Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy and Mechanism in Alcohol Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04141501}{source link}.
\item Keith G. Heinzerling, Karina Sergi, Micah Linton, Rhianna Rich, Brittany Youssef, Inez Bentancourt, Jennifer E. Bramen, Prabha Siddarth, L. Schwartzberg, Daniel F. Kelly (2023). \textit{Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2023.1215972}{doi:10.3389/fpsyt.2023.1215972}.
\item Brian S. Barnett, Miranda Arakelian, David S. Beebe, Jared Ontko, Connor Riegal, Willie O. Siu, Jeremy Weleff, Harrison G. Pope (2023). \textit{American Psychiatrists' Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A7-Year Follow-Up Survey}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1089/psymed.2023.0036}{doi:10.1089/psymed.2023.0036}.
\item Guy M. Goodwin (2023). \textit{The psychedelic experience and treatment-resistant depression}. World Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1002/wps.21140}{doi:10.1002/wps.21140}.
\item Kargbo RB. (2023). \textit{Tryptamines and Mental Health: Activating the 5-HT Receptor for Therapeutic Potential.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1021/acsmedchemlett.3c00390}{doi:10.1021/acsmedchemlett.3c00390}.
\item Lobe Sciences Ltd. (2023). \textit{Phase 1, Open-Label, One-Treatment, Single-Dose, One-Period, Pharmacokinetic Study of Psilocin 4 mg as Its Mucic Acid Salt (L-130) Form, in Healthy Subjects Under Fasted Conditions}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06035900}{source link}.
\item Lawrence Canale, Dhvanit Raval, Preet Chatha, Katie Penn, Claudia Weber, Catherine Stout, Jeremy Weleff (2023). \textit{Classic Psychedelics for the Treatment of Depressive Disorders: An Update for Psychiatrists in Training}. American Journal of Psychiatry Residents Journal. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.ajp-rj.2023.190103}{doi:10.1176/appi.ajp-rj.2023.190103}.
\item Wolfgang AS, Hoge CW. (2023). \textit{Psychedelic-Assisted Therapy in Military and Veterans Healthcare Systems: Clinical, Legal, and Implementation Considerations.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s11920-023-01446-4}{doi:10.1007/s11920-023-01446-4}.
\item Marc J. Weintraub, Jessica Jeffrey, Charles S. Grob, Megan Ichinose, R. Lindsey Bergman, Ziva D. Cooper, David J. Miklowitz (2023). \textit{Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1089/psymed.2023.0018}{doi:10.1089/psymed.2023.0018}.
\item Herrmann Z, Levin AW, Cole SP, Slabaugh S, Barnett B, Penn A, Jain R, Raison C, Rajanna B, Jain S (2023). \textit{Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2023.0030}{doi:10.1089/psymed.2023.0030}.
\item Emmanuelle A. D. Schindler, Peter S. Hendricks (2023). \textit{Adapting psychedelic medicine for headache and chronic pain disorders}. Expert Review of Neurotherapeutics. [published; OpenAlex]. \href{https://doi.org/10.1080/14737175.2023.2246655}{doi:10.1080/14737175.2023.2246655}.
\item Sharma P, Nguyen QA, Matthews SJ, Carpenter E, Mathews DB, Patten CA, Hammond CJ. (2023). \textit{Psilocybin history, action and reaction: A narrative clinical review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811231190858}{doi:10.1177/02698811231190858}.
\item Charles L. Raison, Gerard Sanacora, Joshua Woolley, Keith G. Heinzerling, Boadie W. Dunlop, Randall Brown, Rishi Kakar, Michael Hassman, Rupal Trivedi, Reid Robison, Natalie Gukasyan, Sandeep M. Nayak, Xiaojue Hu, Kelley C. O’Donnell, Benjamin Kelmendi, Jordan Sloshower, Andrew Penn, Ellen Bradley, Daniel F. Kelly, Tanja Mletzko, Christopher R. Nicholas, Paul R. Hutson, Gary Tarpley, Malynn Utzinger, Kelsey Lenoch, Kasia Warchol, Theraysa Gapasin, Mike C. Davis, Courtney Nelson-Douthit, Steffanie H Wilson, Carrie Brown, William Linton, Matthew W. Johnson, Stephen Ross, Roland R. Griffiths (2023). \textit{Single-Dose Psilocybin Treatment for Major Depressive Disorder}. JAMA. [published; OpenAlex]. \href{https://doi.org/10.1001/jama.2023.14530}{doi:10.1001/jama.2023.14530}.
\item Natália Bernardi Videira, Vijayalekshmi Nair, Valérie Paquet, Dean Calhoun (2023). \textit{The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits}. Journal of Applied Toxicology. [published; OpenAlex]. \href{https://doi.org/10.1002/jat.4533}{doi:10.1002/jat.4533}.
\item Robert Gramling, Emily Bennett, Keith Curtis, William A. Richards, Donna M. Rizzo, Francesca Arnoldy, Logan P Hegg, Jon Porter, Heather Honstein, Susanna Pratt, Elise C. Tarbi, Maija Reblin, Paul Thambi, Manish Agrawal (2023). \textit{Developing a Direct Observation Measure of Therapeutic Connection in Psilocybin-Assisted Therapy: A Feasibility Study}. Journal of Palliative Medicine. [published; OpenAlex]. \href{https://doi.org/10.1089/jpm.2023.0189}{doi:10.1089/jpm.2023.0189}.
\item Nick Zagorski (2023). \textit{Australia Legalizes Psychedelics for Use in Depression, PTSD Therapy}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2023.09.9.20}{doi:10.1176/appi.pn.2023.09.9.20}.
\item Usona Institute (2023). \textit{A Phase 1, Two-Part Study in Healthy Volunteers to Evaluate The Effect of Psilocybin on Cardiac Repolarization and The Effect of Food on Psilocybin Pharmacokinetics}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05478278}{source link}.
\item Anna Jaremek, Joanna Kępa, Norbert Kandefer, Michał Wyszkowski, Aleksandra Grabarczyk, Anna Pawlak, Sylwia Grad, Małgorzata Gregorek, Paweł Gregorek (2023). \textit{Psilocybin's Emerging Role in Combating Depressive Disorder}. Journal of Education Health and Sport. [published; OpenAlex]. \href{https://doi.org/10.12775/jehs.2023.40.01.011}{doi:10.12775/jehs.2023.40.01.011}.
\item Amanda E. Downey, Maxine Boyd, Anita V. Chaphekar, Joshua Woolley, Marissa Raymond-Flesch (2023). \textit{“But the reality is it's happening”: A qualitative study of eating disorder providers about psilocybin-assisted psychotherapy}. International Journal of Eating Disorders. [published; OpenAlex]. \href{https://doi.org/10.1002/eat.24041}{doi:10.1002/eat.24041}.
\item Schindler EAD. (2023). \textit{The Potential of Psychedelics for the Treatment of Episodic Migraine.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s11916-023-01145-y}{doi:10.1007/s11916-023-01145-y}.
\item Jing X, Hoeh NR, Menkes DB. (2023). \textit{Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1017/s147895152300069x}{doi:10.1017/s147895152300069x}.
\item Ibrahim IB, Videbech P, Straszek SPV. (2023). \textit{Psychedelic drugs in the treatment of psychiatric disorders.}. Unknown journal. [published; Europe PMC]. \href{https://europepmc.org/article/MED/37615227}{source link}.
\item Terri D’Arrigo (2023). \textit{Med Check: FDA, Anti-Amyloid Beta Vaccine, Clinical Trials of Psychedelics, and Lumryz}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2023.08.8.3}{doi:10.1176/appi.pn.2023.08.8.3}.
\item Brain and Cognition Discovery Foundation (2023). \textit{The Efficacy and Tolerability of Psilocybin in Participants With Treatment-Resistant Depression: a Phase 2, Randomized Feasibility Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05029466}{source link}.
\item Nicolas Garel, Julien Thibault Lévesque, Dasha A. Sandra, Justin Lessard-Wajcer, Elizaveta Solomonova, Michael Lifshitz, Stéphane Richard-Devantoy, Kyle T. Greenway (2023). \textit{Imprinting: expanding the extra-pharmacological model of psychedelic drug action to incorporate delayed influences of sets and settings}. Frontiers in Human Neuroscience. [published; OpenAlex]. \href{https://doi.org/10.3389/fnhum.2023.1200393}{doi:10.3389/fnhum.2023.1200393}.
\item Unknown authors (2023). \textit{A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.1089/psymed.2023.00071}{doi:10.1089/psymed.2023.00071}.
\item Brennan B, Kelman A, Belser AB. (2023). \textit{A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/2ab59}{doi:10.31234/osf.io/2ab59}.
\item Guy M. Goodwin, Megan Croal, David Feifel, John R. Kelly, Lindsey Marwood, Sunil Mistry, Veronica O’Keane, Stéphanie Knatz Peck, Hollie Simmons, Claudia Sisa, S. C. Stansfield, Joyce Tsai, Sam Williams, Ekaterina Malievskaia (2023). \textit{Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication}. Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1038/s41386-023-01648-7}{doi:10.1038/s41386-023-01648-7}.
\item Hovmand OR, Poulsen ED, Arnfred S, Storebø OJ. (2023). \textit{Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811231180276}{doi:10.1177/02698811231180276}.
\item Grace Wade (2023). \textit{Psychedelic drug psilocybin shows promise treating anorexia in early trials}. The New Scientist. [published; OpenAlex]. \href{https://doi.org/10.1016/s0262-4079(23)01394-5}{doi:10.1016/s0262-4079(23)01394-5}.
\item Kozak Z, Johnson MW, Aaronson ST. (2023). \textit{Assessing potential of psilocybin for depressive disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/13543784.2023.2273493}{doi:10.1080/13543784.2023.2273493}.
\item Valerie A. Canady (2023). \textit{FDA issues first draft guidance on psychedelic research}. Mental Health Weekly. [published; OpenAlex]. \href{https://doi.org/10.1002/mhw.33697}{doi:10.1002/mhw.33697}.
\item Halucenex Life Sciences Inc. (2023). \textit{Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05243329}{source link}.
\item Winston De La Haye, G Walcott, Jordan Eaton, Jhoelle Beckford, Janelle D. Greene (2023). \textit{Psychedelic Assisted Psychotherapy preparing your target using psychohistoriography: a Jamaican perspective}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2023.1136990}{doi:10.3389/fpsyt.2023.1136990}.
\item Terri D’Arrigo (2023). \textit{Experts Offer Tips on Talking With Patients About Psychedelics}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2023.07.7.51}{doi:10.1176/appi.pn.2023.07.7.51}.
\item Koning E, Brietzke E. (2023). \textit{Psilocybin-assisted psychotherapy as a potential treatment for eating disorders: a narrative review of preliminary evidence.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.47626/2237-6089-2022-0597}{doi:10.47626/2237-6089-2022-0597}.
\item Tooba Noor, Areej Shakil, Aimen Waqar Khan, Syeda Mahrukh Fatima Zaidi, Hussain Sohail Rangwala, Burhanuddin Sohail Rangwala (2023). \textit{Psilocybin therapy: A novel approach to treating depression}. International Journal of Surgery Global Health. [published; OpenAlex]. \href{https://doi.org/10.1097/gh9.0000000000000175}{doi:10.1097/gh9.0000000000000175}.
\item Brandon Weiss, Induni Ginige, Lu Shannon, Bruna Giribaldi, Ashleigh Murphy-Beiner, Roberta Murphy, Michelle Baker-Jones, Jonny Martell, David Nutt, Robin Carhart-Harris, David Erritzøe (2023). \textit{Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression}. Psychological Medicine. [published; OpenAlex]. \href{https://doi.org/10.1017/s0033291723001514}{doi:10.1017/s0033291723001514}.
\item Strauss D, Ghosh S, Murray Z, Gryzenhout M. (2023). \textit{Global species diversity and distribution of the psychedelic fungal genus Panaeolus}. Unknown journal. [published; Europe PMC]. \href{https://europepmc.org/article/AGR/IND608043020}{source link}.
\item Gold ND, Podrebarac SK, White LA, Marini C, Simon NM, Mittelman MS, Ross S, Bogenschutz MP, Petridis PD (2023). \textit{Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2022.0011}{doi:10.1089/psymed.2022.0011}.
\item Scott Hoener, Aaron Wolfgang, David A. Nissan, Edmund G. Howe (2023). \textit{Ethical considerations for psychedelic-assisted therapy in military clinical settings}. Journal of Medical Ethics. [published; OpenAlex]. \href{https://doi.org/10.1136/jme-2023-108943}{doi:10.1136/jme-2023-108943}.
\item James Rucker (2023). \textit{Evidence versus expectancy: the development of psilocybin therapy}. BJPsych Bulletin. [published; OpenAlex]. \href{https://doi.org/10.1192/bjb.2023.28}{doi:10.1192/bjb.2023.28}.
\item Heal DJ, Smith SL, Belouin SJ, Henningfield JE. (2023). \textit{Psychedelics: Threshold of a Therapeutic Revolution.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.neuropharm.2023.109610}{doi:10.1016/j.neuropharm.2023.109610}.
\item Whelan TP, Daly E, Puts NA, Malievskaia E, Murphy DG, McAlonan GM. (2023). \textit{Bridging the translational neuroscience gap: Development of the ‘shiftability’ paradigm and an exemplar protocol to capture psilocybin-elicited ‘shift’ in neurobiological mechanisms in autism}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2023.05.25.23290521}{doi:10.1101/2023.05.25.23290521}.
\item Junhong Liu, Yuanyuan Wang, Ke Xia, Jinfeng Wu, Danhao Zheng, Aoling Cai, Haitao Yan, Ruibin Su (2023). \textit{Acute psilocybin increased cortical activities in rats}. Frontiers in Neuroscience. [published; OpenAlex]. \href{https://doi.org/10.3389/fnins.2023.1168911}{doi:10.3389/fnins.2023.1168911}.
\item University of Wisconsin, Madison (2023). \textit{Recall of Experience and Conscious Awareness in Psilocybin Treatment of Depression (The RECAP Study): Pilot Phase in Healthy Adult Volunteers}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04842045}{source link}.
\item Lasch A, Schweikert T, Dora E, Kolb T, Schurig HL, Walther A. (2023). \textit{[Psilocybin-Assisted Treatment of Depression, Anxiety and Substance use Disorders: Neurobiological Basis and Clinical Application].}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1055/a-2046-5202}{doi:10.1055/a-2046-5202}.
\item Raithatha SA, Hagel JM, Matinkhoo K, Yu L, Press D, Cook SG, Sharma G, D D, Jensen G, Lee JB, Cai C, Gallant J, Bains JS, Tucker JE, Facchini PJ. (2023). \textit{Novel psilocin prodrugs with altered pharmacological properties as candidate therapies for treatment-resistant anxiety disorders}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2023.05.16.540994}{doi:10.1101/2023.05.16.540994}.
\item Strauss D, Ghosh S, Murray Z, Gryzenhout M. (2023). \textit{Global species diversity and distribution of the psychedelic fungal genus Panaeolus.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.heliyon.2023.e16338}{doi:10.1016/j.heliyon.2023.e16338}.
\item University of Wisconsin, Madison (2023). \textit{A Phase 1 Study Comparing the Pharmacokinetics and Safety of Intravenous and Oral Psilocybin}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05467761}{source link}.
\item Goodwin GM, Croal M, Marwood L, Malievskaia E (2023). \textit{Unblinding and demand characteristics in the treatment of depression.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2023.02.030}{doi:10.1016/j.jad.2023.02.030}.
\item Alan K. Davis, Adam W. Levin, Paul Nagib, Stacey B. Armstrong, Rafael Lancelotta (2023). \textit{Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD}. BMJ Open. [published; OpenAlex]. \href{https://doi.org/10.1136/bmjopen-2022-068884}{doi:10.1136/bmjopen-2022-068884}.
\item Brandon Weiss, David Erritzøe, Bruna Giribaldi, David Nutt, Robin Carhart-Harris (2023). \textit{A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811231167848}{doi:10.1177/02698811231167848}.
\item Bennett JN, Blough MD, Mitchell I, Galloway L, Bains R. (2023). \textit{A Phase I trial to inform clinical protocols for the safe administration of psilocybin-assisted psychotherapy}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2023.04.12.23288325}{doi:10.1101/2023.04.12.23288325}.
\item David Nutt (2023). \textit{Psychedelic Medicine: From Brain Science to Clinical Trials}. Biological Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.biopsych.2023.02.022}{doi:10.1016/j.biopsych.2023.02.022}.
\item Khan I, Jaura TA, Tukruna A, Arif A, Tebha SS, Nasir S, Mukherjee D, Masroor N, Yosufi A. (2023). \textit{Use of Selective Alternative Therapies for Treatment of OCD.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.2147/ndt.s403997}{doi:10.2147/ndt.s403997}.
\item Zia FZ, Baumann MH, Belouin SJ, Dworkin RH, Ghauri MH, Hendricks PS, Henningfield JE, Lanier RK, Ross S, Berger A. (2023). \textit{Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.neuropharm.2023.109528}{doi:10.1016/j.neuropharm.2023.109528}.
\item Feduccia A, Agin-Liebes G, Price CM, Grinsell N, Paradise S, Rabin DM. (2023). \textit{The need for establishing best practices and gold standards in psychedelic medicine.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jad.2023.03.083}{doi:10.1016/j.jad.2023.03.083}.
\item Domanegg K, Sommer WH, Meinhardt MW. (2023). \textit{Psychedelic Targeting of Metabotropic Glutamate Receptor 2 and Its Implications for the Treatment of Alcoholism.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3390/cells12060963}{doi:10.3390/cells12060963}.
\item Brett J, Knock E, Korthuis PT, Liknaitzky P, Murnane KS, Nicholas CR, Patterson JC, Stauffer CS. (2023). \textit{Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3389/fpsyt.2023.1123424}{doi:10.3389/fpsyt.2023.1123424}.
\item Wulff AB, Nichols CD, Thompson SM. (2023). \textit{Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.neuropharm.2023.109504}{doi:10.1016/j.neuropharm.2023.109504}.
\item Turkia M. (2023). \textit{Understanding psychedelic 'mystical experience'-A case example}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/dh92g}{doi:10.31234/osf.io/dh92g}.
\item Turkia M. (2023). \textit{Underground small-group therapy of treatment-resistant depression and complex post-traumatic stress disorder (C-PTSD) with psilocybin-A retrospective case study}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/t6k9b}{doi:10.31234/osf.io/t6k9b}.
\item Unknown authors (2023). \textit{Understanding psychedelic 'mystical experience'-A case example}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/dh92g\_v1}{source link}.
\item Unknown authors (2023). \textit{Underground small-group therapy of treatment-resistant depression and complex post-traumatic stress disorder (C-PTSD) with psilocybin-A retrospective case study}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/t6k9b\_v1}{source link}.
\item Steven W. Cotten, Frederick G. Strathmann, Frederick S. Barrett, Laura Labay, James Mullally, Alexander M. Sherwood, Frank Wiegand (2023). \textit{Psychedelics for Medicinal Use: How Will This Alter the Collective Laboratory Consciousness?}. Clinical Chemistry. [published; OpenAlex]. \href{https://doi.org/10.1093/clinchem/hvad016}{doi:10.1093/clinchem/hvad016}.
\item Jha MK, Mathew SJ. (2023). \textit{Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1176/appi.ajp.20230025}{doi:10.1176/appi.ajp.20230025}.
\item Meghan Hibicke, Hannah M. Kramer, Charles D. Nichols (2023). \textit{A Single Administration of Psilocybin Persistently Rescues Cognitive Deficits Caused by Adolescent Chronic Restraint Stress Without Long-Term Changes in Synaptic Protein Gene Expression in a Rat Experimental System with Translational Relevance to Depression}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1089/psymed.2022.0012}{doi:10.1089/psymed.2022.0012}.
\item Ashish Sarangi, Omotola Akinkunmi (2023). \textit{Psychedelics for the Neuropsychiatric Symptoms of Alzheimer's disease}. American Journal of Geriatric Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.jagp.2022.12.201}{doi:10.1016/j.jagp.2022.12.201}.
\item Jacob S. Aday, Zachary Skiles, Noa Eaton, Lisa Fredenburg, Mollie Pleet, Jessica Mantia, Ellen Bradley, Gisele Fernandes-Osterhold, Joshua Woolley (2023). \textit{Personal Psychedelic Use Is Common Among a Sample of Psychedelic Therapists: Implications for Research and Practice}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1089/psymed.2022.0004}{doi:10.1089/psymed.2022.0004}.
\item Jeffery Heilman (2023). \textit{The History, Legalization and Potentials of Psilocybin-Assisted Psychotherapy}. Journal of Scientific Exploration. [published; OpenAlex]. \href{https://doi.org/10.31275/20222633}{doi:10.31275/20222633}.
\item van der Meer PB, Fuentes JJ, Kaptein AA, Schoones JW, de Waal MM, Goudriaan AE, Kramers K, Schellekens A, Somers M, Bossong MG, Batalla A. (2023). \textit{Therapeutic effect of psilocybin in addiction: A systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3389/fpsyt.2023.1134454}{doi:10.3389/fpsyt.2023.1134454}.
\item Guy M. Goodwin, Scott T. Aaronson, Oscar Alvarez, Merve Atli, James Bennett, Megan Croal, Charles DeBattista, Boadie W. Dunlop, David Feifel, David J. Hellerstein, Muhammad Ishrat Husain, John R. Kelly, Molly Lennard-Jones, Rasmus Wentzer Licht, Lindsey Marwood, Sunil Mistry, Tomáš Páleníček, Ozlem Redjep, Dimitris Repantis, Robert A. Schoevers, Batya Septimus, Hollie Simmons, Jair C. Soares, Metten Somers, S. C. Stansfield, Jessica R. Stuart, Hannah H. Tadley, Nisha K. Thiara, Joyce Tsai, Mourad Wahba, Sam Williams, Rachel I. Winzer, Allan H. Young, Matthew B. Young, Sid Zisook, Ekaterina Malievskaia (2023). \textit{Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life}. Journal of Affective Disorders. [published; OpenAlex]. \href{https://doi.org/10.1016/j.jad.2023.01.108}{doi:10.1016/j.jad.2023.01.108}.
\item Washington University School of Medicine (2023). \textit{SV2A Marker of Synaptogenesis in a Clinical Trial of Psilocybin for Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05601648}{source link}.
\item von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, Seifritz E, Nowak A, Nowak P, Jäncke L, Preller KH, Vollenweider FX. (2023). \textit{Corrigendum to 'Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial'.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.eclinm.2023.101841}{doi:10.1016/j.eclinm.2023.101841}.
\item Stokłosa I, Więckiewicz G, Stokłosa M, Piegza M, Pudlo R, Gorczyca P. (2023). \textit{Medications for the Treatment of Alcohol Dependence-Current State of Knowledge and Future Perspectives from a Public Health Perspective.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3390/ijerph20031870}{doi:10.3390/ijerph20031870}.
\item Benjamin R. Lewis, Kevin Byrne, John Hendrick, Eric L. Garland, Paul Thielking, Anna C. Beck (2023). \textit{Group format psychedelic-assisted therapy interventions: Observations and impressions from the HOPE trial}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2022.00222}{doi:10.1556/2054.2022.00222}.
\item Keith Heinzerling (2023). \textit{Pilot Trial of Visual Healing®, a Nature-themed Virtual Immersive Experience, to Optimize Set and Setting in Psilocybin-assisted Therapy for Alcohol Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04410913}{source link}.
\item Jonina Rabinowitz, Shaul Lev-Ran, Raz Gross (2023). \textit{The association between naturalistic use of psychedelics and co-occurring substance use disorders}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2022.1066369}{doi:10.3389/fpsyt.2022.1066369}.
\item Guy M. Goodwin, Megan Croal, J. Chai-Rees, Lindsey Marwood, S. Mistry, Anna Nowakowska, H. Clifton Simmons, Jeng-Yu Tsai (2022). \textit{Withdrawal of antidepressants does not impact the efficacy of COMP360 psilocybin therapy: results from a phase IIb randomised controlled trial}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2023.103487}{doi:10.1016/j.nsa.2023.103487}.
\item Peter Hess (2022). \textit{Going on Trial: Serotonin drug; psilocybin phase 2; placebo response data}. The Transmitter. [published; OpenAlex]. \href{https://doi.org/10.53053/etcr6498}{doi:10.53053/etcr6498}.
\item Peter Hess (2022). \textit{Going on Trial: Arbaclofen reboot; cell implants; psilocybin microdoses}. The Transmitter. [published; OpenAlex]. \href{https://doi.org/10.53053/nbdr8957}{doi:10.53053/nbdr8957}.
\item John R. Rossiter (2022). \textit{Psychedelic Drug Therapy for Mental Disorders?}. Open Journal of Medical Psychology. [published; OpenAlex]. \href{https://doi.org/10.4236/ojmp.2023.123010}{doi:10.4236/ojmp.2023.123010}.
\item Kious B, Schwartz Z, Lewis B (2022). \textit{Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811221133461}{doi:10.1177/02698811221133461}.
\item Jack E. Henningfield, Judy Ashworth, David J. Heal, Sharon L. Smith (2022). \textit{Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811221140004}{doi:10.1177/02698811221140004}.
\item Leah Feulner, Thanpicha Sermchaiwong, Nathan Rodland, David Galarneau (2022). \textit{Efficacy and Safety of Psychedelics in Treating Anxiety Disorders}. Ochsner Journal. [published; OpenAlex]. \href{https://doi.org/10.31486/toj.23.0076}{doi:10.31486/toj.23.0076}.
\item Gail A. Edelsohn, Dominic Sisti (2022). \textit{Past Is Prologue: Ethical Issues in Pediatric Psychedelics Research and Treatment}. Perspectives in biology and medicine. [published; OpenAlex]. \href{https://doi.org/10.1353/pbm.2023.0007}{doi:10.1353/pbm.2023.0007}.
\item Natalie Gukasyan (2022). \textit{On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression}. Med. [published; OpenAlex]. \href{https://doi.org/10.1016/j.medj.2022.12.003}{doi:10.1016/j.medj.2022.12.003}.
\item IsHak WW, Garcia P, Pearl R, Dang J, William C, Totlani J, Danovitch I. (2022). \textit{The Impact of Psilocybin on Patients Experiencing Psychiatric Symptoms: A Systematic Review of Randomized Clinical Trials.}. Unknown journal. [published; Europe PMC]. \href{https://europepmc.org/article/MED/37387703}{source link}.
\item Herrmann Z, Earleywine M, De Leo J, Slabaugh S, Kenny T, Rush AJ (2022). \textit{Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2022.2125467}{doi:10.1080/02791072.2022.2125467}.
\item Kruger DJ, Glynos NG, Fields CW, Herberholz M, Boehnke KF (2022). \textit{An Assessment of Psychedelic Knowledge Among People Using Psychedelics Naturalistically.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2022.2142709}{doi:10.1080/02791072.2022.2142709}.
\item Acero VP, Cribas ES, Browne KD, Rivellini O, Burrell JC, O'Donnell JC, Das S, Cullen DK (2022). \textit{Bedside to bench: the outlook for psychedelic research.}. Frontiers in pharmacology. [published; PubMed]. \href{https://doi.org/10.3389/fphar.2023.1240295}{doi:10.3389/fphar.2023.1240295}.
\item Freidel N, Kreuder L, Rabinovitch BS, Chen FY, Huang RST, Lewis EC (2022). \textit{Psychedelics, epilepsy, and seizures: a review.}. Frontiers in pharmacology. [published; PubMed]. \href{https://doi.org/10.3389/fphar.2023.1326815}{doi:10.3389/fphar.2023.1326815}.
\item Robin von Rotz, Eva Maria Schindowski, Johannes Jungwirth, Anna Schuldt, Nathalie M. Rieser, Katharina Zahoranszky, Erich Seifritz, Albina Nowak, Peter J.C.M. Nowak, Lutz Jäncke, Katrin H. Preller, Franz X. Vollenweider (2022). \textit{Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial}. EClinicalMedicine. [published; OpenAlex]. \href{https://doi.org/10.1016/j.eclinm.2022.101809}{doi:10.1016/j.eclinm.2022.101809}.
\item Unknown authors (2022). \textit{High dose of psilocybin effective for treatment-resistant depression}. The Brown University Psychopharmacology Update. [published; OpenAlex]. \href{https://doi.org/10.1002/pu.30970}{doi:10.1002/pu.30970}.
\item Meghan DellaCrosse, Mollie Pleet, Emma Morton, Amir Ashtari, Kimberly Sakai, Josh Woolley, Erin E. Michalak (2022). \textit{“A sense of the bigger picture:” A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use}. PLoS ONE. [published; OpenAlex]. \href{https://doi.org/10.1371/journal.pone.0279073}{doi:10.1371/journal.pone.0279073}.
\item Emma Morton, Kimberly Sakai, Amir Ashtari, Mollie Pleet, Erin E. Michalak, Josh Woolley (2022). \textit{Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of ‘magic mushroom’ consumption}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811221131997}{doi:10.1177/02698811221131997}.
\item Friederike Holze, A. Becker, Karolina E. Kolaczynska, Urs Duthaler, Matthias E. Liechti (2022). \textit{Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants}. Clinical Pharmacology \& Therapeutics. [published; OpenAlex]. \href{https://doi.org/10.1002/cpt.2821}{doi:10.1002/cpt.2821}.
\item Kelly DF, Kelly DF, Heinzerling K, Sharma A, Gowrinathan S, Sergi K, Mallari RJ. (2022). \textit{Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1227/neu.0000000000002275}{doi:10.1227/neu.0000000000002275}.
\item Prokopios Magiatis, Evangelos Dadiotis, Romanos Konstantinos Antonopoulos, K Ioannidis, V Mitsis, E Melliou, Zacharoula Gonou-Zagou (2022). \textit{Direct Quantitation of Psilocybin and Psilocin by One-Dimensional 1H and 31P qNMR in a revived Greek specimen of Psilocybe cyanescens}. Planta Medica. [published; OpenAlex]. \href{https://doi.org/10.1055/s-0042-1759062}{doi:10.1055/s-0042-1759062}.
\item Hartogsohn I, Petranker R (2022). \textit{Set and setting in microdosing: an oft-overlooked principle.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-022-06249-8}{doi:10.1007/s00213-022-06249-8}.
\item Gukasyan N, Schreyer CC, Griffiths RR, Guarda AS (2022). \textit{Psychedelic-Assisted Therapy for People with Eating Disorders.}. Current psychiatry reports. [published; PubMed]. \href{https://doi.org/10.1007/s11920-022-01394-5}{doi:10.1007/s11920-022-01394-5}.
\item Irizarry R, Winczura A, Dimassi O, Dhillon N, Minhas A, Larice J. (2022). \textit{Psilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.7759/cureus.31796}{doi:10.7759/cureus.31796}.
\item Hamna Raheel, Unaiza Naeem, Asim Shaikh, Omer Ahmed Shaikh (2022). \textit{The psychedelic renaissance: can psilocybin possibly combat depression?}. International Journal of Surgery Global Health. [published; OpenAlex]. \href{https://doi.org/10.1097/gh9.0000000000000089}{doi:10.1097/gh9.0000000000000089}.
\item Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, DeBattista C, Dunlop BW, Eisen K, Feifel D, Forbes M, Haumann HM, Hellerstein DJ, Hoppe AI, Husain MI, Jelen LA, Kamphuis J, Kawasaki J, Kelly JR, Key RE, Kishon R, Knatz Peck S, Knight G, Koolen MHB, Lean M, Licht RW, Maples-Keller JL, Mars J, Marwood L, McElhiney MC, Miller TL, Mirow A, Mistry S, Mletzko-Crowe T, Modlin LN, Nielsen RE, Nielson EM, Offerhaus SR, O'Keane V, Páleníček T, Printz D, Rademaker MC, van Reemst A, Reinholdt F, Repantis D, Rucker J, Rudow S, Ruffell S, Rush AJ, Schoevers RA, Seynaeve M, Shao S, Soares JC, Somers M, Stansfield SC, Sterling D, Strockis A, Tsai J, Visser L, Wahba M, Williams S, Young AH, Ywema P, Zisook S, Malievskaia E. (2022). \textit{Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.}. New England Journal of Medicine. [published; Europe PMC]. \href{https://doi.org/10.1056/nejmoa2206443}{doi:10.1056/nejmoa2206443}.
\item Jensen ME, Jensen ME, Stenbæk DS, Juul TS, Fisher PM, Ekstrøm CT, Knudsen GM, Fink-Jensen A. (2022). \textit{Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial).}. BMJ Open. [published; Europe PMC]. \href{https://doi.org/10.1136/bmjopen-2022-066019}{doi:10.1136/bmjopen-2022-066019}.
\item Beckley Psytech Limited (2022). \textit{An Exploratory Open-Label, Phase 1b, Ascending Dose Study to Evaluate the Effects of Oral 3-[2-(Dimethylamino)Ethyl]-1h-indol-4-yl Dihydrogen Phosphate (Psilocybin, BPL-PSILO) on Cognition in Patients With Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04905121}{source link}.
\item Ko K, Kopra EI, Cleare AJ, Rucker JJ. (2022). \textit{Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jad.2022.09.168}{doi:10.1016/j.jad.2022.09.168}.
\item Ledwos N, Rosenblat JD, Blumberger DM, Castle DJ, McIntyre RS, Mulsant BH, Husain MI. (2022). \textit{A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1097/jcp.0000000000001608}{doi:10.1097/jcp.0000000000001608}.
\item Dworkin RH, Anderson BT, Andrews N, Edwards RR, Grob CS, Ross S, Satterthwaite TD, Strain EC (2022). \textit{If the Doors of Perception Were Cleansed, Would Chronic Pain be Relieved? Evaluating the Benefits and Risks of Psychedelics.}. The journal of pain. [published; PubMed]. \href{https://doi.org/10.1016/j.jpain.2022.05.003}{doi:10.1016/j.jpain.2022.05.003}.
\item Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, Mennenga SE, O'Donnell K, Owens LT, Podrebarac S, Rotrosen J, Tonigan JS, Worth L. (2022). \textit{Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1001/jamapsychiatry.2022.2096}{doi:10.1001/jamapsychiatry.2022.2096}.
\item Butler M, Jelen L, Rucker J (2022). \textit{Expectancy in placebo-controlled trials of psychedelics: if so, so what?}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-022-06221-6}{doi:10.1007/s00213-022-06221-6}.
\item Dougherty RF, Clarke P, Alti M, Kuc J, Schlosser D, Dunlop BW, Hellerstein DJ, Aaronson ST, Zisook S, Young AH, Carhart-Harris R, Goodwin G, Ryslik GA. (2022). \textit{Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language Processing}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/kh3cx}{doi:10.31234/osf.io/kh3cx}.
\item Unknown authors (2022). \textit{Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language Processing}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/kh3cx\_v1}{source link}.
\item Michael Eisenstein (2022). \textit{The psychedelic escape from depression}. Nature. [published; OpenAlex]. \href{https://doi.org/10.1038/d41586-022-02872-9}{doi:10.1038/d41586-022-02872-9}.
\item Stoliker D, Novelli L, Vollenweider FX, Egan GF, Preller KH, Razi A. (2022). \textit{Effective connectivity of emotion and cognition under psilocybin}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2022.09.06.22279626}{doi:10.1101/2022.09.06.22279626}.
\item Barba T, Buehler S, Kettner H, Radu C, Cunha BG, Nutt DJ, Erritzoe D, Roseman L, Carhart-Harris R. (2022). \textit{Effects of psilocybin versus escitalopram on rumination and thought suppression in depression.}. BJPsych Open. [published; Europe PMC]. \href{https://doi.org/10.1192/bjo.2022.565}{doi:10.1192/bjo.2022.565}.
\item Johnston CB, Mangini M, Grob C, Anderson B. (2022). \textit{The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jagp.2022.08.007}{doi:10.1016/j.jagp.2022.08.007}.
\item Lyes M, Yang KH, Castellanos J, Furnish T. (2022). \textit{Microdosing psilocybin for chronic pain: a case series.}. Pain. [published; Europe PMC]. \href{https://doi.org/10.1097/j.pain.0000000000002778}{doi:10.1097/j.pain.0000000000002778}.
\item special to C EN Attabey Rodríguez Benítez (2022). \textit{Psychedelics’ binding depends on receptor mutations}. C\&EN Global Enterprise. [published; OpenAlex]. \href{https://doi.org/10.1021/cen-10031-scicon6}{doi:10.1021/cen-10031-scicon6}.
\item Brian S. Barnett, Jeremy Weleff (2022). \textit{Psychedelics in the Treatment of Substance Use Disorders}. Psychiatric Annals. [published; OpenAlex]. \href{https://doi.org/10.3928/00485713-20220804-01}{doi:10.3928/00485713-20220804-01}.
\item Johannesdottir A, Sigurdsson E. (2022). \textit{[The use of psilocybin for treatment-resistant depression].}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.17992/lbl.2022.09.706}{doi:10.17992/lbl.2022.09.706}.
\item Kurtz JS, Patel NA, Gendreau JL, Yang C, Brown N, Bui N, Picton B, Harris M, Hatter M, Beyer R, Sahyouni R, Diaz-Aguilar LD, Castellanos J, Schuster N, Abraham ME (2022). \textit{The Use of Psychedelics in the Treatment of Medical Conditions: An Analysis of Currently Registered Psychedelics Studies in the American Drug Trial Registry.}. Cureus. [published; PubMed]. \href{https://doi.org/10.7759/cureus.29167}{doi:10.7759/cureus.29167}.
\item Breeksema JJ, Kuin BW, Kamphuis J, van den Brink W, Vermetten E, Schoevers RA. (2022). \textit{Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811221116926}{doi:10.1177/02698811221116926}.
\item Neşe Devenot, Trey Conner, Richard Doyle (2022). \textit{Dark Side of the Shroom: Erasing Indigenous and Counterculture Wisdoms with Psychedelic Capitalism, and the Open Source Alternative}. Anthropology of Consciousness. [published; OpenAlex]. \href{https://doi.org/10.1111/anoc.12154}{doi:10.1111/anoc.12154}.
\item Brian Peacock (2022). \textit{A-118 Psychedelic Interventions for Neuropsychological Conditions}. Archives of Clinical Neuropsychology. [published; OpenAlex]. \href{https://doi.org/10.1093/arclin/acac060.118}{doi:10.1093/arclin/acac060.118}.
\item Rosenblat JD, Husain MI, Lee Y, McIntyre RS, Mansur RB, Castle D, Offman H, Parikh SV, Frey BN, Schaffer A, Greenway KT, Garel N, Beaulieu S, Kennedy SH, Lam RW, Milev R, Ravindran AV, Tourjman V, Ameringen MV, Yatham LN, Taylor V. (2022). \textit{The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/07067437221111371}{doi:10.1177/07067437221111371}.
\item Prouzeau D, Conejero I, Voyvodic PL, Becamel C, Abbar M, Lopez-Castroman J. (2022). \textit{Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s11920-022-01361-0}{doi:10.1007/s11920-022-01361-0}.
\item Gitte Moos Knudsen (2022). \textit{Prophylactic Effects of Psilocybin on Chronic Cluster Headache: an Open-label Clinical Trial and Neuroimaging Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04280055}{source link}.
\item Watts R, Kettner H, Geerts D, Gandy S, Kartner L, Mertens L, Timmermann C, Nour MM, Kaelen M, Nutt D, Carhart-Harris R, Roseman L. (2022). \textit{The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world.}. Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1007/s00213-022-06187-5}{doi:10.1007/s00213-022-06187-5}.
\item Terri D’Arrigo (2022). \textit{Med Check: Psilocybin for OCD, Nuplazid Vote, and More}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2022.08.8.2}{doi:10.1176/appi.pn.2022.08.8.2}.
\item James A. Kaduk, Alexander M. Sherwood, Robert B. Kargbo, Kristi W. Kaylo, Poncho Meisenheimer, Nicholas V. Cozzi (2022). \textit{Psilocybin: crystal structure solutions enable phase analysis of prior art and recently patented examples}. Acta Crystallographica Section A Foundations and Advances. [published; OpenAlex]. \href{https://doi.org/10.1107/s2053273322097261}{doi:10.1107/s2053273322097261}.
\item University of California, San Diego (2022). \textit{Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04661514}{source link}.
\item Madsen MK, Petersen AS, Stenbæk DS, Sørensen IM, Schiønning H, Fjeld T, Nykjær CH, Ulv Larsen SM, Grzywacz M, Mathiesen T, Klausen IL, Overgaard-Hansen O, Brendstrup-Brix K, Linnet K, Johansen SS, Fisher PM, Jensen RH, Knudsen GM. (2022). \textit{Psilocybin-induced reduction in chronic cluster headache attack frequency correlates with changes in hypothalamic functional connectivity}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2022.07.10.22277414}{doi:10.1101/2022.07.10.22277414}.
\item Bosch OG, Halm S, Seifritz E. (2022). \textit{Psychedelics in the treatment of unipolar and bipolar depression.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1186/s40345-022-00265-5}{doi:10.1186/s40345-022-00265-5}.
\item da Costa SC, Oesterle T, Rummans TA, Richelson E, Gold M. (2022). \textit{Psychedelic drugs for psychiatric disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jns.2022.120332}{doi:10.1016/j.jns.2022.120332}.
\item Wake Network, Inc. (2022). \textit{Randomized Double Blind Placebo Controlled Assessing the Efficacy of Micro-dosed Psilocybin in Reducing Anxiety and or Depression Levels in Adults}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04989972}{source link}.
\item Inouye A, Wolfgang A. (2022). \textit{3,4-Methylenedioxymethamphetamine (MDMA)-Assisted Therapy in Hawaii: A Brief Review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.7759/cureus.26402}{doi:10.7759/cureus.26402}.
\item Kevin F. Boehnke, Alan K. Davis, Jenna McAfee (2022). \textit{Applying Lessons From Cannabis to the Psychedelic Highway}. JAMA Health Forum. [published; OpenAlex]. \href{https://doi.org/10.1001/jamahealthforum.2022.1618}{doi:10.1001/jamahealthforum.2022.1618}.
\item Hibicke M, Nichols CD. (2022). \textit{Validation of the forced swim test in Drosophila, and its use to demonstrate psilocybin has long-lasting antidepressant-like effects in flies.}. Scientific Reports. [published; Europe PMC]. \href{https://doi.org/10.1038/s41598-022-14165-2}{doi:10.1038/s41598-022-14165-2}.
\item Annie M. McCartney, H. T. McGovern, Alexander De Foe (2022). \textit{Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2022.00211}{doi:10.1556/2054.2022.00211}.
\item Anthony Principe (2022). \textit{Neuropharmacological analysis of the anti-addictive and therapeutic effects of psilocybin}. SURG Journal. [published; OpenAlex]. \href{https://doi.org/10.21083/surg.v14i1.6870}{doi:10.21083/surg.v14i1.6870}.
\item Manish Agrawal, Paul Thambi, Sarah Shnayder (2022). \textit{The safety and efficacy of psilocybin therapy in patients with cancer and major depressive disorder.}. Journal of Clinical Oncology. [published; OpenAlex]. \href{https://doi.org/10.1200/jco.2022.40.16\_suppl.12097}{doi:10.1200/jco.2022.40.16\_suppl.12097}.
\item Henner RL, Keshavan MS, Hill KP. (2022). \textit{Review of potential psychedelic treatments for PTSD.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jns.2022.120302}{doi:10.1016/j.jns.2022.120302}.
\item Sotille R, Singh H, Weisman A, Vida T. (2022). \textit{Unraveling the Mysteries of Mental Illness With Psilocybin.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.7759/cureus.25414}{doi:10.7759/cureus.25414}.
\item National Institute of Mental Health, Czech Republic (2022). \textit{Psilocybin Versus Ketamine - Fast Acting Antidepressant Strategies in Treatment-resistant Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05383313}{source link}.
\item Andrew Hodge, Suporn Sukpraprut-Braaten, Robert Strayhan (2022). \textit{The Efficacy of Psilocybin in the Treatment of Depression andAnxiety: A Meta-Analysis}. Current Psychiatry Research and Reviews. [published; OpenAlex]. \href{https://doi.org/10.2174/2666082218666220513142002}{doi:10.2174/2666082218666220513142002}.
\item University of Zurich (2022). \textit{Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy in Major Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT03715127}{source link}.
\item Scott Aaronson, Tammy Miller, Samuel Rudow, MacKenzie Forbes, Trisha Suppes (2022). \textit{P388. Open Label Psilocybin Administration in Severely Treatment Resistant Depression}. Biological Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.biopsych.2022.02.624}{doi:10.1016/j.biopsych.2022.02.624}.
\item Rossi GN, Hallak JEC, Bouso Saiz JC, Dos Santos RG. (2022). \textit{Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges.}. Expert Opinion on Drug Safety. [published; Europe PMC]. \href{https://doi.org/10.1080/14740338.2022.2066650}{doi:10.1080/14740338.2022.2066650}.
\item Raut SB, Marathe PA, van Eijk L, Eri R, Ravindran M, Benedek DM, Ursano RJ, Canales JJ, Johnson LR. (2022). \textit{Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.pharmthera.2022.108195}{doi:10.1016/j.pharmthera.2022.108195}.
\item Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, Erritzoe D, Roseman L, Nutt D, Carhart-Harris R. (2022). \textit{Increased global integration in the brain after psilocybin therapy for depression.}. Nature Medicine. [published; Europe PMC]. \href{https://doi.org/10.1038/s41591-022-01744-z}{doi:10.1038/s41591-022-01744-z}.
\item Jones G, Ricard JA, Lipson J, Nock MK. (2022). \textit{Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample.}. Scientific Reports. [published; Europe PMC]. \href{https://doi.org/10.1038/s41598-022-08085-4}{doi:10.1038/s41598-022-08085-4}.
\item Hackl B, Todt H, Kubista H, Kubista H, Hilber K, Koenig X. (2022). \textit{Psilocybin Therapy of Psychiatric Disorders Is Not Hampered by hERG Potassium Channel-Mediated Cardiotoxicity.}. The International Journal of Neuropsychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1093/ijnp/pyab085}{doi:10.1093/ijnp/pyab085}.
\item Murphy R, Kettner H, Zeifman R, Giribaldi B, Kartner L, Martell J, Read T, Murphy-Beiner A, Baker-Jones M, Nutt D, Erritzoe D, Watts R, Carhart-Harris R. (2022). \textit{Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.}. Frontiers in Pharmacology. [published; Europe PMC]. \href{https://doi.org/10.3389/fphar.2021.788155}{doi:10.3389/fphar.2021.788155}.
\item Zhai W, Li L, Zhao J, Xiang P, Liu M, Shi Y, Dang Y. (2022). \textit{Tentative identification of in vitro metabolites of O-acetylpsilocin (psilacetin, 4-AcO-DMT) by UHPLC-Q-Orbitrap MS.}. Drug Testing and Analysis. [published; Europe PMC]. \href{https://doi.org/10.1002/dta.3255}{doi:10.1002/dta.3255}.
\item Pots W, Chakhssi F. (2022). \textit{Psilocybin-Assisted Compassion Focused Therapy for Depression.}. Frontiers in Psychology. [published; Europe PMC]. \href{https://doi.org/10.3389/fpsyg.2022.812930}{doi:10.3389/fpsyg.2022.812930}.
\item Michael Avissar, Adrian Jacques H. Ambrose (2022). \textit{Demystifying Psychedelic Treatments in Psychiatry: Is Ego Dissolution the Solution?}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2022.04.4.35}{doi:10.1176/appi.pn.2022.04.4.35}.
\item McClure-Begley TD, Roth BL. (2022). \textit{The promises and perils of psychedelic pharmacology for psychiatry.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1038/s41573-022-00421-7}{doi:10.1038/s41573-022-00421-7}.
\item Mertens LJ, Koslowski M, Betzler F, Evens R, Gilles M, Jungaberle A, Jungaberle H, Majić T, Ströhle A, Wolff M, Wellek S, Gründer G. (2022). \textit{Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) - Rationale and study design.}. Neuroscience Applied. [published; Europe PMC]. \href{https://doi.org/10.1016/j.nsa.2022.100104}{doi:10.1016/j.nsa.2022.100104}.
\item van Amsterdam J, van den Brink W. (2022). \textit{The therapeutic potential of psilocybin: a systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/14740338.2022.2047929}{doi:10.1080/14740338.2022.2047929}.
\item Hodge AT, Sukpraprut-Braaten S, Narlesky M, Strayhan RC. (2022). \textit{The Use of Psilocybin in the Treatment of Psychiatric Disorders with Attention to Relative Safety Profile: A Systematic Review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/02791072.2022.2044096}{doi:10.1080/02791072.2022.2044096}.
\item Kargbo RB, Sherwood AM, Meisenheimer P, Lenoch K, Abebe S. (2022). \textit{Psilocybin: Characterization of the Metastable Zone Width (MSZW), Control of Anhydrous Polymorphs, and Particle Size Distribution (PSD).}. ACS Omega. [published; Europe PMC]. \href{https://doi.org/10.1021/acsomega.1c06708}{doi:10.1021/acsomega.1c06708}.
\item Ziff S, Stern B, Lewis G, Majeed M, Gorantla VR. (2022). \textit{Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.7759/cureus.21944}{doi:10.7759/cureus.21944}.
\item Müller F, Kraus E, Holze F, Becker A, Ley L, Schmid Y, Vizeli P, Liechti ME, Borgwardt S. (2022). \textit{Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants.}. Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1007/s00213-022-06066-z}{doi:10.1007/s00213-022-06066-z}.
\item Sakurai H, Yonezawa K, Tani H, Mimura M, Bauer M, Uchida H. (2022). \textit{Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1055/a-1714-9097}{doi:10.1055/a-1714-9097}.
\item Jurriaan F. M. Strous (2022). \textit{Psilocybine vergeleken met escitalopram bij depressie}. Pure Amsterdam UMC. [published; OpenAlex]. \href{https://pure.amsterdamumc.nl/en/publications/b99a8d48-a871-49d6-978c-969dd09a6dae}{source link}.
\item Strous JFM. (2022). \textit{[Psilocybin compared with escitalopram for depression].}. PubMed. [published; Europe PMC]. \href{https://europepmc.org/article/MED/35138714}{source link}.
\item Hase A, Erdmann M, Limbach V, Hasler G. (2022). \textit{Analysis of recreational psychedelic substance use experiences classified by substance.}. Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1007/s00213-022-06062-3}{doi:10.1007/s00213-022-06062-3}.
\item Valerie A. Canady (2022). \textit{Pennsylvania bill seeks clinical research on psychedelics}. Mental Health Weekly. [published; OpenAlex]. \href{https://doi.org/10.1002/mhw.33077}{doi:10.1002/mhw.33077}.
\item Bender D, Hellerstein DJ. (2022). \textit{Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s00213-021-06049-6}{doi:10.1007/s00213-021-06049-6}.
\item Rucker JJ, Marwood L, Ajantaival RJ, Bird C, Eriksson H, Harrison J, Lennard-Jones M, Mistry S, Saldarini F, Stansfield S, Tai SJ, Williams S, Weston N, Malievskaia E, Young AH. (2022). \textit{The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation.}. Journal of Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811211064720}{doi:10.1177/02698811211064720}.
\item Unknown authors (2021). \textit{Psilocybin may be effective for treatment-resistant depression}. Pharmaceutical journal/The pharmaceutical journal. [published; OpenAlex]. \href{https://doi.org/10.1211/pj.2022.1.164911}{doi:10.1211/pj.2022.1.164911}.
\item G. Goodwin, Scott T. Aaronson, Boadie W. Dunlop, D. Feifel, David J. Hellerstein, L. Marwood, S. Mistry, Metten Somers, S.C. Stansfield, J. Tsai, S. Williams, Allan H. Young, Sidney Zisook, E. Malievskaia (2021). \textit{The efficacy of COMP360 psilocybin therapy in treatment-resistant depression: exploratory results from a phase IIb randomised controlled trial}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2022.100213}{doi:10.1016/j.nsa.2022.100213}.
\item G.M. Goodwin, Scott T. Aaronson, Boadie W. Dunlop, David Feifel, David J. Hellerstein, N. Hewitt, L. Marwood, S. Mistry, Metten Somers, S.C. Stansfield, J. Tsai, S. Williams, Antony Young, Sidney Zisook, E. Malievskaia (2021). \textit{The safety and efficacy of COMP360 psilocybin therapy in treatment-resistant depression: results from a phase IIb randomised controlled trial}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2022.100511}{doi:10.1016/j.nsa.2022.100511}.
\item John Bailey, Joanna Kempner (2021). \textit{Standards Without Labs: Drug Development in the Psychedelic Underground}. Citizen Science Theory and Practice. [published; OpenAlex]. \href{https://doi.org/10.5334/cstp.527}{doi:10.5334/cstp.527}.
\item F. N. Smith, Joanna C. Neill, Verity Wainwright (2021). \textit{An Interpretative Phenomenological Analysis of the use of psilocybin by veterans with symptoms of trauma}. Drug Science Policy and Law. [published; OpenAlex]. \href{https://doi.org/10.1177/20503245221124117}{doi:10.1177/20503245221124117}.
\item Agin-Liebes G, Davis AK. (2021). \textit{Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach.}. Current topics in behavioral neurosciences. [published; Europe PMC]. \href{https://doi.org/10.1007/7854\_2021\_282}{doi:10.1007/7854\_2021\_282}.
\item Sarris J, Pinzon Rubiano D, Day K, Galvão-Coelho NL, Perkins D. (2021). \textit{Psychedelic medicines for mood disorders: current evidence and clinical considerations.}. PubMed. [published; Europe PMC]. \href{https://doi.org/10.1097/yco.0000000000000759}{doi:10.1097/yco.0000000000000759}.
\item Sherwood AM, Kargbo RB, Kaylo KW, Cozzi NV, Meisenheimer P, Kaduk JA. (2021). \textit{Psilocybin: crystal structure solutions enable phase analysis of prior art and recently patented examples.}. Acta Crystallographica Section C Structural Chemistry. [published; Europe PMC]. \href{https://doi.org/10.1107/s2053229621013164}{doi:10.1107/s2053229621013164}.
\item Plotnik L, Gibbs G, Graham T. (2021). \textit{Psilocybin Conspectus: Status, Production Methods, and Considerations.}. International journal of medicinal mushrooms. [published; Europe PMC]. \href{https://doi.org/10.1615/intjmedmushrooms.2021041921}{doi:10.1615/intjmedmushrooms.2021041921}.
\item Raison CL, Jain R, Penn AD, Cole SP, Jain S (2021). \textit{Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2022.831092}{doi:10.3389/fpsyt.2022.831092}.
\item Köck P, Froelich K, Walter M, Lang U, Dürsteler KM. (2021). \textit{A systematic literature review of clinical trials and therapeutic applications of ibogaine.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jsat.2021.108717}{doi:10.1016/j.jsat.2021.108717}.
\item University Hospital, Basel, Switzerland (2021). \textit{LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders: a Randomized, Double-blind, Placebo-controlled Phase II Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT03153579}{source link}.
\item Niles H, Fogg C, Kelmendi B, Lazenby M (2021). \textit{Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies.}. BMC palliative care. [published; PubMed]. \href{https://doi.org/10.1186/s12904-021-00889-x}{doi:10.1186/s12904-021-00889-x}.
\item Pearson C, Siegel J, Gold JA. (2021). \textit{Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jns.2021.120096}{doi:10.1016/j.jns.2021.120096}.
\item Louk J. M. J. Vanderschuren, Paul Willner, Emily M. Jutkiewicz, Bart Ellenbroek (2021). \textit{Announcement of two special issues: behavioural pharmacology of synaptopathies and psychedelic drugs}. Behavioural Pharmacology. [published; OpenAlex]. \href{https://doi.org/10.1097/fbp.0000000000000662}{doi:10.1097/fbp.0000000000000662}.
\item Strickland JC, Johnson MW. (2021). \textit{Human behavioral pharmacology of psychedelics.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/bs.apha.2021.10.003}{doi:10.1016/bs.apha.2021.10.003}.
\item Kozlowska U, Nichols C, Wiatr K, Figiel M. (2021). \textit{From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1111/jnc.15509}{doi:10.1111/jnc.15509}.
\item Spriggs MJ, Douglass HM, Park RJ, Read T, Danby JL, de Magalhães FJC, Alderton KL, Williams TM, Blemings A, Lafrance A, Nicholls DE, Erritzoe D, Nutt DJ, Carhart-Harris RL. (2021). \textit{Study Protocol for "Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study".}. Frontiers in Psychiatry. [published; Europe PMC]. \href{https://doi.org/10.3389/fpsyt.2021.735523}{doi:10.3389/fpsyt.2021.735523}.
\item Maryland Oncology Hematology, PA (2021). \textit{The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04593563}{source link}.
\item Yu CL, Yang FC, Yang SN, Tseng PT, Stubbs B, Yeh TC, Hsu CW, Li DJ, Liang CS. (2021). \textit{Psilocybin for End-of-Life Anxiety Symptoms: A Systematic Review and Meta-Analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.30773/pi.2021.0209}{doi:10.30773/pi.2021.0209}.
\item Barnett BS, Parker SE, Weleff J. (2021). \textit{United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.drugpo.2021.103473}{doi:10.1016/j.drugpo.2021.103473}.
\item Ryan Cross﻿ (2021). \textit{Delix to synthesize psychedelic drugs}. C\&EN Global Enterprise. [published; OpenAlex]. \href{https://doi.org/10.1021/cen-09936-buscon3}{doi:10.1021/cen-09936-buscon3}.
\item Gonda X, Dome P, Neill JC, Tarazi FI. (2021). \textit{Novel antidepressant drugs: Beyond monoamine targets.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1017/s1092852921000791}{doi:10.1017/s1092852921000791}.
\item Benjamin R. Lewis, Kevin Byrne (2021). \textit{Is MDD the right target for early-stage psychedelic-assisted therapy trials?}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2021.00180}{doi:10.1556/2054.2021.00180}.
\item Leger RF, Unterwald EM. (2021). \textit{Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811211044688}{doi:10.1177/02698811211044688}.
\item Tehseen Noorani, Jonny Martell (2021). \textit{New Frontiers or a Bursting Bubble? Psychedelic Therapy Beyond the Dichotomy}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2021.727050}{doi:10.3389/fpsyt.2021.727050}.
\item Muthukumaraswamy SD, Forsyth A, Lumley T. (2021). \textit{Blinding and expectancy confounds in psychedelic randomized controlled trials.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/17512433.2021.1933434}{doi:10.1080/17512433.2021.1933434}.
\item Ryan Cross﻿ (2021). \textit{Beckley raises funds for psychedelic drugs}. C\&EN Global Enterprise. [published; OpenAlex]. \href{https://doi.org/10.1021/cen-09930-buscon17}{doi:10.1021/cen-09930-buscon17}.
\item Peixoto C, Santos F, Rego D, Medeiros H. (2021). \textit{Psychedelics and psychiatric disorders: A emerging role}. Unknown journal. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC9470409}{source link}.
\item Fraga A, Esteves-Sousa D, Facucho-Oliveira J, Albuquerque M, Costa M, Dos Santos P, Moura N, Moutinho A. (2021). \textit{Effects of psilocybin-assisted therapy on treatment-resistant depression}. Unknown journal. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC9480034}{source link}.
\item Descalço N, Medeiros A, Santos C, Borges G. (2021). \textit{Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far?}. Unknown journal. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC9476072}{source link}.
\item Wayne Hall, Michael Farrell (2021). \textit{What can we learn from the history of research on psychedelic drugs in the addictions?}. Addiction. [published; OpenAlex]. \href{https://doi.org/10.1111/add.15560}{doi:10.1111/add.15560}.
\item Psiuk D, Nowak E, Cholewa K, Łopuszańska U, Samardakiewicz M. (2021). \textit{The Potential Role of Serotonergic Hallucinogens in Depression Treatment.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3390/life11080765}{doi:10.3390/life11080765}.
\item Yaden DB, Berghella AP, Regier PS, Garcia-Romeu A, Johnson MW, Hendricks PS. (2021). \textit{Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.drugpo.2021.103380}{doi:10.1016/j.drugpo.2021.103380}.
\item Horton DM, Morrison B, Schmidt J. (2021). \textit{Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1176/appi.psychotherapy.20200055}{doi:10.1176/appi.psychotherapy.20200055}.
\item King's College London (2021). \textit{A Randomised, Placebo Controlled Trial of Psilocybin in Treatment Resistant Depression: A Feasibility Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04959253}{source link}.
\item McCartney A, McGovern H, De Foe A. (2021). \textit{Psychedelic Assisted Therapy for Major Depressive Disorder: A Review}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/9kuhs}{doi:10.31234/osf.io/9kuhs}.
\item Unknown authors (2021). \textit{Psychedelic Assisted Therapy for Major Depressive Disorder: A Review}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/9kuhs\_v1}{source link}.
\item McCulloch DE, Knudsen GM, Barrett FS, Doss M, Deco G, Carhart-Harris R, Rosas F, Preller K, Ramaekers J, Mason N, Müller F, Fisher PM. (2021). \textit{Psychedelic resting-state neuroimaging: a review and perspective on balancing replication and novel analyses}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/64kyg}{doi:10.31234/osf.io/64kyg}.
\item Unknown authors (2021). \textit{Psychedelic resting-state neuroimaging: a review and perspective on balancing replication and novel analyses}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/64kyg\_v1}{source link}.
\item Fogg C, Michaels TI, de la Salle S, Jahn ZW, Williams MT. (2021). \textit{Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies.}. Experimental and Clinical Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1037/pha0000490}{doi:10.1037/pha0000490}.
\item Chao YS, Horton J. (2021). \textit{Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, Anxiety Disorders, Mood Disorders, or Substance Use Disorders}. Canadian Agency for Drugs and Technologies in Health, Ottawa (ON). [published; Europe PMC]. \href{https://europepmc.org/article/MED/36170470}{source link}.
\item Daws R, Timmerman C, Giribaldi B, Sexton J, Wall M, Erritzoe D, Roseman L, Nutt D, Carhart-Harris R. (2021). \textit{Decreased brain modularity after psilocybin therapy for depression.}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-513323/v1}{doi:10.21203/rs.3.rs-513323/v1}.
\item Unknown authors (2021). \textit{Future Directions for Clinical Psilocybin Research: The Relaxed Symptom Network}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.1037/pne0000290}{doi:10.1037/pne0000290}.
\item Lewis-Healey E, Laukkonen RE, van Elk M. (2021). \textit{Future Directions for Clinical Psilocybin Research: The Relaxed Symptom Network}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/q3ymd}{doi:10.31234/osf.io/q3ymd}.
\item Wayne Hall (2021). \textit{The need for publicly funded research on therapeutic use of psychedelic drugs}. World Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1002/wps.20847}{doi:10.1002/wps.20847}.
\item Senese Nicolas, Nguyen Thu, Cologna Stephanie, Rasenick Mark (2021). \textit{Effects of the putative antidepressant psilocin on the lipid-raft proteome and lipid-raft signaling}. The FASEB Journal. [published; Crossref]. \href{https://doi.org/10.1096/fasebj.2021.35.s1.03168}{doi:10.1096/fasebj.2021.35.s1.03168}.
\item University of Zurich (2021). \textit{Characterization of Altered Waking States of Consciousness in Healthy Humans}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT03853577}{source link}.
\item Rucker JJ, Young AH. (2021). \textit{Psilocybin: From Serendipity to Credibility?}. Frontiers in Psychiatry. [published; Europe PMC]. \href{https://doi.org/10.3389/fpsyt.2021.659044}{doi:10.3389/fpsyt.2021.659044}.
\item Henrik Børsting Jacobsen, Audun Stubhaug, Bjørn Holmøy, Tor Morten Kvam, Silje Endresen Rème (2021). \textit{Have Norwegians tried psilocybin, and do they accept it as a medicine?}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2021.00167}{doi:10.1556/2054.2021.00167}.
\item Gard DE, Pleet MM, Bradley ER, Penn A, Gallenstein ML, Riley LS, DellaCrosse M, Garfinkle E, Michalak EE, Woolley JD. (2021). \textit{Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Review of the Research Literature and Published Case Studies}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2021.04.02.21254838}{doi:10.1101/2021.04.02.21254838}.
\item Nelson Descalço, Ana Beatriz Medeiros, Cátia Fernandes Santos, Guilherme Borges (2021). \textit{Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far?}. European Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1192/j.eurpsy.2021.1114}{doi:10.1192/j.eurpsy.2021.1114}.
\item A. Fraga, Daniel Esteves-Sousa, João Facucho-Oliveira, Margarida Albuquerque, M. Costa, Paulo Santos, Nuno Moura, A. Moutinho (2021). \textit{Effects of psilocybin-assisted therapy on treatment-resistant depression}. European Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1192/j.eurpsy.2021.1836}{doi:10.1192/j.eurpsy.2021.1836}.
\item Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ. (2021). \textit{Trial of Psilocybin versus Escitalopram for Depression.}. New England Journal of Medicine. [published; Europe PMC]. \href{https://doi.org/10.1056/nejmoa2032994}{doi:10.1056/nejmoa2032994}.
\item Stanley N. Caroff (2021). \textit{The Return of Psychedelics: Still Time to Prevent Tragedy}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2021.4.8}{doi:10.1176/appi.pn.2021.4.8}.
\item Earleywine M, Ueno LF, Mian MN, Altman BR. (2021). \textit{Cannabis-induced oceanic boundlessness.}. Journal of Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1177/0269881121997099}{doi:10.1177/0269881121997099}.
\item Dos Santos RG, Hallak JE, Baker G, Dursun S. (2021). \textit{Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action.}. Journal of Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1177/0269881120986422}{doi:10.1177/0269881120986422}.
\item Ross S, Agin-Liebes G, Lo S, Zeifman RJ, Ghazal L, Benville J, Franco Corso S, Bjerre Real C, Guss J, Bossis A, Mennenga SE. (2021). \textit{Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer.}. ACS Pharmacology \& Translational Science. [published; Europe PMC]. \href{https://doi.org/10.1021/acsptsci.1c00020}{doi:10.1021/acsptsci.1c00020}.
\item Zeifman RJ, Singhal N, Breslow L, Weissman CR. (2021). \textit{On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1021/acsptsci.1c00024}{doi:10.1021/acsptsci.1c00024}.
\item Muthukumaraswamy S, Forsyth A, Lumley T. (2021). \textit{Blinding and Expectancy Confounds in Psychedelic Randomised Controlled Trials}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/q2hzm}{doi:10.31234/osf.io/q2hzm}.
\item Unknown authors (2021). \textit{Blinding and Expectancy Confounds in Psychedelic Randomised Controlled Trials}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/q2hzm\_v1}{source link}.
\item Dos Santos RG, Bouso JC, Rocha JM, Rossi GN, Hallak JE. (2021). \textit{The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges.}. DOAJ (DOAJ: Directory of Open Access Journals). [published; Europe PMC]. \href{https://doi.org/10.2147/rmhp.s300656}{source link}.
\item Tai SJ, Nielson EM, Lennard-Jones M, Johanna Ajantaival RL, Winzer R, Richards WA, Reinholdt F, Richards BD, Gasser P, Malievskaia E. (2021). \textit{Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research.}. Frontiers in Psychiatry. [published; Europe PMC]. \href{https://doi.org/10.3389/fpsyt.2021.586682}{doi:10.3389/fpsyt.2021.586682}.
\item Joost J. Breeksema, Martijn H B Koolen, Metten Somers, Robert A. Schoevers (2021). \textit{Behandeling met psilocybine}. Data Archiving and Networked Services (DANS). [published; OpenAlex]. \href{https://research.rug.nl/en/publications/5e83b45d-b208-402a-a435-f0380fad6429}{source link}.
\item Breeksema JJ, Koolen MHB, Somers M, Schoevers RA. (2021). \textit{[Treatment with psilocybin: applications for patients with psychiatric disorders].}. PubMed. [published; Europe PMC]. \href{https://europepmc.org/article/MED/33560605}{source link}.
\item Mertens LJ, Preller KH. (2021). \textit{Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1055/a-1341-1907}{doi:10.1055/a-1341-1907}.
\item Galvão-Coelho NL, Marx W, Gonzalez M, Sinclair J, de Manincor M, Perkins D, Sarris J. (2021). \textit{Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s00213-020-05719-1}{doi:10.1007/s00213-020-05719-1}.
\item Unknown authors (2020). \textit{Psilocybin therapy appears as effective as escitalopram, small study finds}. Pharmaceutical journal/The pharmaceutical journal. [published; OpenAlex]. \href{https://doi.org/10.1211/pj.2021.1.91592}{doi:10.1211/pj.2021.1.91592}.
\item Inserra A, De Gregorio D, Gobbi G. (2020). \textit{Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1124/pharmrev.120.000056}{doi:10.1124/pharmrev.120.000056}.
\item Tullis P. (2020). \textit{How ecstasy and psilocybin are shaking up psychiatry.}. Nature. [published; Europe PMC]. \href{https://doi.org/10.1038/d41586-021-00187-9}{doi:10.1038/d41586-021-00187-9}.
\item Bouso JC, Ona G, Dos Santos RG, Hallak JEC. (2020). \textit{Psychedelic Medicines in Major Depression: Progress and Future Challenges.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/978-981-33-6044-0\_26}{doi:10.1007/978-981-33-6044-0\_26}.
\item Castro Santos H, Gama Marques J. (2020). \textit{What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1097/j.pbj.0000000000000128}{doi:10.1097/j.pbj.0000000000000128}.
\item Williams ML, Korevaar D, Harvey R, Fitzgerald PB, Liknaitzky P, O'Carroll S, Puspanathan P, Ross M, Strauss N, Bennett-Levy J (2020). \textit{Translating Psychedelic Therapies From Clinical Trials to Community Clinics: Building Bridges and Addressing Potential Challenges Ahead.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2021.737738}{doi:10.3389/fpsyt.2021.737738}.
\item Emmanuelle A. D. Schindler, R. Andrew Sewell, Christopher Gottschalk, Christina Luddy, L. Taylor Flynn, Hayley Lindsey, Brian Pittman, Nicholas V. Cozzi, Deepak Cyril D’Souza (2020). \textit{Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin}. Neurotherapeutics. [published; OpenAlex]. \href{https://doi.org/10.1007/s13311-020-00962-y}{doi:10.1007/s13311-020-00962-y}.
\item Alan K. Davis, Frederick S. Barrett, Darrick G. May, Mary P Cosimano, Nathan D. Sepeda, Matthew W. Johnson, Patrick H. Finan, Roland R. Griffiths (2020). \textit{Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder}. JAMA Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1001/jamapsychiatry.2020.3285}{doi:10.1001/jamapsychiatry.2020.3285}.
\item Luoma JB, Chwyl C, Bathje G, Davis AK, Lancelotta RL. (2020). \textit{A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/nhbjk}{doi:10.31234/osf.io/nhbjk}.
\item Olivia Gosseries, Charlotte Martial (2020). \textit{The use of psychedelics in the treatment of disorders of consciousness. An interview with Olivia Gosseries by Charlotte Martial.}. Open Repository and Bibliography (University of Liège). [published; OpenAlex]. \href{https://doi.org/10.34700/gv0w-y052}{doi:10.34700/gv0w-y052}.
\item Russ Curtis, Lisen C. Roberts, Elizabeth Graves, Heather Thompson Rainey, D. D. Wynn, Daphne Krantz, Verena Wieloch (2020). \textit{The Role of Psychedelics and Counseling in Mental Health Treatment}. Journal of Mental Health Counseling. [published; OpenAlex]. \href{https://doi.org/10.17744/mehc.42.4.03}{doi:10.17744/mehc.42.4.03}.
\item Gill H, Gill B, Chen-Li D, El-Halabi S, Rodrigues NB, Cha DS, Lipsitz O, Lee Y, Rosenblat JD, Majeed A, Mansur RB, Nasri F, Ho R, McIntyre RS. (2020). \textit{The emerging role of psilocybin and MDMA in the treatment of mental illness.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/14737175.2020.1826931}{doi:10.1080/14737175.2020.1826931}.
\item Nicole Harrington Cirino (2020). \textit{Wait for the Science Before Widespread Use of Psilocybin}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2020.10a32}{doi:10.1176/appi.pn.2020.10a32}.
\item Vitkauskas M, Mathuru AS. (2020). \textit{Total Recall: Lateral Habenula and Psychedelics in the Study of Depression and Comorbid Brain Disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3390/ijms21186525}{doi:10.3390/ijms21186525}.
\item Vargas AS, Luís Â, Barroso M, Gallardo E, Pereira L. (2020). \textit{Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases-A Systematic Review and Meta-Analysis of Clinical Trials.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3390/biomedicines8090331}{doi:10.3390/biomedicines8090331}.
\item John R. Kelly, Matthew Crockett, Laith Alexander, Martin Haran, Amanda Baker, Lisa M. Burke, Christine Brennan, Veronica O’Keane (2020). \textit{Psychedelic science in post-COVID-19 psychiatry}. Irish Journal of Psychological Medicine. [published; OpenAlex]. \href{https://doi.org/10.1017/ipm.2020.94}{doi:10.1017/ipm.2020.94}.
\item Robin Carhart-Harris (2020). \textit{4 Psychedelics: therapeutic mechanisms}. Journal of Neurology Neurosurgery \& Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1136/jnnp-2020-bnpa.4}{doi:10.1136/jnnp-2020-bnpa.4}.
\item James E, Robertshaw TL, Hoskins M, Sessa B. (2020). \textit{Psilocybin occasioned mystical-type experiences.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1002/hup.2742}{doi:10.1002/hup.2742}.
\item Luoma JB. (2020). \textit{A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/sgujx}{doi:10.31234/osf.io/sgujx}.
\item Greenway KT, Garel N, Jerome L, Feduccia AA (2020). \textit{Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments.}. Expert review of clinical pharmacology. [published; PubMed]. \href{https://doi.org/10.1080/17512433.2020.1772054}{doi:10.1080/17512433.2020.1772054}.
\item Natasha L. Mason, Kim P. C. Kuypers, Felix Müller, Johannes T. Reckweg, Desmond H. Y. Tse, Stefan W. Toennes, Nadia R. P. W. Hutten, Jacobus F.A. Jansen, Peter Stiers, Amanda Feilding, Johannes G. Ramaekers (2020). \textit{Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin}. Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1038/s41386-020-0718-8}{doi:10.1038/s41386-020-0718-8}.
\item Ron Shore (2020). \textit{Psychedelics, Safety and Clinical Trial Design}. QSpace (Queen's University Library). [published; OpenAlex]. \href{http://hdl.handle.net/1974/27835}{source link}.
\item Marcus W. Meinhardt, Cansu Güngör, Ivan Skorodumov, Lea J. Mertens, Rainer Spanagel (2020). \textit{Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse}. Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1038/s41386-020-0694-z}{doi:10.1038/s41386-020-0694-z}.
\item Lea T, Amada N, Jungaberle H, Schecke H, Scherbaum N, Klein M (2020). \textit{Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-020-05477-0}{doi:10.1007/s00213-020-05477-0}.
\item University of Wisconsin, Madison (2020). \textit{Pharmacokinetics of Psilocybin in Normal Adult Volunteers}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT02163707}{source link}.
\item Nick Zagorski (2020). \textit{Psychedelics for Psychiatric Disorders: More Research Needed}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2020.4a14}{doi:10.1176/appi.pn.2020.4a14}.
\item Elyes Dahmane, Paul R. Hutson, Jogarao Gobburu (2020). \textit{Exposure-Response Analysis to Assess the Concentration-QTc Relationship of Psilocybin/Psilocin}. Clinical Pharmacology in Drug Development. [published; OpenAlex]. \href{https://doi.org/10.1002/cpdd.796}{doi:10.1002/cpdd.796}.
\item N. Milne, Philip Tinggaard Thomsen, Niels Aage Tvis Knudsen, P. Rubaszka, Mette Kristensen, Irina Borodina (2020). \textit{Metabolic engineering of Saccharomyces cerevisiae for the de novo production of psilocybin and related tryptamine derivatives}. Metabolic Engineering. [published; OpenAlex]. \href{https://doi.org/10.1016/j.ymben.2019.12.007}{doi:10.1016/j.ymben.2019.12.007}.
\item Katie O’Connor (2020). \textit{Can Psychedelics Radically Change SUD Treatment?}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2020.2a12}{doi:10.1176/appi.pn.2020.2a12}.
\item Meghan Hibicke, Alexus N. Landry, Hannah M. Kramer, Zoe K. Talman, Charles D. Nichols (2020). \textit{Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression}. ACS Chemical Neuroscience. [published; OpenAlex]. \href{https://doi.org/10.1021/acschemneuro.9b00493}{doi:10.1021/acschemneuro.9b00493}.
\item Janis Fricke, Robert B. Kargbo, Lars Regestein, Claudius Lenz, Gundela Peschel, Miriam A. Rosenbaum, Alexander M. Sherwood, Dirk Hoffmeister (2020). \textit{Scalable Hybrid Synthetic/Biocatalytic Route to Psilocybin}. Chemistry - A European Journal. [published; OpenAlex]. \href{https://doi.org/10.1002/chem.202000134}{doi:10.1002/chem.202000134}.
\item Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, Kalin NH, McDonald WM, the Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research. (2020). \textit{Psychedelics and Psychedelic-Assisted Psychotherapy.}. Diseño interior. [published; Europe PMC]. \href{https://doi.org/10.1176/appi.ajp.2019.19010035}{doi:10.1176/appi.ajp.2019.19010035}.
\item Foldi CJ, Liknaitzky P, Williams M, Oldfield BJ. (2020). \textit{Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3389/fnins.2020.00043}{doi:10.3389/fnins.2020.00043}.
\item Sofia Gyllvik (2019). \textit{The Therapeutic Potential of Psilocybin and 3,4-Methylenedioxymethamphetamine in the Treatment of Depression and Post-Traumatic Stress Disorder}. Diva portal (Dalarna University Library). [published; OpenAlex]. \href{http://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-18729}{source link}.
\item Reham Shaba (2019). \textit{Development of an improved psilocybin synthesis}. Uppsala University Publications (Uppsala University). [published; OpenAlex]. \href{http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-420295}{source link}.
\item Dalton Budhram, Preet Dhaliwal (2019). \textit{Psilocybin Therapy for Depression: A Scoping Review Protocol}. Open MIND. [published; OpenAlex]. \href{https://osf.io/4syt6}{source link}.
\item Shore R, Ioudovski P, Goldie C, McKeown S, Dumont E, Queen’s University, Kingston On. (2019). \textit{Mapping Psilocybin-Assisted Therapies: A Scoping Review}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2019.12.04.19013896}{doi:10.1101/2019.12.04.19013896}.
\item Laura Mertens, M.B. Wall, L. Roseman, L. Demetriou, D.J. Nutt, R.L. Carhart-Harris (2019). \textit{P.609 Therapeutic mechanisms of psychedelic drugs: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression}. European Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1016/j.euroneuro.2019.09.593}{doi:10.1016/j.euroneuro.2019.09.593}.
\item Nick Zagorski (2019). \textit{Johns Hopkins Opens Research Center on Psychedelics}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2019.10a16}{doi:10.1176/appi.pn.2019.10a16}.
\item Dos Santos RG, Bouso JC, Hallak JEC. (2019). \textit{Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1186/s12888-019-2288-z}{doi:10.1186/s12888-019-2288-z}.
\item Megha Satyanarayana (2019). \textit{Modified E. coli pump out psilocybin}. C\&EN Global Enterprise. [published; OpenAlex]. \href{https://doi.org/10.1021/cen-09739-scicon9}{doi:10.1021/cen-09739-scicon9}.
\item Kelley C. O’Donnell, Sarah E. Mennenga, Michael P. Bogenschutz (2019). \textit{Psilocybin for depression: Considerations for clinical trial design}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2019.026}{doi:10.1556/2054.2019.026}.
\item Muttoni S, Ardissino M, John C. (2019). \textit{Classical psychedelics for the treatment of depression and anxiety: A systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jad.2019.07.076}{doi:10.1016/j.jad.2019.07.076}.
\item Carhart-Harris RL, Friston KJ. (2019). \textit{REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1124/pr.118.017160}{doi:10.1124/pr.118.017160}.
\item Richard Simoneaux (2019). \textit{The Potential of Psilocybin Administration in Terminal Cancer Patients}. Oncology Times. [published; OpenAlex]. \href{https://doi.org/10.1097/01.cot.0000574916.46844.cf}{doi:10.1097/01.cot.0000574916.46844.cf}.
\item Janis Fricke, Alexander M. Sherwood, Robert B. Kargbo, Andrew Orry, Felix Blei, Andreas Naschberger, Bernhard Rupp, Dirk Hoffmeister (2019). \textit{Enzymatic Route toward 6-Methylated Baeocystin and Psilocybin}. ChemBioChem. [published; OpenAlex]. \href{https://doi.org/10.1002/cbic.201900358}{doi:10.1002/cbic.201900358}.
\item Meghan Hibicke, Alexus N. Landry, Zoe K. Talman, Charles D. Nichols (2019). \textit{Psychedelics Improve the Mental Health of Rats}. The FASEB Journal. [published; OpenAlex]. \href{https://doi.org/10.1096/fasebj.2019.33.1\_supplement.666.1}{doi:10.1096/fasebj.2019.33.1\_supplement.666.1}.
\item Richard Doblin, Merete Bruun Christiansen, Lisa Jerome, Brad Burge (2019). \textit{The Past and Future of Psychedelic Science: An Introduction to This Issue}. Journal of Psychoactive Drugs. [published; OpenAlex]. \href{https://doi.org/10.1080/02791072.2019.1606472}{doi:10.1080/02791072.2019.1606472}.
\item Hutten NRPW, Mason NL, Dolder PC, Kuypers KPC (2018). \textit{Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2019.00672}{doi:10.3389/fpsyt.2019.00672}.
\item Fricke J, Lenz C, Wick J, Blei F, Hoffmeister D. (2018). \textit{Production Options for Psilocybin: Making of the Magic.}. Chemistry - A European Journal. [published; Europe PMC]. \href{https://doi.org/10.1002/chem.201802758}{doi:10.1002/chem.201802758}.
\item Wasko MJ, Witt-Enderby PA, Surratt CK. (2018). \textit{DARK Classics in Chemical Neuroscience: Ibogaine.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1021/acschemneuro.8b00294}{doi:10.1021/acschemneuro.8b00294}.
\item Ross S. (2018). \textit{Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/09540261.2018.1482261}{doi:10.1080/09540261.2018.1482261}.
\item Aixalà M, Dos Santos RG, Hallak JEC, Bouso JC. (2018). \textit{Psychedelics and Personality.}. ACS Chemical Neuroscience. [published; Europe PMC]. \href{https://doi.org/10.1021/acschemneuro.8b00237}{doi:10.1021/acschemneuro.8b00237}.
\item Nichols DE. (2018). \textit{Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD).}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1021/acschemneuro.8b00043}{doi:10.1021/acschemneuro.8b00043}.
\item Nielson EM, May DG, Forcehimes AA, Bogenschutz MP. (2018). \textit{The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions.}. Frontiers in Pharmacology. [published; Europe PMC]. \href{https://doi.org/10.3389/fphar.2018.00132}{doi:10.3389/fphar.2018.00132}.
\item Bogenschutz MP, Podrebarac SK, Duane JH, Amegadzie SS, Malone TC, Owens LT, Ross S, Mennenga SE. (2018). \textit{Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder.}. Frontiers in Pharmacology. [published; Europe PMC]. \href{https://doi.org/10.3389/fphar.2018.00100}{doi:10.3389/fphar.2018.00100}.
\item Roseman L, Nutt DJ, Carhart-Harris RL. (2018). \textit{Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.}. Frontiers in Pharmacology. [published; Europe PMC]. \href{https://doi.org/10.3389/fphar.2017.00974}{doi:10.3389/fphar.2017.00974}.
\item Link Swanson (2017). \textit{Unlearning to See: Linking the Perceptual and Clinical Effects of Psychedelic Drugs.}. eScholarship (California Digital Library). [published; OpenAlex]. \href{https://escholarship.org/uc/item/67x0n7rq}{source link}.
\item Thomas Cody Swift (2017). \textit{Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Psychological Distress}. Western CEDAR (Western Washington University). [published; OpenAlex]. \href{https://cedar.wwu.edu/pci/lectures\_events/holistic\_pain\_management/3}{source link}.
\item Bogenschutz MP, Ross S. (2017). \textit{Therapeutic Applications of Classic Hallucinogens.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/7854\_2016\_464}{doi:10.1007/7854\_2016\_464}.
\item Canal CE. (2017). \textit{Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/164\_2018\_107}{doi:10.1007/164\_2018\_107}.
\item Rucker JJH, Iliff J, Nutt DJ. (2017). \textit{Psychiatry \& the psychedelic drugs. Past, present \& future.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.neuropharm.2017.12.040}{doi:10.1016/j.neuropharm.2017.12.040}.
\item Brown RT, Nicholas CR, Cozzi NV, Gassman MC, Cooper KM, Muller D, Thomas CD, Hetzel SJ, Henriquez KM, Ribaudo AS, Hutson PR. (2017). \textit{Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults.}. Clinical Pharmacokinetics. [published; Europe PMC]. \href{https://doi.org/10.1007/s40262-017-0540-6}{doi:10.1007/s40262-017-0540-6}.
\item Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ. (2017). \textit{Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.}. Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1007/s00213-017-4771-x}{doi:10.1007/s00213-017-4771-x}.
\item Kyzar EJ, Nichols CD, Gainetdinov RR, Nichols DE, Kalueff AV. (2017). \textit{Psychedelic Drugs in Biomedicine.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.tips.2017.08.003}{doi:10.1016/j.tips.2017.08.003}.
\item Reiche S, Hermle L, Gutwinski S, Jungaberle H, Gasser P, Majić T. (2017). \textit{Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.pnpbp.2017.09.012}{doi:10.1016/j.pnpbp.2017.09.012}.
\item Barrett FS, Robbins H, Smooke D, Brown JL, Griffiths RR. (2017). \textit{Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions.}. Frontiers in Psychology. [published; Europe PMC]. \href{https://doi.org/10.3389/fpsyg.2017.01238}{doi:10.3389/fpsyg.2017.01238}.
\item Jonathan Nash (2017). \textit{Navigating Psychedelic Medicines through (Inter)national Regulation}. Northumbria Research Link (Northumbria University). [published; OpenAlex]. \href{http://nrl.northumbria.ac.uk/id/eprint/31692/1/\_\_Client\_H\%24\_Documents\_Breaking\%20Convention\%202017\%20Final.pptx}{source link}.
\item Thomas K, Malcolm B, Lastra D. (2017). \textit{Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/02791072.2017.1320734}{doi:10.1080/02791072.2017.1320734}.
\item Carhart-Harris RL, Goodwin GM. (2017). \textit{The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1038/npp.2017.84}{doi:10.1038/npp.2017.84}.
\item Thomas W. Flanagan, Melaine N. Sebastian, Charles D. Nichols (2017). \textit{Anti-inflammatory effects of serotonin 5-HT2A receptor activation in ovalbumin-induced allergic asthma models}. The FASEB Journal. [published; OpenAlex]. \href{https://doi.org/10.1096/fasebj.31.1\_supplement.820.4}{doi:10.1096/fasebj.31.1\_supplement.820.4}.
\item Nichols DE, Johnson MW, Nichols CD. (2016). \textit{Psychedelics as Medicines: An Emerging New Paradigm.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1002/cpt.557}{doi:10.1002/cpt.557}.
\item Rucker JJ, Jelen LA, Flynn S, Frowde KD, Young AH. (2016). \textit{Psychedelics in the treatment of unipolar mood disorders: a systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/0269881116679368}{doi:10.1177/0269881116679368}.
\item Michael P. Bogenschutz, Alyssa A. Forcehimes (2016). \textit{Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism}. Journal of Humanistic Psychology. [published; OpenAlex]. \href{https://doi.org/10.1177/0022167816673493}{doi:10.1177/0022167816673493}.
\item Patra S. (2016). \textit{Return of the psychedelics: Psilocybin for treatment resistant depression.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.ajp.2016.08.010}{doi:10.1016/j.ajp.2016.08.010}.
\item Howland RH. (2016). \textit{Antidepressant, Antipsychotic, and Hallucinogen Drugs for the Treatment of Psychiatric Disorders: A Convergence at the Serotonin-2A Receptor.}. Journal of Psychosocial Nursing and Mental Health Services. [published; Europe PMC]. \href{https://doi.org/10.3928/02793695-20160616-09}{doi:10.3928/02793695-20160616-09}.
\item Tylš F, Páleníček T, Kadeřábek L, Lipski M, Kubešová A, Horáček J. (2016). \textit{Sex differences and serotonergic mechanisms in the behavioural effects of psilocin.}. Behavioural Pharmacology. [published; Europe PMC]. \href{https://doi.org/10.1097/fbp.0000000000000198}{doi:10.1097/fbp.0000000000000198}.
\item Filip Tylš, Michaela Viktorinová, Dominika Prokopcova, Jakub Korčák, Renata Androvičová, Martin Brunovský, Jiřı́ Horáček (2016). \textit{PM506. Psilocybin Clinical Trial: Acute Effects and its relationship to the brain activity as measured by quantitative EEG}. The International Journal of Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1093/ijnp/pyw041.506}{doi:10.1093/ijnp/pyw041.506}.
\item Tyls F, Michaela Viktorinova T, Prokopcova D, Korcak J, Androvicova R, Brunovsky M, Horacek J. (2016). \textit{PM506. Psilocybin Clinical Trial: Acute Effects and its relationship to the brain activity as measured by quantitative EEG}. Unknown journal. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC5616440}{source link}.
\item Nichols DE. (2016). \textit{Psychedelics.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1124/pr.115.011478}{doi:10.1124/pr.115.011478}.
\item Dos Santos RG, Osório FL, Crippa JA, Riba J, Zuardi AW, Hallak JE. (2016). \textit{Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/2045125316638008}{doi:10.1177/2045125316638008}.
\item Stephen Mo Hanan (2015). \textit{The Psyche in Psychedelic}. Tikkun. [published; OpenAlex]. \href{https://doi.org/10.1215/08879982-3328661}{doi:10.1215/08879982-3328661}.
\item Jochen Gartz, Georg Wiedemann (2015). \textit{Discovery of a new caerulescent Psilocybe mushroom in Germany: Psilocybe germanica sp.nov.}. Drug Testing and Analysis. [published; OpenAlex]. \href{https://doi.org/10.1002/dta.1795}{doi:10.1002/dta.1795}.
\item Bogenschutz MP, Johnson MW. (2015). \textit{Classic hallucinogens in the treatment of addictions.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.pnpbp.2015.03.002}{doi:10.1016/j.pnpbp.2015.03.002}.
\item Baumeister D, Barnes G, Giaroli G, Tracy D (2014). \textit{Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles.}. Therapeutic advances in psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1177/2045125314527985}{doi:10.1177/2045125314527985}.
\item Halberstadt AL. (2014). \textit{Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.bbr.2014.07.016}{doi:10.1016/j.bbr.2014.07.016}.
\item Rick Doblin (2013). \textit{Stanislav Grof's Contributions to FDA Drug Development Research with Psychedelics}. CIIS Digital Commons (California Institute of Integral Studies). [published; OpenAlex]. \href{https://digitalcommons.ciis.edu/stanislavgrof2014/12}{source link}.
\item Nichols DE. (2013). \textit{The Heffter Research Institute: past and hopeful future.}. Journal of Psychoactive Drugs. [published; Europe PMC]. \href{https://doi.org/10.1080/02791072.2014.873688}{doi:10.1080/02791072.2014.873688}.
\item Burdick BV, Adinoff B. (2013). \textit{A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment.}. The American Journal of Drug and Alcohol Abuse. [published; Europe PMC]. \href{https://doi.org/10.3109/00952990.2013.811513}{doi:10.3109/00952990.2013.811513}.
\item Young SN. (2013). \textit{Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin.}. Фундаментальные исследования (Fundamental Research). [published; Europe PMC]. \href{https://doi.org/10.1503/jpn.120128}{doi:10.1503/jpn.120128}.
\item Bogenschutz MP. (2013). \textit{Studying the effects of classic hallucinogens in the treatment of alcoholism: rationale, methodology, and current research with psilocybin.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.2174/15733998113099990002}{doi:10.2174/15733998113099990002}.
\item Carhart-Harris RL, Leech R, Williams TM, Erritzoe D, Abbasi N, Bargiotas T, Hobden P, Sharp DJ, Evans J, Feilding A, Wise RG, Nutt DJ. (2012). \textit{Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin.}. The British Journal of Psychiatry. [published; Europe PMC]. \href{https://doi.org/10.1192/bjp.bp.111.103309}{doi:10.1192/bjp.bp.111.103309}.
\item Manevski N, Kurkela M, Höglund C, Mauriala T, Court MH, Yli-Kauhaluoma J, Finel M. (2009). \textit{Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1124/dmd.109.031138}{doi:10.1124/dmd.109.031138}.
\item Frecska E, Luna LE. (2006). \textit{The adverse effects of hallucinogens from intramural perspective.}. PubMed. [published; Europe PMC]. \href{https://europepmc.org/article/MED/17211054}{source link}.
\item Riba J, Rodríguez-Fornells A, Barbanoj MJ. (2002). \textit{Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s00213-002-1237-5}{doi:10.1007/s00213-002-1237-5}.
\item Passie T, Seifert J, Schneider U, Emrich HM. (2002). \textit{The pharmacology of psilocybin.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/1355621021000005937}{doi:10.1080/1355621021000005937}.
\item Fischer R, Hill RM, Warshay D. (1969). \textit{Effects of psychodysleptic drug psilocybin on visual perception. Changes in brightness preference.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/bf01899102}{doi:10.1007/bf01899102}.
\item Snyder SH, Faillace L, Hollister L. (1967). \textit{2,5-dimethoxy-4-methyl-amphetamine (STP): a new hallucinogenic drug.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1126/science.158.3801.669}{doi:10.1126/science.158.3801.669}.
\item Abramson HA, Rolo A. (1965). \textit{Lysergic acid diethylamide (LSD-25). 38. Comparison with action of methysergide and psilocybin on test subjects.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3109/02770906509106904}{doi:10.3109/02770906509106904}.
\end{enumerate}
\end{document}
